




Mechanisms Regulating Osteoblast Response to  























In Partial Fulfillment 
of the Requirements for the Degree 
Doctor of Philosophy in the 













Mechanisms Regulating Osteoblast Response to 


























Approved by:   
   
Dr. Barbara D. Boyan, Advisor 
School of Biomedical Engineering 
Georgia Institute of Technology 
 Dr. Nael McCarty 
School of Medicine 
Emory University 
   
Dr. Zvi Schwartz 
School of Biomedical Engineering 
Georgia Institute of Technology 
 Dr. Anthony Norman 
Department of Biochemistry 
University of California, Riverside 
   
Dr. Andrés J. García 
School of Mechanical Engineering 
Georgia Institute of Technology 
  
   






First and foremost, I would like to thank my advisors Dr. Barbara Boyan and Dr. 
Zvi Schwartz.  Dr. Boyan was kind enough to take a materials science student into a lab 
focused heavily on the biological side of biomaterials engineering.  I had done research 
in the orthopaedic implant area, but I had never actually tested cell response to material 
surfaces.  Dr. Boyan has helped teach me that understanding the underlying biology and 
host response is central to the proper design of biomedical devices.  In addition, I would 
like to thank Dr. Boyan for her personal support throughout my graduate studies.  Dr. 
Boyan allowed me the freedom to participate in business school and programs like 
TI:GER that have helped me develop skills that will be valuable to me in my future 
career.  Very few advisors would allow students this freedom, so for that I am extremely 
thankful.  I would also like to thank my co-advisor Dr. Schwartz, who helped guide me 
through the thesis project.  He has helped me in designing experiments so that the 
techniques applied are consistent and repeatable.  Dr, Schwartz has also pressured me 
to work hard and continuously try to improve the quality of my work. 
I also greatly appreciate the help of my committee in shaping the direction of my 
thesis.  Dr. Andres Garcia has helped me through the thesis work, course work, and the 
qualifier to think more deeply about cell-surface interactions.  Dr. Nael McCarty has also 
been helpful to my thesis and to my understanding of biology.  Dr. McCarty‟s biology 
course was my first graduate level biology and has been critical in helping me adapt to 
research in the Boyan lab.  I would also like to thank Dr. Anthony Norman, whose papers 
and advice have required me to think more broadly about the roles of membrane and 
nuclear vitamin D receptors. 
I would also like to extend my appreciation to my labmates.  Sayeed Safavynia, 
Gary Seeba, John Douly, and Leang Chhung have all been extremely helpful in culturing 
iv 
 
cells throughout my Ph.D.  Sayeed Safavynia, Reyhaan Chaudhri, and Sharon Hyzy 
have been extremely supportive in their roles as lab manager over the past few years.  I 
also have to thank the undergraduate students who have helped me over the past few 
years.  These students include Naghmeh “Naz” Majdi, Michael Chervonski, Malcolm 
Blanchard, and Jonathan Martinez.  Naz and Michael have contributed extensively to the 
KRSR, VDR, and caveolae studies presented herein this thesis.  I would also like to 
thank Dr. Ramsey Kinney who was my labmate and also my „big brother‟ in college.  
Ramsey‟s opinions, though not always asked for, have been valuable in shaping some 
of the thoughts in this thesis.  Dr. Rene Olivares-Navarrete, Dr. Liping Wang, Dr. Yun 
Wang, and Dr. Hai Yao have also been extremely helpful in providing advice on topics 
throughout the thesis.  I also appreciate the support of my fellow graduate students 
including Jennifer Hurst-Kennedy, Brandy Rogers, Ming Zhong, Dr. Tracy Denison, 
Kevin Wong, Jessica Mata, Dr. Alice Zhao, Chris Lee, Jiaxian Chen, Andrew Raines, 
Chris Herman, Maryam Doroudi, Khairat Elbaradie, Jamie Lazin, and Reyhaan 
Chaudhri. 
 I am thankful for my friends and family who have supported me throughout the 
Ph.D. process.  My mother and father have encouraged me when I have struggled with 
experiments and have been accepting when I have had to leave on holidays to go feed 
cells.  My brother and sister have always been encouraging of my graduate studies, but 
have not so secretly wondered if I would ever graduate.  I was also lucky enough to 
meet my fiancé, Ashley Struck, while in graduate school.  When I met Ashley over two 
and a half years ago I told her that I was nearing graduation.  Fortunately, she is an 
incredibly patient and understanding person.  I am so grateful for the love and support of 
Ashley throughout the Ph.D. process.  Finishing would have been difficult without the 
support of Ashley, my friends, and my family. 
v 
 
TABLE OF CONTENTS 
 
ACKNOWLEDGEMENTS ............................................................................................... iii 
LIST OF TABLES .......................................................................................................... vii 
LIST OF FIGURES ....................................................................................................... viii 
SUMMARY ...................................................................................................................... x 
CHAPTER 1:  Introduction .............................................................................................. 1 
1.1. Bone Anatomy and Physiology ........................................................................ 2 
1.2. Total Joint Replacements ................................................................................. 6 
1.3. Host Response to Orthopaedic Biomaterials ...................................................11 
1.4. Osteoblast interactions with surfaces ..............................................................14 
1.5. Regulation of osteoblast differentiation............................................................18 
1.6. Engineering Surfaces for Orthopaedic and Dental Implants ............................21 
1.7. Vitamin D ........................................................................................................26 
1.8. Caveolae .........................................................................................................32 
1.9. Summary and Thesis Objective ......................................................................36 
CHAPTER 2:  General Methodology .............................................................................40 
2.1. Implant Surface Models ..................................................................................40 
2.2. In Vitro Osteoblast Models ..............................................................................44 
2.3. Assessment of Osteoblast Phenotype .............................................................46 
CHAPTER 3:  
The Role of Integrin β1 in Osteoblast Response to Surface Microtopography and 
1α,25(OH)2D3 ................................................................................................................50 
3.1. Introduction .....................................................................................................50 
3.2. Materials and methods ....................................................................................52 
3.3. Results ............................................................................................................56 
3.4. Discussion ......................................................................................................61 
5.5. Conclusion ......................................................................................................64 
CHAPTER 4:  
Role of the α5β1 Integrin in Mediating the Response to Surface Energy and 
Microtopography ............................................................................................................65 
4.1. Introduction .....................................................................................................65 
4.2. Materials and Methods ....................................................................................67 
4.3. Results ............................................................................................................76 






CHAPTER 5:  
Osteoblast Response to Peptide Functionalized Implant Surfaces ................................84 
5.1. Introduction .....................................................................................................84 
5.2 Methods ..........................................................................................................89 
5.3 Results ............................................................................................................95 
5.4. Discussion ......................................................................................................99 
5.5. Conclusions .................................................................................................. 103 
CHAPTER 6:  
VDR Mediates the Osteogenic Effects of 1α,25(OH)2D3 .............................................. 104 
6.1. Introduction ................................................................................................... 104 
6.2. Materials and Methods .................................................................................. 107 
6.3. Results .......................................................................................................... 111 
6.4. Discussion .................................................................................................... 116 
6.5. Conclusions .................................................................................................. 119 
CHAPTER 7:  
Altered Response of Caveolin-1 Deficient Osteoblasts to 1α,25(OH)2D3                        
and Surface Microtopography ...................................................................................... 120 
7.1. Introduction ................................................................................................... 120 
7.2. Materials and Methods .................................................................................. 123 
7.3. Results .......................................................................................................... 126 
7.4. Discussion .................................................................................................... 131 
7.5. Conclusion .................................................................................................... 134 
CHAPTER 8:  Discussion ............................................................................................ 135 
8.1. Cell Response to Surfaces ............................................................................ 135 
8.2. Multifunctional Peptide Coated Implant Surfaces .......................................... 138 
8.3. Vitamin D and Caveolae ............................................................................... 139 
8.4. Future Studies ............................................................................................... 141 
REFERENCES ............................................................................................................ 144 






LIST OF TABLES 
1.1: Relevant properties of materials used in orthopaedic and dental implants ........... 9 
 
5-1: Molecular weight, grafting ratio, peptide functionalization, polymer/protein 
adsorption and peptide surface density for all polymers and peptides used 
in creating ligand functionalized surfaces ........................................................... 91 
 
A-1: Pooled surface data - VDR (+/+) and VDR (-/-) osteoblasts ............................. 166 
 
A-2: Pooled 1α25(OH)2D3 data - VDR (+/+) and VDR (-/-) osteoblasts .................... 166 
 
A-3: Pooled surface data – Cav-1 (+/+) and Cav-1 (-/-) osteoblasts......................... 167 
 






LIST OF FIGURES 
I NTRODUCTION 
1-1: Schematic demonstrating the hierarchical nature of bone .................................... 3 
1-2: Bone remodeling process .................................................................................... 5 
1-3: Model of a total hip implant .................................................................................. 8 
1-4: Major integrin signaling pathways ...................................................................... 17 
1-5: Osteoblast differentiation ................................................................................... 19 
1-6: Methods for modifying implant surface properties .............................................. 21 
1-7: Genomic actions of 1α,25(OH)2D3 ...................................................................... 29 
1-8: Proposed membrane 1α,25(OH)2D3 signaling pathway ...................................... 31 
 
GENERAL METHODOLOGY 
2-1: Morphology of PT, SLA, and TPS titanium surfaces ........................................... 41 
2-2: Comparison of SLA to bone wafers treated with osteoclasts .............................. 42 
 
INTEGRIN β1 
3-1: RT-PCR and qRT-PCR demonstrating a 65% reduction in β1 integrin mRNA .... 56 
3-2: Effect of surface roughness and 1α,25(OH)2D3 on cell number .......................... 57 
3-3: Effect of surface roughness and 1α,25(OH)2D3 on alk. phos. activity ................. 58 
3-4: Effect of surface roughness and 1α,25(OH)2D3 on osteocalcin levels................. 58 
3-5: Effect of surface roughness and 1α,25(OH)2D3 on osteoprotegerin levels .......... 59 
3-6: Effect of surface roughness and 1α,25(OH)2D3 on PGE2 levels ......................... 60 
3-7: Effect of surface roughness and 1α,25(OH)2D3 on TGF-β1 levels ...................... 60 
 
INTGERIN α5 
4-1: qRT-PCR of ITGA5/GapDH expression levels ................................................... 70 
4-2: Two representative western blots for ITGA5 and GapDH ................................... 71 
4-3: Attachment of control MG63 and α5-shRNA clones 52 and 53 ........................... 72 
4-4: Images of control MG63 and α5-shRNA clones on FN-coated surfaces following 
centrifugation at 350g ........................................................................................ 73 
4-5: Flow cytometry of the α5 integrin in control MG63 and α5-shRNA cells ............... 74 
4-6: Alpha integrin expression in control MG63 and α5-shRNA MG63 cells. .............. 75 
4-7: Effect of surface roughness and 1α,25(OH)2D3 on cell number .......................... 77 
4-8: Effect of surface roughness and 1α,25(OH)2D3 on alk. phos. activity ................. 78 
4-9 Effect of surface roughness and 1α,25(OH)2D3 on osteocalcin levels................. 78 
4-10: Effect of surface roughness and 1α,25(OH)2D3 on TGF-β1 levels ...................... 79 
4-11: Effect of surface roughness and 1α,25(OH)2D3 on osteoprotegerin levels .......... 80 
 
MULTIFUNCTIONAL PEPTIDE SURFACES 
5-1: Schematic of peptide-functionalized PLL-g-PEG ................................................ 93 
5-2: Cell number on peptide-functionalized PLL-g-PEG surfaces .............................. 95 
5-3: Alk. phos. activity on peptide-functionalized PLL-g-PEG surfaces ...................... 96 
5-4: Osteocalcin levels on peptide-functionalized PLL-g-PEG surfaces .................... 97 
5-5: Active and latent TGF-β1 on peptide-functionalized PLL-g-PEG surfaces .......... 98 







VDR KNOCKOUT OSTEOBLASTS 
6-1: Pdia3 and VDR gene expression in MG63 cells ............................................... 111 
6-2: Baseline comparison of VDR(+/+) and VDR(-/-) osteoblasts ............................ 112 
6-3: Comparison of cell number in VDR(+/+) and VDR(-/-) osteoblasts ................... 113 
6-4: Comparison of alk. phos. activity in VDR(+/+) and VDR(-/-) osteoblasts .......... 114 
6.5: Comparison of osteocalcin levels in VDR(+/+) and VDR(-/-) osteoblasts ......... 114 
6.6: Comparison of PGE2 levels in VDR(+/+) and VDR(-/-) osteoblasts .................. 115 
6.7: Active and latent TGF-β1 in VDR(+/+) and VDR(-/-) osteoblasts ...................... 116 
 
CAVEOLIN-1 KNOCKOUT OSTEOBLASTS 
7-1: Baseline comparison of Cav-1(+/+) and Cav-1(-/-) osteoblasts ........................ 127 
7-2: Comparison of cell number in Cav-1(+/+) and Cav-1(-/-) osteoblasts ............... 128 
7-3: Comparison of alk. phos. activity in Cav-1(+/+) and Cav-1(-/-) osteoblasts ...... 128 
7-4: Comparison of osteocalcin levels in Cav-1(+/+) and Cav-1(-/-) osteoblasts...... 129 
7-5: Comparison of PGE2 in Cav-1(+/+) and Cav-1(-/-) osteoblasts ........................ 130 
7-6: Active and latent TGF-β1 in Cav-1(+/+) and Cav-1(-/-) osteoblasts .................. 131 
 
APPENDIX 
8-1: Gene Expression in VDR (+/+) and VDR(-/-) Cells – Surfaces #1 .................... 158 
8-2: Gene Expression in VDR (+/+) and VDR(-/-) Cells – Surfaces #2 .................... 159 
8-3: Gene Expression in VDR (+/+) and VDR(-/-) Cells – 1α25(OH)2D3 #1.............. 160 
8-4: Gene Expression in VDR (+/+) and VDR(-/-) Cells – 1α25(OH)2D3 #2.............. 161 
8-5: Gene Expression in Cav-1 (+/+) and Cav-1(-/-) Cells – Surfaces #1 ................ 162 
8-6: Gene Expression in Cav-1 (+/+) and Cav-1(-/-) Cells – Surfaces #2 ................ 163 
8-7: Gene Expression in Cav-1 (+/+) and Cav-1(-/-) Cells – 1α25(OH)2D3 #1 .......... 164 












A comprehensive understanding of the interactions between orthopaedic and 
dental implant surfaces with the surrounding host tissue is essential in the design of 
advanced biomaterials that better promote bone growth and osseointegration of 
implants.  Dental implants with roughened surfaces and high surface energy are well 
known to promote osteoblast differentiation in vitro and promote increased bone-to-
implant contact in vivo.  In addition, increased surface roughness increases osteoblasts 
response to the vitamin D metabolite 1α,25(OH)2D3.  However, the exact mechanisms 
mediating cell response to surface properties and 1α,25(OH)2D3 are still being 
elucidated.  The central aim of the thesis is to investigate whether integrin signaling in 
response to rough surface microtopography enhances osteoblast differentiation and 
responsiveness to 1α,25(OH)2D3.  The hypothesis is that the integrin α5β1 plays a role in 
osteoblast response to surface microtopography and that 1α,25(OH)2D3 acts through 
VDR-independent pathways involving caveolae to synergistically enhance osteoblast 
response to surface roughness and 1α,25(OH)2D3.  To test this hypothesis the objectives 
of the studies performed in this thesis were: 1) to determine if α5β1 signaling is required 
for osteoblast response to surface microstructure; 2) to determine if increased 
responsiveness to 1α,25(OH)2D3 requires the vitamin D receptor, 3) to determine if 
rough titanium surfaces functionalized with the peptides targeting integrins (RGD) and 
transmembrane proteoglycans (KRSR) will enhance both osteoblast proliferation and 
differentiation, and 4) to determine whether caveolae, which are associated with integrin 
and 1α,25(OH)2D3 signaling, are required for enhance osteogenic response to surface 
microstructure and 1α,25(OH)2D3.  
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The results demonstrate that integrins, VDR, and caveolae play important roles 
in mediating osteoblast response to surface properties and 1α,25(OH)2D3.  Silencing of 
the β1 integrin in osteoblast-like MG63 cells significantly reduced osteogenic response to  
surface topography and 1α,25(OH)2D3.  Silencing of the α5 subunit did not alter the 
response of MG63 cells to changing surface roughness or chemistry, although future 
work must confirm these results given similar cell surface α5 integrin expression 
observed in control and α5-silenced cells.  Multifunctional RGD, KRSR, and KSSR 
coated surfaces show that RGD increased osteoblast proliferation and reduced 
differentiation, KRSR had no affect on osteoblast phenotype, and KSSR increased 
osteoblast differentiation.  These results suggest that titanium surfaces can be modified 
to manipulate proliferation and differentiation and that RGD/KSSR functionalized 
surfaces could be further investigated for use as osteointegrative surfaces.  The results 
using VDR deficient osteoblasts demonstrate that 1α,25(OH)2D3 acts via VDR-
dependent mechanisms in cells cultured on titanium surfaces that support terminal 
differentiation.  In caveolae deficient osteoblasts, 1α,25(OH)2D3 affected cell number, 
alkaline phosphatase activity, and TGF-β1 levels, although levels of osteocalcin and 
PGE2 were not affected.  These results are consistent with the hypothesis that VDR is 
required for the actions of 1α,25(OH)2D3, but that caveolae-dependent membrane 
1α,25(OH)2D3 signaling modulates traditional VDR signaling.  The exact mechanisms for 
this interaction remain to be shown.  Overall, these results are important in better 
understanding the role of β1 integrin partners in mediating osteoblast response to 
implant surfaces and in understanding how integrin signaling can alter osteoblast 




CHAPTER 1:  Introduction 
 
Modern orthopaedic implants have been enormously successful in relieving pain 
and restoring basic joint function for hundreds of thousands of patients each year; 
however, increased patient lifetime and activity levels are creating demand for advances 
in device performance.  Orthopaedic implant design has traditionally relied on advances 
in materials engineering and manufacturing processes to make biomaterials more 
biocompatible and less susceptible to fatigue and wear [1-3].  Approaches inspired by 
the underlying biology and biological response to implants have the potential to create 
biomaterials that actively direct host cell and tissue response to form a strong bone-
implant interface [4, 5].  A comprehensive understanding of the mechanisms guiding 
interactions between the implant surface, attached osteoblasts, and the surrounding host 
tissue will allow engineers to design surfaces that better promote bone growth and 
osseointegration of the implant.  Moreover, an increased understanding of the 
mechanisms regulating bone turnover and the response of osteoblasts to hormones, 
growth factors, or other biologics could lead to combination therapies that aid in 
osseointegration of implants. 
The present set of studies presented herein this thesis are aimed at 1) gaining a 
better understanding of mechanisms underlying osteoblast response to implant surface 
topography and chemistry, 2) determining whether specific ligands can actively recruit 
osteoblasts and promote an osteogenic phenotype, and 3) exploring the mechanisms 
through which the vitamin D metabolite 1α,25(OH)2D3 can act to enhance the response 
of osteoblasts to surface energy and chemistry.  The following sections in this chapter 
will explore the relevant general background material that serves as a basis for the aims 
of this thesis.  These topics include bone anatomy and physiology, osteoblast biology, 
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and host response to biomaterials.  There will also be discussion of current orthopaedic 
implant technology and advanced surface engineering techniques that can be used to 
improve upon current designs.  Next, there will be discussion of vitamin D physiology, 
1α,25(OH2)D3 signaling mechanisms, and the effects of 1α,25(OH2)D3 on 
osteointegration of implants.  Finally, this chapter will conclude with a summary of the 
objectives of this thesis with regard to the highlighted clinical and scientific needs. 
 
1.1. Bone Anatomy and Physiology 
Bone is a dynamic tissue that provides critical structural, metabolic, and 
physiological functions for the body.  Bone is the most rigid and strongest material in the 
body.  It has yield strength between 90-140 MPa, comparable to some metals, yet its 
density is only 1.6 g/cm3, making it an extraordinarily efficient structure [6, 7].  More 
importantly, bone constantly undergoes remodeling, a process that both repairs bone 
and helps it adapt to changing stress conditions.  No artificial material has such 
resilience to decades of fatigue loading.  Bone protects vital internal organs and the long 
bones house bone marrow, which is the source of haematopoiesis.  Bones provide the 
shape and structure through which muscles are able to transmit force to create 
movement.  Bone also serves as a reservoir for calcium and phosphorus, which can be 
released through bone resorption to help maintain overall mineral ion homeostasis. 
Bone is a highly organized nanocomposite material made up primarily of collagen 
I, carbonate-substituted hydroxyapatite [Ca10(PO4)6OH2], water, and cells [8].  The 
hierarchical organization of bone makes it strong, tough, and lightweight, and provides a 
structure through which cells can maintain and remodel bone.  The hierarchical nature of 
bone is shown in Figure 1-1 on the following page [9].  At the macroscopic level, bones 
are composed of either cortical or cancellous bone.  Cortical bone is highly compact and 
composes the outer layer of all bones as well as the diaphysis of long bones [8].  
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Cortical bone makes up more than 80% of total bone mass and gives bone much of its 
resistance to bending, compressive, and torsional forces [6, 8].  Cancellous, or 
trabecular bone, is composed of a porous network of bone spicules that align along 
directions of stress in the metaphyses and epiphyses of long bones or in the interior of 
vertebrae.  Trabecular bone is roughly four times less dense than cortical bone and 
undergoes much more turnover due to its high surface area.  Because of this difference 
in turnover, trabecular bone is more susceptible than cortical bone to bone mass loss 
caused by osteoporosis [10].   
 
Figure 1-1:  Schematic demonstrating the hierarchical nature of bone from the 
macroscale to the nanoscale [9]. 
 
In immature bone, such as found in early development or in a fracture callous, 
collagen fibers are randomly oriented to form what is called woven bone.  In mature 
bone, such as found in both cortical or trabecular bone, collagen fibers align to form into 
3-7 µm thick lamellae of uniform orientation [9].  Cortical bone is highly dense and the 
lamellae are very organized.  Osteons are the major functional unit of cortical bone and 
are usually aligned along the length of long bones.  Osteons are up to 500 µm in 
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diameter and contain multiple lamellae wrapped in layers around central a Haversian 
canal [6].  The alignment of fibers in adjacent lamellae is slightly offset; likely providing 
increased strength in torsion.  The Haversian canal contains blood vessels or nerves 
that support osteocytes embedded within the osteons.  These cells are critical in 
maintaining mature bone and providing sensory information to surrounding cells.   
At the molecular level, bone is composed primarily of collagen I and 
hydroxyapatite, although a number of bone specific proteins are involved in bone matrix 
organization and the nucleation of hydroxyapatite crystals [6, 9].  Hydroxyapatite crystals 
form in nanoscale sheets within specific spaces of the collagen fibrils.  This 
nanocrystalline organization increases strength and toughness and reduces the potential 
for crack propagation.  The collagen fibrils and the c-axis (strongest axis) of the 
hydroxyapatite crystals both align along the direction of maximum stress.  These 
collagen fibrils are arranged in to the larger fibers that make up woven and lamellar 
bone.  Overall, the complex organization of bone at different length scales makes it an 
extremely efficient structure and also gives bone its ability to detect and continuously 
repair microdamage without compromising its overall structural integrity.   
 
Bone Remodeling 
Bone turnover is a highly regulated process that enables bone to regenerate 
itself, adapt to changing stress environments, and mobilize calcium to meet metabolic 
needs [6].  This process is described below and shown in Figure 1-2.  Old or damaged 
bone is resorbed by osteoclasts via a process called bone resorption.  Osteoclasts are 
large multinucleated cells of hematopoietic lineage derived from the fusion of monocytes 
and macrophages.  Osteoclasts are activated and recruited to sites of microfracture by 
factors such as macrophage colony stimulating factor (M-CSF) and receptor activator of 
nuclear factor κβ ligand (RANKL) [11].  Active osteoclasts can be identified be their 
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ruffled cell borders, which seal and degrade the underlying bone in the resorption pit.  
Osteoclasts resorb bone through the release of hydrogen ions, matrix metalloproteases, 
and multiple hydrolytic enzymes.   
 
Figure 1-2:  Bone remodeling process [6, 8].  Old bone is resorbed by osteoclasts.  New 
bone is formed by osteoblasts, which eventually terminally differentiate into osteocytes. 
 
New bone is formed by osteoblasts, which are cells of mesenchymal lineage 
derived from osteoprogenitor cells located in the periosteum or bone marrow.  
Osteoprogenitors differentiate into osteoblasts, a process that will be discussed 
extensively in section 1.5.  Osteoblasts form new bone matrix, called osteoid, which is 
later mineralized as osteoblasts mature.  As osteoblasts become surrounded by 
mineralized matrix, they become osteocytes.  Osteocytes are terminally differentiated 
cells that are important in maintenance of deposited bone, mechanosensation, and 
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calcium homeostasis.  Osteocytes rest in fluid-filled spaces called lacuna and 
communicate with surrounding cells via extensions called canniculae.  Eventually, bone 
suffers microdamage and osteocytes undergo apoptosis, upon which time osteoclasts 
are recruited and the renewal of bone continues.  
 
1.2. Total Joint Replacements 
Total joint replacement has been an invaluable tool for relieving joint pain and 
restoring basic function for hundreds of thousands of patients each year suffering from 
traumatic injuries or from debilitating diseases such as late stage osteoarthritis, 
rheumatoid arthritis, or avascular necrosis [10].  Osteoarthritis is a painful degenerative 
disease in which the articular cartilage and subchondral bone are progressively 
damaged and worn, eventually necessitating surgical intervention.  Osteoarthritis affects 
more than 60% of people over the age of 65 and is the primary cause of more than 39 
million physician visits in the U.S. each year [12, 13].  Osteoarthritis is typically treated 
with non-steroidal anti-inflammatory drugs (NSAIDs), changes in diet and exercise, 
corticosteroids, arthroscopic surgery, and in severe cases total joint replacement [14].  
Osteoarthritis accounts for half of NSAID prescriptions [12] and roughly 90% of the 
285,000 hip implants and 523,000 knee implants each year in the U.S (2005 data) [13, 
15].  Aging population trends, increasing obesity rates, and the treatment of younger 
patients is projected to increase the number of hip implants and knee implants in the 
U.S. per year to 572,000 and 3,480,000, respectively, by 2030 [15, 16].  Moreover, 
patients today expect implants to last their lifetime and to restore an active lifestyle.  
Such changing demographics and performance requirements are putting tremendous 
pressure on implant manufactures to deliver more innovative implant designs. 
Current orthopaedic implant design is being driven by increased demand for 
longer lasting implants, for minimally invasive surgery, and for use in younger, more 
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active patients.  Orthopaedic implants currently have an expected lifetime of more than 
15 years in 85-90% of patients [7].  Such survival rates are a testament to the success of 
advances in biomaterials, implant design and manufacturing, and surgical techniques; 
however, increased life expectancies, lifestyle changes, and treatment of younger 
patients means many more patients will require revision surgeries over their lifetime [15].  
Revision surgeries are difficult, expensive, dangerous to the patient, and statistically are 
less successful than primary surgeries [7].  Young patients present a unique problem 
because the increased activity puts more stress and wear on the implant.  Even recent 
studies using advanced ceramic bearing surfaces have only shown 15-year implant 
survival rates of only 72% in patients fewer than 30 years old [17].  In addition, there is 
increasing pressure to treat more patients with osteoporosis or other comorbidities that 
affect bone ingrowth around an implant [3].  Such problems require technological 
improvements that further improve osteointegration and reduce long-term wear.   
 
Implant Technology:  A Focus on the Hip Implant 
The total hip implant provides an illustrative example of the challenges facing 
engineers in designing better implants.  A hip implant must be engineered to carry loads 
in excess of 1400 pounds, to survive years of fatigue loading, to be highly resistant to 
wear and corrosion, to be highly biocompatible, and to establish good long-term fixation 
with the host bone [1-3, 18].  The design of the modern hip implant still resembles the 
original design of Charnley from the 1960‟s, although the underlying materials have 
advanced [18].  A modern hip implant, shown in Figure 1-3, consists of three major 
components: the acetabular cup, the femoral head, and the femoral neck and stem.  The 
femoral head and the acetabular cup of the implant replace the ball and socket portion of 
the natural hip joint.  The metallic back of the acetabular cup is fixated to the pelvis, 
while the femoral component is fixated into the femur.  The metallic components of 
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modern implants are usually made of fatigue resistant alloys of titanium (Ti-6Al-4V) or 
cobalt-chromium (CoCr).  The acetabular cup has traditionally contained a plastic insert 
made of ultrahigh molecular weight polyethylene (UHMWPE); although companies have 
begun to market metal-on-metal and ceramic-ceramic wear systems.  Wear rates for 
UHMWPE systems are generally about 0.1mm per year compared to 0.01mm per year 
or less for metal-on-metal (CoCr) or ceramic-on-ceramic (zirconia or alumina based) 
systems [18]; however, long-term clinical data has not yet proven which systems yield 
the highest long-term survival rates.  While improved wear surfaces are certainly crucial 
to improving implant performance, the present thesis is focused more on the potential for 
improvements in bone-bonding surfaces and the osteointegration of titanium implants.   
 
Figure 1-3: Model of a hip implant.  Modified from the Medical Multimedia Group [19]. 
Titanium in Orthopaedic and Dental Implant Design 
Titanium and its alloys are frequently used in orthopaedic and dental implants 














ease of processing [20].  Titanium atoms can be arranged in two different phases: the 
hexagonal close packed (hcp) α phase or the body centered cubic β phase.  Pure 
titanium is stable in the α phase at room temperature.  The Ti-6Al-4V alloy is an α+β 
alloy where the aluminum atoms stabilize the α phase and the vanadium atoms stabilize 
the β phase.  All alloys of titanium form a thin, passivating layer of oxide (primarily TiO2) 
that is responsible for its resistance to corrosion and its good biocompatibility.   
The most common metals used in orthopaedic implants are cpTi, Ti-6Al-4V, and 
CoCr [20].  Commercially pure titanium is used predominantly in dental implants since 
wear is not an issue.  The properties and characteristics of these metals and other 
materials used in implants are shown below in Table 1 [1, 7].  Clear tradeoffs exist in the 
use of cpTi, Ti-6Al-4V, and CoCr for different components in implant design. Ti-6Al-4V is  
Table 1: Relevant properties of materials used in orthopaedic and dental implants. 
 
generally preferred over cpTi in high load bearing applications because it has higher 
strength, wear resistance, and fatigue resistance; however, cpTi has superior 
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vanadium ions.   Both forms of titanium are more biocompatible than either CoCr or 
stainless steel.  Unfortunately, the relatively soft surface layer of titanium makes it 
susceptible to fretting corrosion and corrosion cracking under heavy wear.  Because of 
problems with fretting wear of titanium, CoCr alloys are frequently used as a wear 
component of orthopaedic implants.  CoCr alloys have excellent wear properties, 
corrosion resistance, and fatigue resistance, but they are less biocompatible than 
titanium alloys.  CoCr alloys also have a higher elastic modulus than titanium, which can 
increase the risk of osteolysis and fracture due to stress shielding of bone surrounding 
the implant.  Furthermore, many have or develop hypersensitivity to Co, Cr, or Ni [21].  
The release of such metal ions and particles can cause metallosis, inflammation, and 
peri-implant osteolysis.   For these reasons, titanium is the most preferred material for 
the components of implants that interface directly with bone and depend on 
osteointegration for function. 
 
Long-term Failure of Orthopaedic Implants 
 Early problems with implants, such as infection and breakage, are largely 
avoided today because of improved surgical techniques, improved implant designs, 
more stringent manufacturing standards, and the use of strong alloys.  Long-term failure 
of implants is most often attributed to implant loosening, which can cause severe pain, 
loss of joint function, and necessitate revision surgery [1].  Roughly 30-40% of hip 
implant patients show radiographic signs of femoral loosening by 10 years [22].  More 
than 10% of patients with orthopaedic implants will require a revision surgery within 15 
years of their primary surgery [23].  The cascade of events leading to implant loosening 
is complex, although most these problems can be traced to two root causes: 1) bone 
resorption (osteolysis) due to cellular response to wear particles generated from the 
articulating surfaces, and 2) osteolysis due to poor long-term biocompatibility and/or loss 
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of fixation at the bone-biomaterial interface.  These problems are inherently due to the 
materials selected for implantation and suboptimal engineering of the surfaces 
interfacing with the biological environment [23].  The development of a stable bone-
material interface that promotes long-term fixation is essential to reducing implant 
loosening and extending implant lifetime.   
 
1.3. Host Response to Orthopaedic Biomaterials 
The interaction of a biomaterial with the biological environment is dependent on 
the composition and topography of the surface, the chemical nature of adsorbed 
proteins, and the physiological response of local host tissue [1].  This complex and 
dynamic process begins even before a device is implanted into the body. Metallic 
surfaces made of titanium or cobalt-chrome alloys quickly form an oxide layer after 
exposure to air.  In addition, organic and inorganic particles from the air rapidly adsorb to 
the surface.  This layer usually increases the material‟s hydrophobicity, changing the 
surface proteins and affecting protein adsorption [24].  Once a biomaterial is implanted, 
a protein monolayer adsorbs to the surface within a fraction of a second.  Most proteins 
are amphiphilic and only partially soluble in an aqueous environment.  Entropic forces 
drive adsorption of proteins to the surface in an effort to minimize energy [25].  The 
process of adsorption causes the proteins to partially unfold.  The conformation a protein 
exhibits on a surface depends on the protein‟s primary amino acid sequence, which 
determines the secondary and tertiary structures through non-covalent binding; however, 
final structure of a protein is sensitive to the surrounding aqueous environment, the local 
pH, temperature, time of adsorption, and the interaction with nearby surfaces or other 
proteins, lipids, and ions.   Moreover, the conformation, unfolding rate, and the degree of 
biological functionality of proteins vary by surface and depend on protein size, shape, 
and binding affinity for the surface.  The first proteins to bind are those in high 
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concentration and those that diffuse quickly to the surface.  Over time, the surface 
evolves as large, high affinity proteins replace proteins with less affinity according in a 
process called the Vroman effect.  Serum proteins such as fibrinogen, albumin, 
vitronectin, fibronectin, and various immunoglobulins are among first proteins to attach 
and are crucial in initiating early clotting and inflammatory responses [26]. 
 
Peri-implant Healing Process 
The first host response in peri-implant healing is the formation of a blood clot, or 
haematoma at the implant site [27, 28].  Thus, the first cells to come in contact with the 
implant are not predominantly osteoprogenitor cells, but are platelets, erythrocytes, 
neutrophils, leukocytes, and other cells present in the blood.  The clot typically lasts a 
few days and is accompanied by acute inflammation of the injured tissue.  Neutrophils 
are present at the injury site for the first few days.  These first responders are largely 
responsible for identifying and destroying invading pathogens.  Neutrophils are 
subsequently replaced by cells characteristic of chronic inflammation including 
monocytes, macrophages, and lymphocytes.  These leukocytes fight infection, degrade 
damaged tissue, and control the healing response based on the release of various 
mitogens and cytokines.   The formation of granulation tissue occurs within a few days of 
implantation and can last for several weeks.  Granulation tissue is highly vascular and 
contains a high concentration of macrophages, leukocytes, and fibroblasts.  Growth 
factors such as platelet derived growth factor (PDGF) and transforming growth factor β1 
(TGF-β1) are important mitogens for recruiting fibroblasts, which produce the provisional 
extracellular matrix in granulation tissue.  Angiogenic factors like vascular endothelial 
growth factor (VEGF) and fibroblast growth factor 2 (FGF2) initiate new blood vessel 
formation necessary for wound healing and the formation of bone.   
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In materials with poor biocompatibility, undesired host response can lead toward 
foreign body reaction and fibrosis of the implant.  Foreign body reaction is characterized 
by chronic inflammation and the appearance of foreign body giant cells, which are large, 
multinucleated cells created by the fusion of macrophages for the purpose of 
surrounding and degrading the implanted biomaterial.  Persistent foreign body reaction 
ultimately leads to fibrous encapsulation of the implant.  Fibrosis occurs when the body 
forms a dense layer of fibroconnective tissue around the implant.  Unfortunately, the 
strength of the bond between this scar tissue and the implant is not strong.  The clinical 
result of a fibrous response is implant loosening, likely necessitating surgical revision. 
Ideally, direct bone apposition, or osteointegration, occurs at bone-implant 
interface and creates lasting long-term fixation.  In peri-implant healing, osteoprogenitor 
cells are primarily derived from the marrow because of the presence of newly 
vascularized granulation tissue [27].  Osteoprogenitors may be recruited to the surface 
by growth factors such as PDGF, FGF-2, or bone morphogenic proteins released by 
cells at the implant surface [27, 29].  The formation of bone requires recruitment and 
proliferation of osteoprogenitor cells as well as differentiation of these cells into mature 
osteoblasts.  Mature osteoblasts secrete osteoid and mineralize it to form newly woven 
bone similar to new bone seen in fracture healing.  Osteointegration occurs through the 
osteoconduction of these cells along the surface and through appositional bone growth 
[27].  Remodeling occurs continuously over the subsequent weeks and months to further 
strengthen the implant-bone interface.  The level of bone-to-implant contact, a 
histological measure of osteointegration, is strongly affected by implant surface 
chemistry and topography [30, 31].  The following sections will discuss the direct 
interactions of osteoblasts with implant surfaces, how surface engineering can enhance 




1.4. Osteoblast Interactions with Surfaces 
Osteoblast proliferation, morphology, and phenotypic expression, along with 
intercellular signaling and recruitment, are indirectly affected by implant surface 
properties via the adsorbed protein layer [24].  As discussed in the previous section, 
surface properties affect biological response by controlling not only which proteins 
adsorb to the surfaces, but how these proteins are presented to cells.  
 
Integrins 
Cells interact with the extracellular matrix via receptors called integrins [32].  
Integrins are heterodimeric glycoproteins consisting of a pair of α and β membrane-
spanning subunits.  There are currently known to be 18 different α subunits and 8 
different β subunits that can be assembled into at least 24 different αβ dimer 
combinations [33], each of which may have unique binding specificity and sets of 
downstream signaling events.  This vast array of combinations means that different 
tissues generally express different sets of integrins.  For instance, osteoblasts have 
been shown to express the integrins α1β1, α2β1 α3β1, α4β1, α5β1 α6β1, α8β1, αVβ3, αVβ5, 
[34], although reports in the literature vary on the relative expression levels of these 
integrins in bone cells [35-38].  Expression of integrins can also vary according to the 
composition of the surrounding ECM and to the state of maturation of the cell.  In 
addition, standard tissue culture on tissue culture polystyrene surfaces and the culture of 
cells on surfaces of varying chemistry and topography can alter integrin expression [38, 
39].  For instance, increasing the roughness of titanium surfaces leads to higher 
expression of α2β1 and lower expression of α5β1 [40].  These results correlate with higher 
levels of osteocalcin, an indicator of osteoblastic differentiation.  Moreover, α2β1 has 
been shown to regulate differentiation of MG63 cells in response to increasing surface 
roughness [41].  These results together suggest that integrins can affect cell 
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differentiation, and vice versa, that cell differentiation can affect integrin expression or 
activity. 
Integrins bind to specific recognition sequences in proteins, such as the RGD 
(arginine, glycine, aspartic acid) binding domain of fibronectin or the GFOGER (glycine- 
phenylalanine-hydroxyproline-glycine-glutamine-arginine) binding domain of collagen I; 
although binding site accessibility and binding affinity are most certainly affected by 
secondary and tertiary protein structure [42].  Many integrins also require secondary 
binding of „synergy sites‟ to initiate maximum signaling effectiveness [43].  Binding of 
individual integrins to the ECM is relatively weak, but ligand binding initiates clustering of 
multiple integrins to form a larger signaling complex.  The cytoplasmic tails of clustered 
integrins bind to a multitude of adapter proteins that can connect integrins to the 
cytoskeleton, protein kinases and lipases, various growth factor receptors, and even 
caveolin-1 [44].  Clusters of integrins further arrange into larger focal adhesion 
complexes that are critical to cell attachment.  Focal adhesions are points of attachment 
between the cell and the substrate that are often located at the end of cell extensions 
called filopodia.  Such complexes maximize the cell-substrate binding strength.  
Furthermore, these complexes act as signaling nexuses that allow interaction between 
integrins, growth factor receptors, caveolae, and many other signaling pathways [44].   
 
Integrin Signaling 
Integrin signaling can activate a variety of different pathways to affect cell 
motility, survival, cytoskeletal organization, cell cycle progression, growth factor 
signaling, and cell differentiation [44].  Signaling is mediated by numerous adapter 
proteins and protein kinases as described in the text below and in Figure 1-4.  Proteins 
such as focal adhesion kinase (FAK), integrin linked kinase (ILK), src-family kinases, 
talin, vinculin, α-actinin, and paxillin are important in early integrin signaling and the 
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formation of the focal adhesion complex [44, 45].  In addition, these factors promote 
actin polymerization and the formation of stress fibers.  Cytoskeletal rearrangement and 
change in cell shape can be spatially controlled by integrins via Rac, Rho, and cdc42 
dependent mechanisms [44].  Binding of some integrins promotes cell survival through 
phosphorylation of phosphoinositol-3-kinase (PI3K) and Akt and the inhibition of pro-
apoptotic proteins such as Bcl-2 associated death protein (BAD) or caspase-9 [44, 46].   
In osteoblasts, binding of the α5β1 integrin to fibronectin increases activity of PI3K, Akt, 
and Bcl-2, which in turn reduces caspase activity and promotes cell survival [47, 48].  
Integrin signaling can also directly affect cell cycle progression to promote proliferation of 
cells.  In osteoblasts, the α5β1 integrin has been shown to act through JNK and MAP 
kinase-mediated pathways to phosphorylate c-Jun and c-Fos, which form the activator 
protein 1 (AP-1) heterodimer, a transcription factor complex that promotes cell 
proliferation and also induces expression of several osteogenic target genes [44, 49].  
Integrins signaling can also directly target pathways that affect cell differentiation.  
Several integrins can act through protein kinase C (PKC) and extracellular related 
kinases 1 and 2 (ERK1/2) mediated pathways, which have been shown to increase 
RunX2 transcriptional activity and increase osteoblastic differentiation [44, 50].  
Interestingly, many membrane associated receptors, including the membrane 
1,25(OH)2D3 receptor Pdia3, also use JNK-mediated or ERK 1/2-mediated signaling 
pathways to affect cell proliferation and differentiation [44, 51].  The existence of such 
overlapping systems means that integrin signaling can modulate growth factor signaling, 
or vice versa, at many points in this pathway [52].  Integrin binding can directly increase 
growth factor receptor activity through conformational changes, or it can increase activity 
of Raf, MEK, and ERK 1/2 via phosphorylation by p21-activated kinase (PAK) or PKC.  
In fact, signaling of many growth factors is anchorage dependent, meaning that integrin 
binding is required for activation of growth factor signaling pathways.  Treatment of 
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attached cells with various growth factors leads to sustained activation of FAK or ERK 
1/2; however, treatment of suspended cells results in only transient and weak activation 
of ERK 1/2 [52, 53].  Conversely, growth factors are often required to sustain ERK 1/2 
activation by integrins.  Thus, integrins, growth factors, and steroid hormones often act 
synergistically to enhance signals essential for regulating osteoblast phenotype. 
 
Figure 1-4: Major integrin signaling pathways affecting cell motility, survival, cytoskeletal 














































1.5. Regulation of Osteoblast Differentiation 
Osteoblast differentiation is a highly complex process that is regulated by 
extracellular matrix cues, growth factors, hormones, and mechanical forces.  Runx2, a 
protein in the Runt-related family of transcription factors, is a master regulator of 
osteoblast function [54].  Runx2 appears in early osteochondral progenitor cells, well 
before the appearance of osteocalcin or other osteoblastic genes.  Target genes of 
Runx2 include many bone proteins including osteocalcin, osteopontin, osterix, and bone 
sialoprotein [55].  Expression of Runx2 in non-bone cells is sufficient to induce 
production of bone specific proteins and to induce mineralization in some cell types; 
however, optimal mineralized bone matrix formation requires coordination with multiple 
other bone proteins [56, 57].  Because of the strong actions of Runx2, its expression 
levels and transcriptional activity are kept under tight control by various inhibitors or 
cofactors at different points in osteoblastic maturation.  Immature osteoblasts produce a 
number of RunX2 inhibitors including TWIST1, Stat1, and Schnurri 3 [54].  Some 
inhibitors ensure proper closure of craniofacial joints by delaying osteoblastic 
differentiation, while others, potentially Schnurri 3, may be important in regulating adult 
bone mass [54, 58].  Osteoblast differentiation occurs in several distinct stages and is 
described briefly in the text below and in Figure 1-5 on the following page.   
Commitment of mesenchymal stem cells into osteoprogenitor cells requires 
upregulation of the transcription factors Runx2 and Msx2, and downregulation of 
transcription factors for adipocyte, myoblast, or chondrocyte commitment.  
Osteoprogenitor cells have a high proliferative potential, which is important for achieving 
sufficient osteoblast population at a fracture site.  The transition of osteoprogenitors to 
mature osteoblasts requires expression of osterix, a transcription factor upregulated 
strongly by BMPs, but also by Runx2 [54, 59].  Osterix is required for activation of many 
Runx2 target genes.  Early markers for osteoblast differentiation include alkaline 
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phosphatase, bone sialoprotein, and collagen 1.  Osteocalcin is a late marker for 
differentiation and is produced at an increasing rate leading up to mineralization.  
Osteoblasts also have diminishing proliferative potential as they mature.  Mature 
osteoblasts express the transcription factor activating transcription factor 4 (ATF-4), 
which is important in late stage differentiation of osteoblasts.  Osteoblasts terminally 
differentiate into osteocytes and bone-lining cells; however, 60-80% of the osteoblasts 
originally present in the resorption pit cannot be found, and presumably have undergone 
apoptosis [60].  Osteocytes are largely responsible for mechanical sensation and the 
maintenance of formed bone.  Osteocytes are post-mitotic and can undergo apoptosis in 
the absence of mechanical loading or in the presence of microdamage.  It is likely that 
osteocyte apoptosis and the various signaling molecules released concomitantly are 
essential in alerting surrounding cells to begin the bone remodeling process again.  
 













































The Effect of Growth Factors on Osteoblast Differentiation 
 Osteoblast phenotype can be modulated by numerous growth factors that are 
able to either promote or inhibit differentiation at different stages of osteoblast maturity.  
Osteoblast differentiation can be modulated through autocrine, paracrine, or endocrine 
signaling.  Both canonical and non-canonical WNT/β-catenin signaling pathways are 
critical to bone development and regulation of osteoblast phenotype, particularly at early 
stages of differentiation [61].  Moreover, cell interaction with implant surfaces involves 
Wnt signaling.  Mesenchymal stem cells grown on SLA and modSLA surfaces have 
increased levels of WNT5a, a powerful promoter of osteogenic commitment and 
differentiation via non-canonical signaling [62].  Members of the TGF-β superfamily, 
including TGF-β1 and BMPs, can also have potent effects on osteoblasts.  BMP-2, BMP-
4, and BMP-7 strongly promote osteoblastogenesis and osteogenic differentiation [63].  
Other BMPs can either promote or inhibit osteogenesis.  BMPs act through smads that 
can complex to Runx2 or other transcription factors to target osteogenic genes such as 
Dlx5 or osterix [64].  BMPs can also act through ERK 1/2 or JNK dependent pathways, 
which can lead to crosstalk between BMP and integrin signaling.  In fact, activation of 
BMP-2 signaling requires integrin mediated activation of FAK [65].  BMPs also can affect 
osteoblast interaction with implant surfaces.  BMP-2 treatment has been shown to alter 
α5β1 integrin localization and increase FAK expression on osteoblasts grown on Ti-6Al-
4V surfaces [66].  Moreover, rough cpTi surfaces enhance BMP-2 expression in 
macrophages, perhaps indicating an important role of surface roughness induced BMP 
expression in the recruitment of osteoprogenitor cells [67].  Osteoblast differentiation is 
also affected by the actions of endocrine signals such as parathyroid hormone (PTH) 
and 1α,25(OH)2D3, which will be extensively discussed in section 1.7.  In summary, 
osteoblast differentiation is tightly regulated by a complex interplay between integrin, 
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growth factor, and endocrine signaling pathways that ensures proper spatial and 
temporal control of the bone formation processes. 
 
1.6. Engineering Surfaces for Orthopaedic and Dental Implants 
Orthopaedic and dental implant designers have been chemically and 
mechanically modifying the surfaces of implants for several decades now in an effort to 
improve osteointegration of implants.  Commonly used techniques for surface 
modification include chemical treatment (etching), surface roughening, surface coating, 
thin-film deposition, and biological modification through the use of protein adsorption or 
and self assembled monolayers (SAMs) [1, 5].  These techniques will be briefly reviewed 
in the text below and are summarized in Figure 1-6. 
 
Figure 1-6:  Commonly used methods for modifying implant surface properties. 
 
Surface Topography 
Clinical experience and research studies over the past few decades have 
demonstrated that roughening of the bone-bonding components of titanium implants 
increases osteointegration and long-term fixation [31, 68, 69].  In vivo studies have 
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shown that titanium implants with rough surfaces have higher pullout strengths and 
higher bone-to-implant contact area than implants with smooth surfaces [31, 68].  This 
improvement in performance is due in part to increased mechanical interlock, but it is 
also due to the direct effects of microtopography on osteoblast phenotype.  In vitro 
studies have shown that titanium surfaces with rough microtopographies enhance 
phenotypic maturation of osteoblasts, as indicated by increased production of local 
regulatory factors such as prostaglandin E2 (PGE2), TGF-β1, and osteoprotegerin [70].  
Osteoblast cultured on rough surfaces also exhibit a cuboidal morphology indicative of 
osteoblastic differentiation, whereas osteoblasts cultured on smooth surfaces exhibit a 
flattened, more fibroblastic phenotype [71].  In addition, rough surfaces enhance the 
response to 1α,25(OH)2D3 in a synergistic way.  The mechanisms controlling the 
response of osteoblasts to surface roughness are not fully elucidated; however it is likely 
that integrins mediate these effects in conjunction with the actions of autocrine and 
paracrine signals. This topic will be discussed in Chapters 3 and 4. 
Surface roughening can be created using a variety of techniques, each of which 
yields differing micro- and nanoscale features.  Methods commonly used include 
titanium plasma spraying or grit blasting, which produce microscale features, and acid-
etching or anodization, which produce nanoscale features [68].  Details regarding the 
production and characterization of the titanium discs used in this thesis are discussed in 
Chapter 2.  Efforts have been made to unravel the response of osteoblasts to 
topographical features of specific sizes [72-74].  Interestingly, upregulation of PGE2, 
active TGF-β1, and osteocalcin required the presence of both micro- and nanoscale 
topographical features created through photolithography and acid-etching, respectively 
[72].  The sand-blasted, acid etched (SLA) surfaces used throughout this thesis have 
such micro- and nano-scale features, and have been shown to increase osteoblast 
differentiation versus smooth surfaces.  Interestingly, the SLA topography visually 
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mimics native osteoclast resorption pits (see Figure 2-1), although the exact 
mechanisms of osteoblast response to implant surface topography are being unraveled.   
 
Surface Chemistry and Surface Energy 
 Modification of the surface chemistry and surface energy of titanium substrates 
has been shown to have profound effects on osteoblast proliferation and differentiation.  
Engineers have long looked at the hydrophobicity of a surface and its effect on the 
protein adsorption, protein conformation, cell attachment, and cell phenotype [1].  In 
general, hydrophobic surfaces, or low energy surfaces, bind proteins strongly, causing 
them to unfold and perhaps denature.  Hydrophilic surfaces, or high energy surfaces, 
affect protein folding to a lesser degree, which may yield more biologically active 
conformations of adsorbed proteins.  Bone formation and osteoblast response is 
enhanced on hydrophilic versus hydrophobic implant surfaces [75, 76]. However, cell 
response to surfaces is not simply a function of hydrophobicity.  It is related to chemical 
nature of molecules exposed at the surface.  For instance, osteoblasts grown on SAM-
surfaces terminated with hydroxyl and amine groups have increased levels of alkaline 
phosphatase, BSP, and osteocalcin and increased mineralization versus osteoblasts 
grown on surfaces terminated with methyl or carboxyl groups [77].  These differences in 
surface chemistry affect fibronectin adsorption and conformation, which directly leads to 
changes in integrin binding and osteoblast response [78].  The titanium oxide layer of 
pure titanium is composed primarily of TiO2, but also has free –OH and –O
2- groups that 
can interact with water molecules to make the surface very hydrophilic.  However, such 
high energy surfaces can rapidly adsorb hydrocarbons and other contaminants from the 
atmosphere to make the surface very hydrophobic.  Immersion of freshly etched titanium 
into an isotonic solution can maintain hydrophilic properties.  Dental implants made with 
hydrophilic modified SLA (modSLA or SLActiveTM) surfaces have been shown to 
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enhance osteoblastic differentiation in vitro and increase bone-to-implant contact in vivo 
compared to standard SLA surfaces [76, 79]. 
 
Surfaces Coatings and Thin Films 
Coatings have been an attractive option for biomaterials design because of the 
opportunity to use bioactive surfaces without compromising the mechanical properties of 
the underlying bulk material.  Plasma sprayed coatings of hydroxyapatite (HA) and other 
calcium phosphates are highly osteoconductive and have been shown to promote the 
closure of large (~1mm) bone gaps [80].  Unfortunately, concerns with the use of HA 
coatings have limited their clinical use.  These problems include 1) rapid dissolution of 
HA and breakdown of the bone-implant interface, 2) mechanical failure of the coating-
substrate interface, and 3) the release of wear-inducing particles.  Despite these 
perceived problems, modern HA-coated implants have statistically comparable long-term 
survival rates to uncoated titanium implants [68, 81].   
 
Biologically Modified Surfaces 
 Many researchers believe that the next generation of orthopaedic and dental 
implants will be biologically modified to elicit controlled cell response at the tissue-
implant interface [5].  Surfaces functionalized with specific proteins or peptides can aid 
osteointegration of implants by favoring adherence of osteoprogenitor cells and 
subsequently promoting osteoblastic differentiation.  For instance, titanium surfaces 
coated with fibronectin or collagen I enhance osteoblast attachment, proliferation, and 
differentiation [36, 82, 83].  However, reports are mixed on whether adsorbed fibronectin 
and collagen I affect bone formation in vivo [83-85].  Passive adsorption results in 
random protein conformations, which can reduce biological activity of the coating and 
possibly induce immunogenicity.  In addition, the adsorbed protein layer is quickly 
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remodeled in vivo [5].  Because of these shortcomings, researchers have investigated 
using short peptides and methods to link them to the surface of the implant.  Various 
peptides (respective full-length protein) have been shown to affect osteoblast attachment 
including RGD (fibronectin, multiple others), GFOGER (collagen I), FHRRIKA (bone 
sialoprotein), PHSRN (fibronectin), and DGEA (collagen I).  In vivo, RGD has been 
shown reported to increase osteointegration in some studies [86-88], but not others [89, 
90].  The biological activity of RGD is less potent than that of native fibronectin or the 
fibronectin fragment FNIII7-10 [42, 91].  Single peptides have certainly shown promising 
results in promoting osteointegration; however, such peptides lack the biological activity 
of full-length proteins.  For instance, the biological activity of RGD is far less potent than 
that of native fibronectin or the fibronectin fragment FNIII7-10, which has the PHSRN 
synergy site [42, 91].  Furthermore, surfaces that contain multiple ligands may target 
distinct signaling pathways that act synergistically to enhance early osteoblast 
proliferation and later differentiation.  The effectiveness of one such multifunctional 
peptide coating of RGD and KRSR will be explored in Chapter 4. 
 Proteins or peptides can be attached to surfaces using complex chemistries that 
present ligands in specific orientation, density, and spatial distribution.  Ligand 
presentation can directly affect integrin binding, presumably by controlling access to 
binding sites.  The density and spatial distribution of ligands can also alter integrin 
binding, especially when synergy sites are involved [42].  Moreover, ligand density and 
distribution can affect focal adhesion assembly, which can enhance attachment strength 
and downstream integrin signaling [92].  The most promising of these techniques is the 
use of SAM surfaces, which include assembling chemistries based on alkanethiols, 
silanes, alkanephosphonates, interpenetrating polymer networks, or poly-L-lysine grafted 
polyethylene glycol (PLL-g-PEG) [93].  SAM surfaces are often used because they limit 
non-specific protein adsorption, which means cells initially interact specifically with the 
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biological groups attached to the SAM surface.  For example, protein adsorption on PLL-
g-PEG coated titanium is significantly reduced compared to uncoated titanium [94].  
Osteoblast attachment and proliferation are also reduced on PLL-g-PEG coated titanium 
surfaces compared to control titanium surfaces; however, ligation of RGD to the PLL-g-
PEG surface significantly increases osteoblast attachment and proliferation compared to 
PLL-g-PEG and uncoated controls [95].  Overall, such biologically modified and self-
assembled systems have promise in orthopaedic implant applications because of their 
cost, ease of use, controlled ligand presentation, and relative stability. 
 
1.7. Vitamin D 
The previous sections have focused on the role of the implant surface in affecting 
osteoblast phenotype and ultimately the degree of osteointegration of the implant. The 
systemic host environment can also play a crucial role in long-term performance of an 
implant.  Hormones such as estrogen, parathyroid hormone (PTH), or vitamin D have 
profound effects on bone formation and turnover.  Vitamin D deficiency (serum 25-
hydroxyvitamin D < 50 nmol/L) is associated with lower bone mineral density, increased 
risk of fracture, and increased risk of osteoporosis [96].  Moreover, dietary 
supplementation of calcium and vitamin D3 can increase bone mineral density and 
reduce the risks of falls and fractures in compliant patients [97, 98].  Vitamin D deficiency 
has also been shown in rats to reduce bone-to-implant contact and push-in force, which 
are measures for osteointegration and implant fixation, respectively [99].  At this time 
there does not appear to be sufficient evidence in humans as to whether calcium and 
vitamin D supplementation has an effect on osteointegration of dental or orthopaedic 
implants; however, 1α,25(OH)2D3 does have direct effects on promoting osteoblast 
differentiation in vivo [8, 100].  Furthermore, osteoblasts plated on surfaces with rough 
microtopography exhibit synergistic increases in osteocalcin and PGE2 when they are 
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treated with 1α,25(OH)2D3 [69].  The following section will explore vitamin D physiology, 
VDR dependent and independent signaling, and the influence of surface properties on 
integrin and vitamin D signaling. 
 
Vitamin D Physiology 
Vitamin D is a steroid hormone that plays a major role in the regulation of calcium 
and phosphate levels and in the maintenance of bone mineral homeostasis.  Vitamin D 
is critical to the development and maintenance of the skeleton, and chronic lack of 
vitamin D causes a disease called rickets in children and osteomalacia in adults, both of 
which are characterized by severe hypocalcemia and skeletal defects [8, 10].  The most 
biologically active metabolite of vitamin D, 1α,25(OH)2D3, is converted from the 
prohormone Vitamin D3 by 25-hydroxylase in the liver and then by 1α-hydroxylase in the 
kidney.  1α,25(OH)2D3 exerts its effects on a variety of tissues in the body, including the 
intestines, kidney, bone, and parathyroid gland.  Feedback loops tightly regulate levels 
of 1α,25(OH)2D3, 24,25R(OH)2D3, PTH, calcium, and phosphorus.  The effects of vitamin 
D on bone are complex and are the compilation of direct effects on bone cells and 
indirect effects via mineral ion regulation [101].  1α,25(OH)2D3 acts on the intestines and 
kidneys to increase calcium and phosphate levels, which increase mineralization by 
increasing the calcium-phosphate ion product.  In osteoblasts, treatment with 
1α,25(OH)2D3 causes an increase in levels of alkaline phosphatase activity and levels of 
osteocalcin, PGE2, and TGF-β1, indicating that vitamin D stimulates osteoblast 
differentiation and the creation of an osteogenic environment [102].  In vivo, 
1α,25(OH)2D3 increases osteoblast differentiation and the formation of osteoid, which is 
quickly mineralized at elevated blood Ca++ levels [8, 100].  However, 1α,25(OH)2D3 also 
upregulates M-CSF and RANKL in osteoblasts, which lead to an increase in 
osteoclastogenesis and bone turnover [8, 103].  The direct effect of 1α,25(OH)2D3 on 
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bone appears to be an increase in bone turnover because of the increase in both 
osteoblast and osteoclast activity, but the overall action of 1α,25(OH)2D3 on bone is to 
increase net bone mineralization because of elevated blood calcium and phosphate.  
Still, some debate remains whether 1α,25(OH)2D3 has an overall positive or negative 
effect on peri-implant bone formation and osteointegration. 
 
Traditional 1α,25(OH)2D3 Signaling 
The molecular actions of 1α,25(OH)2D3 are regulated through two receptors, the 
classic nuclear vitamin D receptor (VDR) and the recently discovered membrane vitamin 
D receptor known as protein disulfide isomerase, family A, member 3 (Pdia3).  Pdia3 is 
also known as endoplasmic reticulum protein 60 (ERp60) and membrane-associated-
rapid response, steroid-binding (1,25D3-MARRS) protein.  The classical effects of 
1α,25(OH)2D3 through the VDR have been widely studied and reviewed [100, 103, 104], 
and are also illustrated in Figure 1-7 on the following page.  Briefly, binding of 
1α,25(OH)2D3 to cytosolic VDR causes a conformational change in VDR and 
dissociation of co-repressor proteins.  This 1,25-bound VDR then heterodimerizes to the 
retinoid X receptor (RXR) and translocates to the nucleus where this complex binds to 
vitamin D response elements (VDREs) in the genome to alter gene expression and cell 
phenotype.  Target genes include alkaline phosphatase, osteocalcin, osteopontin, 
Runx2, LRP5, collagen XIII, p21, 17β-hydroxysteroid dehydrogenase, 24-hydroxylase, 
FGF23, and RANKL [105-108]. These genes have tissue-specific actions on PTH and 
vitamin D metabolism, mineral ion homeostasis, cell cycle regulation, osteoblast 




Figure 1-7:  Genomic actions of 1α,25(OH)2D3 regulated through the VDR and VDREs. 
 
Rapid 1α,25(OH)2D3 Signaling 
While studies have shown that VDR plays a critical role in the genomic response 
to 1α,25(OH)2D3, multiple groups have reported rapid, non-genomic activation of PKC 
and release of intracellular calcium that cannot be accounted for by traditional VDR 
signaling [109-111].  Furthermore, osteoblasts from VDR-deficient mice exhibit rapid 
activation of PKC and release of intracellular calcium when treated with 1α,25(OH)2D3 
[112].  These findings clearly demonstrate that rapid, non-genomic events of 
1α,25(OH)2D3 occur independently of the VDR.  It is now widely believed that Pdia3 is 
the membrane receptor for 1α,25(OH)2D3 [113, 114].  Studies first demonstrated that a 
polyclonal blocking antibody (Ab99) targeting Pdia3  blocked downstream activation of 
PKC by 1α,25(OH)2D3 in chondrocytes [115].  Moreover, rybozyme knockdown of Pdia3 
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in chick intestinal epithelial cells eliminated 1α,25(OH)2D3-mediated rapid release of 
intracellular calcium [116]. 
There are still many questions regarding the exact membrane 1α,25(OH)2D3 
signaling pathway and its downstream targets.  The hypothesized signaling pathway is 
described below and is illustrated in Figure 1-8 on the following page.  The rapid 
1α,25(OH)2D3 signaling cascade likely begins as 1α,25(OH)2D3 binds to Pdia3 present in 
caveolae.  Recent studies have shown that Pdia3 localizes to caveolae, and that mice 
deficient in caveolin-1 and caveolae lack increased PKC activity normally associated 
with treatment of 1α,25(OH)2D3 [117].  The mechanism could act through unknown 
protein intermediaries or G-protein coupled receptors to activate phospholipase A2 
(PLA2) and phospholipase C (PLC) [118, 119].  These lipases cause phosphatidylinositol 
to be cleaved into diacylglycerol (DAG) and inisitol triphosphate (IP3).  IP3 stimulates 
rapid release of intracellular calcium from the endoplasmic reticulum, which is a co-factor 
for activation of PKCα by DAG [117].  DAG is converted to arachidonic acid, which is 
released by PLA2 and can lead to the production prostaglandins such as PGE2 via the 
action of cyclooxygenases [118].  ERK1/2 and other MAP kinases are activated 
downstream of these events and could lead to changes in gene transcription and cell 





Figure 1-8:  Proposed membrane 1α,25(OH)2D3 signaling pathway.  
Despite this knowledge about signaling events following 1α,25(OH)2D3 binding to 
Pdia3, the effects of Pdia3-mediated signaling on bone cell phenotype are still largely 
unknown.  It is likely that Pdia3-mediated signaling of 1α,25(OH)2D3 could be important 
in rapid calcium and phosphate uptake in intestinal cells [113], but genomic signaling via 
VDR also appears to be critical [121].  Pdia3 may also be critical to the 1α,25(OH)2D3-
stimulated release of calcium, phosphate, matrix metalloproteinases, and growth factors 
from matrix vesicles, which lack traditional VDR-mediated genomic signaling [122].  This 
role of Pdia3 may be very important in matrix mineralization.   
Pdia3-mediated signaling of 1α,25(OH)2D3 could also directly interact with 
traditional VDR-mediated pathways, although no direct link has yet been established.  
Various studies have shown that VDR transcriptional activity and its interactions with 
transactivators can be modulated by phosphorylation by PKC-β, PKA, casein kinase II, 
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MAPK, and Ca2++/calmodulin-dependent kinase IV (CaMKIV) [123-126].  Moreover, 
1α,25(OH)2D3 treatment has been demonstrated to increase PKC-β translocation to the 
nucleus [127], where it may phosphorylate VDR at serine 51 and decrease binding to 
VDREs [123].  In contrast, phosphorylation of VDR by CaMKIV, which could be activated 
by the 1α,25(OH)2D3-induced increase in intracellular calcium levels, has been shown to 
significantly enhance VDR transcriptional activity [126, 128].  It is not clear whether 
Pdia3-mediated rapid 1α,25(OH)2D3 signaling enhances, represses, or selectively 
modulates VDR transcriptional activity, or whether these effects are dependent on the 
cell type and state of differentiation of the cell. Moreover, it is possible that Pdia3-
mediated rapid 1α,25(OH)2D3 signaling could affect the phosphorylation and activty of 
other transcription factors.  This possibility leads to the question of whether Pdia3-
mediated rapid 1α,25(OH)2D3 signaling has physiological effects independent of the 
VDR.  This topic will be explored using VDR deficient osteoblasts in Chapter 6.   
 
1.8. Caveolae 
Caveolae are a specialized form of cholesterol-enriched lipid rafts that are 
characterized by 60-80 nm flask-shaped invaginations in the cell membrane [129].    
Caveolae are stabilized by caveolin-1, a small, 22kD protein that forms oligimeric 
scaffolds critical to stabilizing lipid domains and maintaining the cave-like shape of 
caveolae in non-muscle tissues [130].  Caveolin-3 is the critical to the structure of 
caveolae in muscle cells. Caveolin-2 is co-localized with caveolin-1 and is critical to 
proper pulmonary function, but its role in bone remains undefined [131].  Caveolae are 
involved in endocytosis, lipid and cholesterol regulation, and a wide variety of cellular 
signaling pathways.  Caveolae serve as a nexus for many glycosylphosphatidylinositol 
(GPI)-anchored proteins, membrane associated receptors, and secondary messenger 
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proteins. Close proximity of these signaling molecules may enhance crosstalk or provide 
a mechanism for quickly up- or downregulating multiple signaling cascades [132].  
Moreover, caveolae may interact with integrins and focal adhesions to spatially and 
temporally control signaling.  In bone cells, caveolae have been shown to be involved in 
the modulation of extracellular matrix and integrin interactions, mechanical stress 
transduction, BMP signaling, and 1α,25(OH)2D3 signaling [129, 131-133].  In addition, 
caveolae may play a direct role in mineralization via their potential involvement with 
matrix vesicle biogenesis [134].   
Despite the abundance of caveolae and the direct involvement of caveolae in a 
wide variety of signaling pathways, Caveolin-1 deficient [Cav-1(-/-)] mice show 
surprisingly few defects, suggesting that compensatory mechanisms exist to overcome 
the loss of certain signaling pathways in the absence of caveolae [135].  Cav-1(-/-) mice 
are relatively healthy and grow to full size, although some cardiovascular and pulmonary 
problems do develop later in life.  Although the effects of caveolae deficiency are not 
manifested by gross bone abnormalities, recent studies have shown that Cav-1(-/-) mice 
do exhibit an altered bone phenotype [136].  The growth plates of Cav-1(-/-) mice are 
widened and have abnormally high numbers of hypertrophic cells [117].  The femurs of 
Cav-1(-/-) mice show a significant increase in the elastic modulus, cortical bone 
thickness, stiffness, and overall yield strength compared to wild-type bones [137].  In 
addition, osteoblasts in Cav-1(-/-) mice display increased mineral apposition rates and 
bone formation rates compared to osteoblasts in Cav-1(+/+) mice.  Moreover, previous 
studies have shown that knockdown of Cav-1 in stromal cells leads to increased levels 
of Runx2 and osterix.  Taken together, these studies suggest that caveolae may serve to 
suppress signals for osteoblastic differentiation, thus slowing the rate of bone formation. 
The mechanism by which loss of caveolae increases the rate of bone formation 
is unknown; however, caveolae have been shown to be involved in matrix vesicle 
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biogenesis [134], mechanotransduction [129], integrin trafficking and signaling [138], 
BMP signaling [133], and rapid vitamin D signaling [117].  It is unlikely that the role of 
caveolae is simply to delay differentiation as some reports have suggested [136].  
Because of the wide involvement of caveolae in multiple signaling pathways, it is more 
likely that caveolae acts to suppress, enhance, or in other ways modulate different 
osteogenic signals depending on extracellular cues or the state of differentiation of the 
cell.  Interestingly, caveolin-1 has been shown to either enhance or inhibit BMP receptor 
function depending on which isoform of caveolin-1 binds to BMP receptors I or II.  Cav-
1β appears to inhibit BMP signaling, whereas Cav-1α appears to promote it [133].  In 
addition, caveolae may sequester β-catenin, which suppresses canonical Wnt/β-catenin 
signaling important in early osteoblasts [139].  Caveolae may also act in concert with 
Pdia3 to modulate VDR activity through phosphorylation by PKC-β, CaMKIV, or casein 
kinase II mechanisms discussed in the previous section.  Finally, caveolae may affect 
mineralization directly by mediating matrix vesicle biogenesis.  This theory is supported 
by evidence that caveolin-1 is present both in caveolae and matrix vesicles in 
chondrocytes and osteoblasts [134].  Furthermore, overexpression of caveolin-1 leads to 
a large increase in osteoblast matrix mineralization.  Interestingly, studies using 
chondrocytes have shown that 1α,25(OH)2D3 acts through Pdia3 to release 
lysophospholipids that destabilize matrix vesicles [122].  It is theorized that these 
vesicles could then release stored calcium, phosphate, matrix metelloproteinases, and a 
myriad of proteins involved in matrix mineralization [122].  In summary, evidence is 
building that caveolae appear to suppress early osteoblast differentiation through 
regulation of BMP, Wnt, or VDR signaling, but later promote mineralization via matrix 
vesicle biogenesis or other mechanisms.  However, the role of caveolae is wide-ranging 




Caveolae Mediated Interactions Between Integrins and 1α,25(OH)2D3 Signaling 
Rough surface microtopography and 1α,25(OH)2D3 treatment cause a synergistic 
increase in markers for osteoblastic differentiation, including alkaline phosphatase 
activity, and levels of osteocalcin, osteoprotegerin, and PGE2 [69].  Caveolae likely are 
involved in this synergy, since separate studies have shown that integrins can traffic 
through caveolae [140] and that both VDR and Pdia3 are present in caveolae [117, 141].  
Integrin signaling could enhance cell responsiveness to 1α,25(OH)2D3, or vice versa, 
1α,25(OH)2D3 could enhance integrin function through inside-out signaling or by 
crosstalk with downstream signal mediators.  Such crosstalk could be the basis for the 
observation that osteoblasts grown on surface roughness and treated with 1α,25(OH)2D3 
exhibit synergistic increases in markers for osteoblast differentiation. 
Interestingly, caveolae may be directly involved in integrin clustering and 
assembly of focal adhesions.  Studies have shown that knockdown of caveolin-1 
expression decreases the formation rate of focal adhesions and decreases integrin 
signaling [44, 142].  Cav-1 has also been shown to be important in association of src-
family kinases with β1 integrins [142].  Caveolin-1 deficient cells show impaired 
directional migration, spatial recognition, and the establishment of cell polarity due to 
disruption of proper src kinase and RhoGTPase signaling [143].  It is hypothesized that 
such loss of polarity and control of attachment dependent signaling may lead to changes 
in how osteoblasts interpret changes in surface roughness or chemistry (see Chapter 6).  
In addition, integrins α2β1 and α5β1, which are highly expressed in osteoblasts, have 
been shown to traffic through caveolae.  In summary, loss of cav-1 has been shown to 
decrease the stability and number of focal adhesions [144], alter Ras/Erk, PI3K/Akt and 
Rac/Pak signaling [138], alter growth factor and steroid hormone signaling [117, 138], 
and disrupt cell polarization and migration [143]. These roles of caveolae point to the 
36 
 
possibility that caveolae might be important in integrating osteoblast responses to 
changing surface roughness and 1α,25(OH)2D3. 
Integrin binding has also been shown to regulate caveolae internalization, which 
may enhance spatial and temporal sensing by regulating the activity of caveolae-
dependent signaling pathways [138, 145].  Integrin activation at focal adhesions recruits 
and sequesters phosphorylated (tyrosine 14) caveolin-1 (pY14Cav-1) to the focal 
adhesion complex.  Loss of cell attachment causes translocation of pY14Cav-1 to 
caveolae, which in turn triggers dynamin-2 mediated endocytosis of caveolae.  As 
caveolae are internalized, signaling pathways including Ras/Erk, PI3K/Akt and Rac/Pak 
are rapidly shut down; however, these pathways remain in an active state in caveolin-1 
deficient cells unable to internalize caveolae-associated lipid rafts [138].  Caveolin-1 
deficient cells have increased rates of proliferation.  In fact, many metastatic cancer cell 
lines have mutations in caveolin-1 that increase proliferation, increase migration, and 
enable anchorage independent growth.  Furthermore, membrane 1α,25(OH)2D3 requires 
caveolae.  Signaling of 1α,25(OH)2D3 could be affected through attachment mediated 
control over pY14Cav-1 sequestration.  Conversely, signaling molecules could modulate 
focal adhesion disassembly through cAMP-mediated dephosphoylation of pY14Cav-1 
[138], thus providing a mechanism for growth factor mediated effects on attachment.  In 
summary, evidence supports the theory that caveolae and lipid rafts interact with 
integrins and focal adhesions to modulate signaling, thus providing rapid mechanisms 
for integrin mediated regulation of growth factor signaling, or vice versa, allowing growth 
factors to mediate integrin signaling and focal adhesion assembly. 
 
1.9. Summary and Thesis Objective 
Roughened surfaces used on orthopaedic and dental implants today are known 
to promote osteogenic differentiation in vitro and bone formation in vivo, although 
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relatively little is known about the molecular mechanisms through which osteoblasts 
actually sense differences in surface topography and chemistry.  Moreover, these initial 
signaling events fundamentally alter osteoblast response to growth factors or steroid 
hormones, which lead to further enhancement of osteogenic phenotype.  The previous 
sections have explored the roles of integrins, 1α,25(OH)2D3 receptors, and caveolae in 
mediating osteoblast response to surface properties and 1α,25(OH)2D3; however, many 
questions regarding these signaling pathways still remain unanswered.  Understanding 
these cellular mechanisms could enable biomedical engineers to design surfaces or 
combination therapies that actively promote osteoprogenitor attachment and osteoblast 
differentiation, thus potentially leading to increased bone formation and better long-term 
implant fixation. The development of such advanced biomaterials and combination 
therapies in orthopaedics requires 1) an understanding of the cellular signaling 
processes guiding cell and tissue response to biomaterials, 2) advances in surface 
engineering and biomolecular technology that specifically target these osteogenic 
pathways, and 3) the translation of these biologically inspired designs into actual medical 
products.   
The purpose of the present thesis is to explore how integrins mediate osteoblast 
response to changes in surface chemistry and topography, and whether titanium 
surfaces functionalized with the specific ligands RGD and KRSR can enhance 
osteoblast proliferation and differentiation.  In addition, the purpose of this thesis is to 
determine whether the synergistic effects of surface topography and 1α,25(OH)2D3 
require caveolae to mediate the interaction between integrin and VDR-independent 
pathways.  To address these questions, several studies were undertaken to investigate 
the role of the α5β1 integrin, VDR, and caveolae in response to changing surface 
topography and 1α,25(OH)2D3 treatment.   
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The first aim of the thesis uses shRNA techniques separately targeting the β1 
(Chapter 3) and α5 (Chapter 4) integrin subunits to determine whether loss of these 
integrins disrupts osteoblast response to changes in surface energy and surface 
topography and reduces osteoblast sensitivity to 1α,25(OH)2D3 treatment.  The results 
show that the β1 integrin is required for mediating the response of osteoblast-like MG63 
to surface roughness and topography, and that the response to 1α,25(OH)2D3 is also 
abrogated.  Silencing of the α5 subunit did not appear to alter the response of MG63 
cells to surface properties and 1α,25(OH)2D3, although this finding may be dependent on 
the cell type or the state of differentiation [146].  The results suggest that specific 
integrins are critical in mediating osteoblast phenotypic maturation in response to 
different surface cues. 
The second aim of the thesis (Chapter 5) uses titanium surfaces functionalized 
with the ligands RGD, KRSR, and KSSR to determine whether multi-functional PLL-g-
PEG based surfaces can distinctly target integrin and heparin sulfate binding to increase 
both osteoblast proliferation and differentiation.  The results show that RGD increased 
osteoblast proliferation and reduced differentiation, KRSR had no effect on osteoblast 
phenotype, and KSSR increased osteoblast differentiation.  The results from this aim 
suggest that RGD/KSSR functionalized PLL-g-PEG coated SLA surfaces should be 
further investigated for use as osteointegrative surfaces. 
The third and final aim of the thesis uses osteoblasts derived from VDR (Chapter 
6) and Cav-1 (Chapter 7) knockout mice to determine whether 1α,25(OH)2D3 signaling 
pathways require VDR and Cav-1 to promote osteoblast differentiation, and whether loss 
of these genes alters osteoblast response to surface energy and topography.  The 
results in VDR deficient osteoblasts demonstrate that VDR is required for the effects of 
1α,25(OH)2D3 on all markers for osteoblastic phenotype.  VDR-independent effects on 
osteoblast phenotype were not demonstrated.  In caveolae deficient osteoblasts, 
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1α,25(OH)2D3 affected cell number, alkaline phosphatase activity, and TGF-β1 levels, 
although levels of osteocalcin and PGE2 were not affected.  These results are consistent 
with the hypothesis that VDR is required for the actions of 1α,25(OH)2D3, but that 
caveolae-dependent membrane 1α,25(OH)2D3 signaling modulates traditional VDR 
signaling.   
The results in this thesis demonstrate that integrins, VDR, and caveolae play 
important roles in mediating osteoblast response to surface properties and 
1α,25(OH)2D3.  However, the results also raise many more questions regarding the 
interaction between nuclear and membrane 1α,25(OH)2D3 and how these pathways are 
modulated by integrin binding.  Overall, the results are important in better understanding 
how cells interact with implant surfaces via integrins to affect osteoblast phenotype and 





CHAPTER 2:  General Methodology 
2.1. Implant Surface Models 
One problem limiting direct comparison between many biomaterial studies in the 
scientific literature is the wide variability in processing techniques used to create 
substrates being studied.  Such differences inherently create variability in terms of 
surface roughness, surface morphology, grain size, surface chemistry, and surface 
energy.  While surfaces can be generally compared using measurable parameters such 
as average peak to valley roughness (Ra), any single measurement does not take into 
account changes in other surface properties that may also be influencing cell behavior.  
Thus, it is not only critical to minimize processing variability among surfaces used within 
a particular study, but it is also useful to limit differences in surface characteristics when 
making comparisons between studies.   
In an effort to specifically control surface roughness and surface energy 
throughout these experiments, model titanium disks were created with consistent size, 
surface roughness, morphology, surface energy, grain size, and chemical composition.  
Institut Straumann AG (Basel, Switzerland) provided commercially pure titanium (cpTi) 
discs of differing surface roughness and surface energy.  These surfaces, in order of 
increasing surface roughness, include pre-treatment (PT) cpTi, sand blasted acid etched 
(SLA) cpTi, modified high surface energy SLA (modSLA) cpTi, and titanium plasma 
sprayed (TPS) cpTi.  The production and characteristics of these discs are described in 
detail below and are summarized in Figure 2-1 on the following page.  In addition, tissue 
culture treated polystyrene (TCPS) surfaces were used as controls because of their 
widespread use in cell culture and their transparency, which enables easy monitoring of 




Figure 2-1: Morphology of PT, SLA, and TPS titanium surfaces viewed using scanning 
electron electron microscopy. Adapted from Zhao [147]. Note: modSLA surfaces have 
identical surface morphology to SLA surfaces.  The table shows values for average peak 
to valley height (roughness; Ra) and advancing contact angles measurements [76]. 
 
The production of PT, SLA, modSLA, and TPS discs was performed by Institute 
Straumann AG under stringent protocols similar to those methods used in the production 
of dental implants [148].  Briefly, cpTi discs were cut from 1 mm-thick sheets of grade 2 
commercially pure titanium (ASTM F67) to a diameter of 15 mm to match the size of 
wells in a standard 24-well tissue culture plate.  The discs were then cleaned in acetone 
and briefly etched using 2% ammonium fluoride/2% hydrofluoric acid/10% nitric acid 
solution for 30 seconds at 55°C to produce PT surfaces.  SLA and modSLA discs were 
sandblasted with alumina (corundum, Al2O3) particles averaging 250 µm in diameter at a 













modSLA discs were degreased in acetone and subsequently etched using a proprietary 
process involving a mixture of hot HCl/H2SO4/H2O at ratio of 1:8:1 [148].  This two-step 
process creates a complex morphology consisting of craters 20-50 μm in diameter (from 
sandblasting) overlaid with micropits between 0.5 and 2 μm in diameter (from etching), 
such that the overall topography mimics that of osteoclast resorption pits as shown in 
Figure 2-2 [149].   
 
Figure 2-2:  Comparison of SLA to bone wafers treated with osteoclasts.  SLA surfaces 
have similar macroscale features as osteoclast resorption pits (left) and similar 
microscale features as the resorbed surface of bone (right).  Adapted from Zhao, Davies, 
and Boyan [27, 147, 150]. 
 
TPS discs have the roughest surface morphology of the discs tested.  TPS discs 
were first sandblasted with alumina particles in a similar manner to SLA and modSLA 
discs as described above.  The surfaces were subsequently coated with titanium (and 
TiO2) using a plasma spray process [151].  Briefly, a high temperature (15,000 – 20,000 
ºF) plasma jet was created by applying a direct current (DC) arc discharge to an Argon 
carrier gas as it flowed through a high velocity nozzle.  Titanium hydride powder was 
introduced into the plasma and the titanium particles were rapidly heated and 
accelerated to high velocity (3,000 m/s) before impacting the titanium substrate.  These 
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molten particles quickly cooled upon impinging the substrate, leaving a highly adherent 
coating of roughened titanium approximately 30µm thick [68].  In preparation for cell 
culture, all PT, SLA, and TPS disks were sterilized by steam autoclaving at 121°C for 15 
minutes.  The sealed modSLA discs were sterilized by gamma irradiation at 25 kGy 
overnight by Institut Straumann AG. 
Titanium PT, SLA, modSLA, and TPS surfaces have been characterized to 
assess surface roughness, surface energy, and surface chemical composition, all of 
which are known to influence osteoblast phenotype.  Surface profilometry has shown 
that PT surfaces have an average peak to valley roughness (Ra) of 0.54 ± 0.3 μm, SLA 
and modSLA surfaces have an Ra of 3.97 ± 0.1 μm, and TPS surfaces have an Ra of 
5.21 ± 0.3 μm [147].  Roughness is only one aspect of surface morphology that can be 
easily measured and understood.  Surface morphologies for PT, SLA, and TPS surfaces 
have been observed using scanning electron microscopy as shown previously in Figure 
2-1.  Surface contact angle measurements showed varying surface energy between PT, 
SLA, and TPS surfaces.  PT and SLA surfaces are fairly hydrophobic (low surface 
energy).  Advancing contact angles of water droplets are 95.76°± 4.0° for PT and 
138.3°± 4.2° for SLA [76].  The advancing contact angle for modSLA is indistinguishable 
from 0°, which indicates that modSLA surfaces are extremely hydrophilic (high surface 
energy).  All surfaces have a 10-30nm thick oxide layer (primarily TiO2), but other 
elements present vary between surfaces.  X-ray electron spectroscopy has shown that 
carbon concentration is 29.2% ± 1.5%, 34.2% ± 2.0%, and 14.9% ± 0.9%, titanium 
concentration is 17.9% ± 1.0%, 14.3% ± 1.4%, and 23.0% ± 1.1%, and oxygen 
concentration is 47.6% ± 1.2%, 50.2% ± 2.6%, and 60.1% ± 0.7%, on PT, SLA, and 
modSLA surfaces, respectively [147].  These results demonstrate that modSLA surfaces 
have significantly less hydrocarbon contamination than PT or SLA surfaces.  The 
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difference in surface energy between SLA and modSLA surfaces is directly related to 
this reduction in hydrocarbon contamination.   
 
2.2. In Vitro Osteoblast Models 
Several different osteoblast cell types were used within this thesis depending on 
the objective of the particular study.  MG63 cells were used for the β1 and α2 knockdown 
studies in chapters 3 and 4.  MG63 cells were also used for the RGD/KRSR study in 
chapter 5.  Cavarial osteoblasts derived from VDR knockout and Cav-1 knockout mice 




MG63 cells were obtained from the American Type Culture Collection (ATCC, 
Rockville, MD).  MG63 cells are an osteoblast-like cell line derived from human 
osteosarcoma cells originally isolated from a 14-year old Caucasian male.  MG63 cells 
have been well characterized previously and show numerous traits of immature 
osteoblasts [69].  MG63 cells show enhanced differentiation in response to increasing 
surface roughness and 1α,25(OH)2D3, as determined by increases in alkaline 
phosphatase activity, osteocalcin levels, and other osteoblastic markers.  MG63 cells 
display a flattened, fibroblast-like morphology when cultured on TCPS surfaces, but 
display a more cuboidal, osteoblast-like morphology on rough surfaces.  These cells do 
not normally mineralize their matrix except under certain culture conditions [150].  MG63 
cells were chosen for implant surface studies because they model an immature 
osteoblast that might contact an implant surface in vivo.  These cells were chosen for 
integrin silencing so that a permanent cell line could be established. 
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Vitamin D Receptor Deficient Osteoblasts  
A colony of VDR deficient mice was established at the Georgia Institute of 
Technology after a generous donation of mice from Marie DeMay of Massachusetts 
General Hospital.  VDR(-/-) mice are completely deficient in functional VDR as 
demonstrated in previous studies [121].  A heterozygous breeding colony was 
maintained in a parasite-free animal facility.  All mouse studies were performed under 
Georgia Tech IACUC approval and procedures.  Mice were kept on a 12 hour light/dark 
cycle and fed a “non-rescue” 1:1 mix of LabdietTM 5001 rodent and 5015 mouse chow 
containing 0.88% calcium, 0.58% phosphorous, and 3.9 IU/gram of vitamin D3.  To 
collect DNA for genotyping, tail snips were performed under light anesthesia using 
isofluorane.  DNA was extracted using a Buccal Amp DNA extraction kit (Epicentre 
Biotechnologies).  VDR(-/-) mice were identified with PCR by the presence of the 
inserted neomycin resistance gene using the following primers: 5‟-GCT GCT CTG ATG 
CCG CCG TGT TC-3‟ and 5‟-GCA CTT CGC CCA ATA GCA GCC AG-3‟.  VDR(+/+) 
mice were identified using the primers 5‟-CTG CCC TGC TCC ACA GTC CTT-3‟ and 5‟-
GCA GAC TCT CCA ATC TGA AGC-3‟, which are specific to the missing exon 2 section 
of the mouse VDR gene.  VDR(+/+) and VDR(-/-) mice were euthanized by CO2 at eight 
weeks old.  Osteoblasts derived from VDR(-/-) mice were the experimental group and 
those from homozygous VDR(+/+) were used as wild-type littermate controls.   
Osteoblasts were immediately isolated from the calvaria of 6-8 mice of each 
group. The calvaria was scraped to remove soft tissue and then diced into pieces 
smaller than 1-2mm.  Calvaria pieces were then enzymatically digested using 
collagenase I and dispase for three 20 minute periods. Cells from the first digestion were 
discarded, but cells from the remaining two digestions were collected and seeded onto 
T-25 flasks for culture and expansion.  Osteoblasts were cultured in DMEM plus 10% 
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FBS and 1% Penicillin/Streptomycin and were expanded through two passages before 
passage onto experimental surfaces. 
 
Caveolin-1 Deficient Osteoblasts 
Caveolin-1 deficient mice were obtained through collaboration with Dr. Hanjoong 
Jo of Emory University.  A heterozygous mouse colony was maintained at the Emory 
University Medical School transgenic mouse facility.  All mouse studies were performed 
under Emory University IACUC approval and procedures. Caveolin-1 deficient mice 
were euthanized by CO2 at eight weeks old.  Osteoblasts derived from Cav-1(-/-) mice 
were the experimental group and those from homozygous Cav-1(+/+) were used as wild-
type littermate controls.  Osteoblasts were immediately isolated from the calvaria of 6-8 
mice of each group. Calvarial osteoblasts were harvested in an identical manner as VDR 
osteoblasts described previously.  Osteoblasts were cultured in DMEM plus 10% FBS 
and 1% Penicillin/Streptomycin and were expanded through two passages before 
passage onto experimental surfaces. 
 
2.3. Assessment of Osteoblast Phenotype 
Osteoblasts phenotype was assessed through measures of osteoblast 
proliferation, differentiation, and local factor production.  These tests are used 
throughout the thesis and are described in detail below: 
 
Cell Number 
Cell number measurements are affected by a combination of factors including 
cell seeding density, attachment, proliferation, and apoptosis.  At cell harvest, which 
varied by experiment, media was collected and cells were washed twice with Dulbecco‟s 
Modified Eagle Medium (DMEM).  Cells from each 24-well plate were then treated with 
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500 µL of 0.25% trypsin solution.  Two 10 minute trypsin treatments were performed to 
detach cells from rough surfaces.  Cells were centrifuged at 1500g and then 
resuspended in saline solution for counting.  Cell number was determined using a 
Coulter automatic cell counter (Z1 cell and particle counter, Beckman Coulter, Fullerton, 
CA), which counts cells based on changes in electrical conductance as cells move 
through a microfluidic tube. 
 
Total Protein:   
After counting, cells were centrifuged and then lysed using 500 µL per well of 
0.05% Triton X-100 followed by three consecutive freeze-thaw cycles.  The cell lysate 
was used to measure total protein levels and alkaline phosphatase activity.  Total protein 
was measured using a commercially available kit (Micro/Macro BCA, Pierce Chemical 
Co., Rockford, IL) and a fluorescence microplate reader at 570nm.  Protein levels are 
used to normalize cellular alkaline phosphatase activity. 
 
Alkaline Phosphatase Specific Activity  
Alkaline phosphatase is a hydrolase that removes phosphates from many 
different molecules and proteins.  Alkaline phosphatase is critical in matrix mineralization 
and is an early marker for osteoblastic differentiation.  Alkaline phosphatase specific 
activity (orthophosphoric monoester phosphohydrolase, alkaline; E.C. 3.1.3.1) was 
assessed by measuring the release of p-nitrophenol from p-nitrophenylphosphate at pH 
10.2.  Activity was assessed using a fluorescence microplate reader at 415nm.  This 






Osteocalcin is a bone and dentin specific protein that is believed to act as a 
negative regulator of bone formation.  Despite its abundance in bone, osteocalcin 
deficient mice actually exhibit increased bone mass [152].  Osteocalcin is considered to 
be a late marker for differentiation that is expressed just prior to mineralization.  
Osteocalcin was measured in the conditioned media using a commercially available 
radioimmunoassay kit (Human Osteocalcin RIA Kit, Biomedical Technologies, 
Stoughton, MA).  Osteocalcin levels were normalized to total cell number. 
 
Active and Latent TGF-β1: 
TGF-β1 is a member of the TGF-β superfamily that has autocrine and paracrine 
effects on cell proliferation and differentiation.  Bone extracellular matrix contains high 
levels of latent TGF-β1.  The role of TGF-β1 in bone is complex, but increases in TGF-
β1 expression are associated with increased osteoblastic differentiation.  TGF-β1 was 
measured using an enzyme-linked immunoassay (ELISA) kit specific for human TGF-β1 
(TGF-β1 Emax
® Immunoassay System, Promega Corp., Madison, WI).  Latent TGF-β1 
was measured prior to acidification of the conditioned media.  Total TGF-β1 was 
measured by acidification of the media with HCl for 10 minutes at room temperature 
followed by neutralization with NaOH.  The amount of latent TGF-β1 was calculated by 
subtracting the amount of active TGF-β1 from the total TGF-β1.  Latent and active TGF-
β1 levels were normalized according to cell number. 
 
Prostaglandin E2 
 Prostaglandin E2 is another autocrine and paracrine factor secreted by 
osteoblasts.  At low levels PGE2 may promote osteoblastic differentiation, but at high 
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levels it promotes osteoclastogenesis [153].  Increasing PGE2 secretion is generally 
associated with increasing osteoblastic differentiation.  PGE2 was measured using a 
commercially available competitive binding radioimmunoassay kit (Prostaglandin E2 RIA 
Kit, Perkin Elmer, Wellesley, MA).  PGE2 levels were normalized to cell number. 
 
Osteoprotegerin 
 Osteoprotegerin is a secreted protein that inhibits osteoclastogenesis by binding 
directly to RANKL and preventing RANK/RANKL signaling.  Affirming this role, OPG 
deficient mice develop osteoporosis at an early age [154].  Secretion of OPG by 
osteoblasts indicates the creation to a microenvironment promoting bone formation over 
resorption.  Osteoprotegerin was measured using a commercially available enzyme-
linked immunoassay (ELISA) kit specific for human osteoprotegerin (DY805, R&D 








The Role of Integrin β1 in Osteoblast Response to Surface 
Microtopography and 1α,25(OH)2D3 
 
3.1. Introduction 
The chemical composition and topography of the surface are important in 
regulating adsorption of proteins and adhesion of cells, which affect cell phenotype, 
response to local and systemic regulatory factors, and the overall biological response to 
the implant [1, 155-157].  In vitro studies show that Ti surface microtopography is 
capable of promoting osteogenic maturation in both osteoblast-like MG63 cells and 
normal human osteoblasts (NHOst cells) [71, 158], as indicated by increases in levels of 
osteocalcin, TGF-β1, PGE2, and OPG [69].  Moreover, increasing surface roughness 
and surface energy enhances the response of osteoblasts to bone anabolic agents such 
as 1α,25(OH)2D3 in a synergistic manner [159].  These studies suggest that the 
increased pull-out strength and bone-to-implant contact observed when implants with 
rough surfaces are used in vivo is due in part to the production of local osteogenic 
factors [31, 68].  By understanding the mechanisms involved with cell response to 
surface properties, materials can be designed to better promote osteointegration and 
long-term implant fixation. 
Osteoblasts interact with their substrate initially via integrin binding to proteins 
adsorbed on the surface of a biomaterial as discuss in detail in section 1.4.  Osteoblasts 
have been shown to express the integrins α1β1, α2β1 α3β1, α4β1, α5β1, α6β1, α8β1, αVβ3, 
αVβ5, [34], but the integrins α2β1 and α5β1 have been shown to be particularly important 
in bone.  The α2β1 integrin binds to type I collagen [14], which is the dominant bone 
matrix protein, and α2β1-mediated binding to extracellular matrix has been reported to 
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regulate osteoblastic differentiation [160, 161]. The integrin pair α5β1 is selective for 
fibronectin; α5β1 binding has been shown to be necessary for bone-like nodule formation 
in vitro when osteoprogenitor cells are grown on tissue culture plastic [162, 163].   
Integrin expression is sensitive to substrate chemistry [164], raising the possibility 
that integrin requirements for osteoblast differentiation may also vary with surface 
chemistry.  Expression of the β1 integrin, which partners with α2 and α5, is increased in 
osteoblast-like MG63 cells cultured on titanium in comparison with tissue culture plastic 
[40].  When these cells are grown on titanium surfaces with rough microtopographies, 
expression of the β1 integrin is further increased.  In contrast, α2 expression is increased 
and α5 expression is decreased.  These results correlate with higher levels of 
osteocalcin, indicating that changing integrin expression might be important in osteoblast 
differentiation.  Integrin β1 mRNA is also regulated by 1α,25(OH)2D3 in a dose-, time-, 
and surface roughness-dependent manner, but it is regulated independently of either α2 
or α5 mRNA.  However, it is not known if this increase in β1 expression is responsible for 
increase in differentiation in response to surface roughness and 1α,25(OH)2D3, or 
whether these events are simply associated. 
In the present paper, we investigated whether the synergistic effects of surface 
roughness and 1α,25(OH)2D3 on osteoblast differentiation are mediated by the β1 
integrin.  In order to determine the specific roles of an integrin in the attachment, 
proliferation and differentiation of osteoblasts, many investigators have relied on the use 
of antibodies to block integrin binding [165, 166].  Integrins are also expressed on non-
binding surfaces of the cell [167, 168]; thus some of the effect of the antibodies may be 
via integrins not involved in cell/substrate interactions, particularly if antibodies are 
added to the culture after initial attachment has occurred.  To overcome this potential for 
artifact, the present study uses RNA interference (RNAi) technology to specifically 
suppress levels of β1 expression. RNAi reduces the production of an individual protein 
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by post-transcriptionally inhibiting or degrading the mRNA for that protein via the 
introduction of a double stranded short hairpin RNA (shRNA) [169]. To test the 
hypothesis that the β1 integrin mediates the response of osteoblasts to the 
microarchitecture of their substrate, MG63 cells were stably transfected with shRNA 
targeting the β1 integrin mRNA.  Control and β1-silenced MG63 cells were plated on Ti 
substrates with different surface microtopographies and treated with 1α,25(OH)2D3 to 
determine whether loss of the β1 integrin altered osteoblast proliferation or differentiation 
in response to these stimuli. 
 
3.2. Materials and Methods 
Titanium Surfaces 
Institut Straumann AG (Basel, Switzerland) supplied the PT, SLA, and TPS 
titanium disks used in this study.  Surfaces were manufactured and characterized as 
described in chapter 2. 
 
Construction of DNA Vector-based shRNA Plasmids 
The selection of coding sequences was determined empirically and was 
analyzed by blast search to avoid significant sequence homologies with other genes. 
Briefly, the β1 integrin shRNA designed by Dr. Liping Wang targets 21 bases starting 
from the base 647 of the ITGB1 gene (NM_002211). Sequences of sense and antisense 
oligonucleotide strands constituting β1 shRNA are 5‟-tcg agg agg att act tcg gac ttc agg 
aat tcg tga agt ccg aag taa tcc tcc ttt tt-3‟ and 5‟-cta gaa aaa gga gga tta ctt cgg act tca 
cga att cct gaa gtc cga agt aat cct cc-3‟, respectively.  In addition, oligonucleotides that 
had scrambled β1 sequences were used as a negative control.  After annealing the 
oligonucleotides, the fragments were cloned into a pSuppressorNeo vector containing a 
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U6 promoter with a GeneSupressorTM system (IMGENEX Corp., San Diego, CA) 
according to manufacturer protocols [170]. 
 
Transfection and Selection of β1-silenced MG63 cells 
MG63 cells were used as a model in this study and are described in chapter 2. 
Cells were cultured in DMEM containing 10% fetal bovine serum (FBS) and 0.5% 
antibiotics (diluted from a stock solution containing 5000U/mL penicillin and 5000U/mL 
streptomycin; GIBCO, Grand Island, NY) and in an atmosphere of 100% humidity and 
5% CO2. The media were changed at 24 h and then at 48 h intervals. At confluence, 
cells were subcultured in a 6-well plate at a plating density of 2 x 105 cells in 0.5 ml of 
growth medium without antibiotics. 
When cells were 90–95% confluent, they were transfected using Lipofectamine 
2000 (Invitrogen, Carlsbad, CA) with either the pSuppressorNeo/ U6 plasmid containing 
the β1 shRNA or the control plasmids according to the manufacturer‟s instructions. 
Briefly, plasmids were incubated with Lipofectamine 2000TM in OPTI-MEMTM reduced 
serum medium (GIBCO) for 20 minutes at room temperature before transfection.  Then, 
the plasmid-Lipofectamine complexes were added to individual wells, each of which 
contained cells and growth medium, and incubated for 48 h at 37ºC.  The effectiveness 
of the β1-shRNA silencing was determined by quantitative reverse transcription 
polymerase chain reaction (qRT-PCR).  To select for cells containing plasmid, following 
the transfection, the growth media were replaced with media containing DMEM, 10% 
FBS, and 400 mg/ml of the antibiotic G418 (Invitrogen). Surviving cells were cultured 
until they reached confluence and then subcultured into T-75 flasks. Confluent cultures 
were subpassaged onto the experimental surfaces. In addition, aliquots of these cells 
were stored at -80ºC for subsequent experiments.  G418 was included in the growth 
medium until cells reached confluence on the test substrates. Two cell lines were 
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selected for these studies.  β1-shRNA MG63 cells exhibited a consistent 65% reduction 
in β1 integrin mRNA.  β1S scrambled MG63 cells contained the scrambled shRNA 
plasmid and exhibited the same β1 mRNA levels as non-transfected MG63 cells. 
 
Real-time PCR Measurement of Integrin β1 mRNA 
The presence of β1 integrin mRNA in the cells was verified by RT-PCR and qRT-
PCR. Total RNA was isolated using the TRIZOL reagent (Invitrogen) from wild-type 
MG63 cells as well as from cells treated with Lipofectamine alone, Lipofectamine plus 
empty plasmid, Lipofectamine plus β1 shRNA, and plasmid containing the scrambled 
shRNA template (N=1 per group). One mg of RNA was reversed transcribed with 200 ng 
each of human β1 integrin sense and antisense primers in a 15 ml volume using the 
Amersham-Pharmacia-Biotech RT kit (Amersham Biosciences, Piscataway, NJ). 
Optimal oligonucleotide primers were designed using Beacon Designer 2.0 software 
(MWG Biotech, High Point, NC). The primers used to amplify human integrin β1 were 
synthesized according to the following sequences: 5‟-caacgaggtcatggttcatgtt-3‟ 
(antisense) and 5‟-caacgaggtcatggttcatgtt-3‟ (sense).  Quantitative RT-PCR was 
performed on an i-cyclerTM (Bio-Rad Laboratories, Hercules, CA) using software i-cycler 
iQTM, version 3.0a.  PCRs were carried out in a total volume of 25 µl in PCR master mix 
containing 12.5 µl SYBR® green, 200 ng each of sense and antisense primer, 25mM 
MgCl2, and 3 µl of the reverse transcription product.  The volume was adjusted with 
diethylpyrocarbonate (DEPC)-treated water. The amplifications were performed in 
duplicate for each sample and the optimal PCR conditions for integrin β1 were 61ºC for 
40 cycles; and for the GapDH, they were 54ºC for 40 cycles. 
To normalize the content of cDNA samples, we used the comparative threshold 
(Ct) cycle method, which consists of the normalization of the number of target gene 
copies versus the endogenous reference gene GAPDH. The Ct is defined as the 
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fractional cycle number at which the fluorescence generated by cleavage of the probe 
passes a set threshold baseline when amplification of the PCR product is first detected. 
Through this method, a single sample, represented in our experiments by cells without 
any treatment, was designed as a calibrator and used for comparison of gene 
expression level of any unknown samples. 
 
Physiological Responses of Osteoblasts MG63 Cells 
Wild type, β1-silenced, and β1-scrambled-transfectants were grown to confluence 
on tissue culture plastic and then subcultured into 24-well plates on six discs each of 
TCPS, PT, SLA, or TPS surfaces.  When the cells reached confluence on tissue culture 
plastic, media in all wells were replaced with experimental media containing ethanol 
vehicle or 108 M 1α,25(OH)2D3.  Cells were cultured an additional 24 hours. At that time, 
cells were harvested and conditioned media were collected.  Osteoblast phenotype was 
assessed by measuring cell number, alkaline phosphatase activity, and levels of 
osteocalcin, TGF-β1, OPG, and PEG2 according to protocols discussed in chapter 2. 
Soluble RANKL was also measured in this study using a commercially available ELISA 
kit (ALPCO Diagnostics, Windham, NH), but levels were undetectable in any of the cells. 
 
Statistical Analysis 
The data presented are from one of two separate sets of experiments, both of 
which yielded comparable results.  Each data point represents the mean ± standard 
error of the mean (SEM) of six independent cultures. Data were analyzed by analysis of 
variance and statistical significance between groups was determined using Bonferroni‟s 






RT-PCR demonstrated that integrin β1 mRNA was present in normal cells as well 
as in the cells treated with Lipofectamine 2000 reagent and control plasmids (Figure 3-
1). β1 shRNA caused about a 65% decrease in the β1 mRNA of MG63 cells compared to 
wild-type cells or cells transfected with the control plasmids. 
 
Figure 3-1: RT-PCR and qRT-PCR demonstrating a 65% reduction in β1 integrin mRNA. 
 
Cell number, alkaline phosphatase activity, and osteocalcin levels were similar in 
wild-type MG63 and β1 scrambled MG63 cells, indicating that plasmid transfection by 
itself does not alter osteoblast phenotype.  This comparison was completed by Liping 
Wang and is reported in the published study [102].  The comparisons presented in this 
thesis are between wild-type MG63 and β1-silenced MG63 cells in response to surface 
roughness and 1α,25(OH)2D3. 
Increasing surface roughness decreased the number of wild-type MG63 cells as 
shown in Figure 3-2.  β1 silencing reduced cell number compared to wild-type MG63 
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cells by approximately 40% on all surfaces. The effect of 1α,25(OH)2D3 on wild-type cells 
was to reduce cell number to the level seen in β1-silenced cells. 1α,25(OH)2D3 also 
decreased the number of β1-silenced cells, but the effect was less robust than on wild-
type MG63 cells. 
 
Figure 3-2:  Effect of surface roughness and 1α,25(OH)2D3 on cell number in wild-type 
MG63 and β1 silenced cells.  * Ti surface vs. Plastic (TCPS); • 1,25 vs. vehicle control; # 
β1 siRNA vs. control 
 
Alkaline phosphatase activity was increased in wild-type cells on rough SLA and 
TPS surfaces and with treatment of 1α,25(OH)2D3 (Figure 3-3).  The effects of β1-
silencing on osteoblast differentiation were surface dependent.  β1-silencing reduced 
alkaline phosphatase specific activity on all titanium surfaces, but the percent reduction 
was greater on the rougher surfaces. 1α,25(OH)2D3 stimulated alkaline phosphatase 
activity in wild-type and β1-silenced cells.  Osteocalcin levels varied in the same manner 
as alkaline phosphatase activity.  β1-silencing caused a small reduction in osteocalcin 
production in cells grown on TCPS and PT surfaces, but caused a large reduction on 
SLA and TPS surfaces (Figure 3-4).  Osteocalcin levels were similar in all β1-silenced 
cells regardless of surface, although a small surface-dependent increase was seen on 




























W i l d  T y p e
W i l d  T y p e  +  1 ,2 5
1  S i RNA






the SLA surface.  1α,25(OH)2D3 had a stimulatory effect on osteocalcin levels in all cells 
but this effect was attenuated significantly in the β1-silenced cells. 
 
Figure 3-3:  Effect of surface roughness and 1α,25(OH)2D3 on alkaline phosphatase 
activity in wild-type MG63 and β1 silenced cells.  * Ti surface vs. Plastic (TCPS); • 1,25 
vs. vehicle control; # β1 siRNA vs. control 
 
Figure 3-4:  Effect of surface roughness and 1α,25(OH)2D3 on osteocalcin levels in wild-
type MG63 and β1 silenced cells.  * Ti surface vs. Plastic (TCPS); • 1,25 vs. vehicle 
control; # β1 siRNA vs. control 
 
Production of local regulatory factors was also sensitive to β1-silencing but the 
consequence of β1-silencing was specific to each of the factors examined.  OPG levels 
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were reduced by approximately 50% in the β1-silenced cells, regardless of surface, 
although β1-silencing did not prevent the surface-dependent increase in OPG production 
(Figure 3-5). 1α,25(OH)2D3 increased OPG in all cultures, regardless of surface.  The 
relative stimulatory effect of the hormone was less robust in wild-type MG63 cells than 
β1-silenced cells.  In the β1-silenced cells, 1α,25(OH)2D3 caused a 100% increase in 
OPG levels compared to vehicle control treatment on all surfaces.  Despite these 
increases, the levels of OPG in the β1-silenced cells grown on SLA and TPS were still 
not as great as those seen in wild-type cultures. 
 
Figure 3-5:  Effect of surface roughness and 1α,25(OH)2D3 on osteoprotegerin levels in 
wild-type MG63 and β1 silenced cells.  * Ti surface vs. Plastic (TCPS); • 1,25 vs. vehicle 
control; # β1 siRNA vs. control 
 
PGE2 production was reduced in β1-silenced cells on all surfaces but the effect of 
silencing on this parameter was relatively small (Figure 3-6).  1α,25(OH)2D3 had no 
discernable effect on PGE2 production by wild-type MG63 cells grown on plastic or PT; 
however, 1α,25(OH)2D3 did have a stimulatory effect on PGE2 levels on SLA and TPS 
surfaces.  The effect of 1α,25(OH)2D3 was slightly less robust in the β1-silenced cells.  
Total levels of TGF-β1 varied with surface roughness in wild type and β1-silenced cells 
(Figure 3-7). Cells transfected with the β1 shRNA produced 40–50% less TGF-β1 on 
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each surface.  1α,25(OH)2D3 increased TGF-β1 slightly in the wild-type cells, but it had 
no significant effects in β1-silenced cells. 
 
Figure 3-6:  Effect of surface roughness and 1α,25(OH)2D3 on PGE2 levels in wild-type 
MG63 and β1 silenced cells.  * Ti surface vs. Plastic (TCPS); • 1,25 vs. vehicle control; # 
β1 siRNA vs. control 
 
 
Figure 3-7:  Effect of surface roughness and 1α,25(OH)2D3 on TGF-β1 levels in wild-
type MG63 and β1 silenced cells.  * Ti surface vs. Plastic (TCPS); • 1,25 vs. vehicle 
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The results in this study provide definitive evidence that the effects of surface 
microarchitecture on osteoblast differentiation and the response to 1α,25(OH)2D3 are 
mediated in part through the β1 integrin.  Silencing of the β1 integrin resulted in reduced 
cell numbers as well as in reductions in alkaline phosphatase specific activity and levels 
of osteocalcin, OPG, PGE2, and TGF-β1.  Moreover, it inhibited the effects of surface 
roughness on these parameters.  These results are consistent with the hypothesis that 
β1 and its heterodimeric partners, particularly α2β1 and α5β1, are critical in mediating 
extracellular matrix cues for osteoblast attachment, proliferation, and differentiation. 
Inhibition of osteoblast proliferation is often associated with enhancement of 
differentiation [171], and it has been shown to occur on titanium surfaces with rough 
microtopographies [158].  However, in the present study the β1-silenced cells had a 
reduced capacity for both proliferation and differentiation.  Attachment of many cell 
types, including osteoblasts, is critical to anchorage dependent signals regulating cell 
cycle control and survival.  For example, multiple groups have shown that the initial 
attachment of osteoblasts or osteoprogenitor cells to Ti surfaces is via α5β1 [37, 146].  
Binding of the α5β1 integrin to fibronectin can act through PI3K and Akt pathways to 
promote cell survival [47, 48], or through JNK and MAP kinase-mediated pathways to 
promote cell proliferation and early differentiation [44, 49].    How the β1 integrin is 
involved in mature osteoblast differentiation is unclear, but it is known be involved in 
numerous signaling pathways.  For example, many integrins activate PKC and ERK1/2 
mediated pathways shown to increase Runx2 transcriptional activity and increase 
osteoblastic differentiation [44, 50].  Moreover, many growth factors, including BMP or 
membrane 1α,25(OH)2D3 receptors present in caveolae, require integrin binding for 
proper signaling [138].  For this reason, it is not surprising that β1-silenced cells have 
both decreased proliferation and differentiation. 
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The β1 integrin partners with α2 and α5 in MG63 cells [172], but is not known if 
one or both heterodimers was affected differentially by the silencing.  It is likely that both 
heterodimers were involved.  Raz et al. previously showed that both α2 and β1 increase 
as a function of time in culture in MG63 cells grown on titanium whereas α5 is reduced 
[40], suggesting that enhanced differentiation mediated by integrins on these substrates 
is dependent on the α2β1 heterodimer. α2β1 binds to type I collagen in the bone 
extracellular matrix , and therefore, might be more important for differentiation once the 
cells become established on their substrate. Subsequent work since this study has 
shown that knockdown of the α2β1 integrin inhibits differentiation of MG63 cells in 
response to surface topography and 1α,25(OH)2D3 [41].  Some studies suggest that α5β1 
mediates attachment and differentiation of osteoprogenitors and possibly early 
osteoblast, but that the α2β1 integrin is required for osteoblast differentiation [146]. 
Integrin β1 deficiency may also affect osteoblast differentiation via changes in 
local factor production.  Our results showed that the levels of OPG, PGE2 and TGF-β1 in 
the conditioned media of the MG63 cells were reduced in the β1-silenced cells.  OPG, 
PGE2 and TGF-β1 are all associated with osteogenesis and previous studies show that 
all are increased in MG63 cultures grown on SLA and TPS surfaces [69].  β1 silencing 
blocked most of the stimulatory effects of surface microroughness on each of these 
parameters.  It has been shown previously that inhibition of prostaglandin production 
blocks the stimulatory effect of surface microarchitecture on osteoblastic differentiation 
[173]. This supports the possibility that a reduction in PGE2 production mediated the 
reduction in differentiation observed in the β1-shRNA treated cells.   
OPG is produced by osteoblasts as a decoy receptor for RANKL, thereby 
suppressing the differentiation of osteoclasts and inducing their apoptosis [154, 174]. 
Soluble RANKL is produced by osteoblasts to deplete local levels of OPG, thereby 
reducing the inhibitory effect of OPG on osteoclast formation and activity. Soluble 
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RANKL was not detectable in the cultures, either in cultures of wild-type cells or in 
cultures of the transfectants.  Others have shown that integrin β1 upregulates RANKL 
expression on osteoblasts [165], while this study showed that β1 may be involved in 
increasing OPG secretion.  The fact that β1 appears to play such dual roles hints at 
complex feedback loops with other receptors. 
1α,25(OH)2D3 is a bone anabolic agent that regulates the differentiation of 
osteoblasts by increasing alkaline phosphatase expression and activity, expression of 
osteocalcin, and production of local factors including OPG, PGE2, and TGF-β1 [69, 175]. 
Growth on surfaces with rough microtopography modifies the response of osteoblasts to 
1α,25(OH)2D3 and effects of microtopography per cell are synergistic with those of 
1α,25(OH)2D3.  β1 silencing reduced the effects of 1α,25(OH)2D3 on alkaline 
phosphatase activity and osteocalcin production.  While alkaline phosphatase and 
osteocalcin are both regulated by 1α,25(OH)2D3, the mechanisms involved are not 
identical [176], suggesting that β1 mediates its effects via multiple pathways shared in 
common with 1α,25(OH)2D3 and integrin signaling.  Previous studies demonstrated that 
surface roughness exerts its effects on TGF-β1 via PKC signaling while the PKA 
pathway was involved in mediating the effects of surface roughness on PGE2 production 
[175]. 1α,25(OH)2D3 modulates osteoblast differentiation via these pathways as well as 
through traditional nuclear vitamin D receptor mechanisms [176, 177]. In addition, the β1 
integrin could modulate these pathways via interactions with caveolae since receptors 
for both 1α,25(OH)2D3 and TGF-β1 have been reported in caveolae.  While it is tempting 
to try to explain the actions of the β1 integrin through one single pathway, such as PKC, 
silencing of the β1 has likely disrupted multiple signaling pathways, making it clear that 






The results indicate that both osteoblast proliferation and differentiation depend 
on β1 integrin signaling.  Moreover, osteoblast response to the effects of increasing 
surface roughness is diminished, and osteoblasts appear to be less responsive to some 
of the effects of 1α,25(OH)2D3.  These results suggest that complex interplay exists 
between integrin and 1α,25(OH)2D3 signaling pathways.  Given the broad importance of 
the β1 integrin demonstrated herein this study, it is now critical to investigate the role of 
specific integrin pairs, such as α2β1 and α5β1, to determine how these integrins regulate 
osteoblast attachment, proliferation, and differentiation in response to implant surface 





Role of the α5β1 Integrin in Mediating the Response to  
Surface Energy and Microtopography 
 
4.1. Introduction 
 The previous chapter demonstrated that the β1 integrin subunit is involved in 
osteoblast response to surface microtopography.  However, osteoblasts possess 
multiple heterodimers of the β1 integrin that play disparate roles in affecting osteoblast 
proliferation and differentiation at different points in osteoblast maturation.  As discussed 
in the previous section, osteoblasts express the integrins α1β1, α2β1 α3β1, α4β1, α5β1, 
α6β1, α8β1, αVβ3, αVβ5 [34].  The integrins α2β1 and α5β1 have been shown to be 
particularly important in osteoblast maturation and bone development.  The α2β1 integrin 
binds to type I collagen [14], which is the dominant bone matrix protein, and α2β1-
mediated binding to the extracellular matrix has been reported to regulate osteoblastic 
differentiation [160, 161].  The α2β1 integrin has also been shown to be critical for 
osteoblast response to surface energy and microtopography, since previous reports 
have shown that silencing of the α2β1 integrin inhibits osteoblast differentiation induced 
by increasing surface roughness [41].  The integrin α5β1 is selective for fibronectin and is 
known to be important in early attachment and differentiation of osteoblast and 
osteoprogenitor cells.  Reports have shown that α5β1 is necessary for bone-like nodule 
formation in osteoprogenitor cells grown on TCPS [162, 163].  Moreover, a recent study 
claims that α5β1 silencing in bone marrow stromal cells reduces cell attachment, 
proliferation, and osteogenic differentiation [146].  Overall, evidence suggests that the 
α5β1 integrin may be involved in early osteoblastic differentiation, but its role in mediating 
the response of osteoblasts to surface microtopography in osteoblasts in unclear. 
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Surface chemistry and topography are well known to effect integrin expression, 
which in turn directs cell response.  Previous studies have shown in MG63 cells grown 
on titanium that both α2 and β1 increase as a function of time in culture and increasing 
surface roughness, whereas α5 is reduced [40].  This change in integrin expression was 
correlated with changes in osteocalcin expression, suggesting a shift from α5β1 to α2β1 
expression as osteoblasts mature.  In addition, integrin β1 mRNA is regulated by 
1α,25(OH)2D3 in a dose-, time-, and surface roughness-dependent manner, but it is 
regulated independently of either α2 or α5 expression.  Previous studies in MG63 cells 
showed an increase in α5β1 binding and FAK activity on TPS and SLA surfaces versus 
PT surfaces [178].  Using blocking antibodies against α5β1 resulted in a decrease in 
proliferation ([3H]-thymidine incorporation) on all surfaces and an increase in alkaline 
phosphatase activity at 7 days post-seeding.  These findings suggest a strong role of 
α5β1 in controlling proliferation, and also suggest α5β1-mediated control of differentiation 
at some time points.  However, no studies have examined the effect of α5β1 silencing on 
production of late markers for differentiation in osteoblasts. 
Multiple groups have shown that the initial attachment of osteoblasts or 
osteoprogenitor cells to titanium surfaces is via α5β1 [37, 146].  In osteoblasts, binding of 
the α5β1 integrin to fibronectin increases activity of PI3K, Akt, and Bcl-2, which in turn 
reduces caspase activity and promotes cell survival [47, 48].  In addition, the α5β1 
integrin can act through JNK and MAP kinase-mediated pathways to phosphorylate c-
Jun and c-Fos, which form activator protein 1 (AP-1), a transcription factor complex that 
promotes cell proliferation and also induces expression of several early osteogenic 
target genes [44, 49]. These studies suggest that the α5β1 integrin signals through a 
wide variety of signaling pathways to promote cell survival, proliferation, and early 
osteoblast differentiation.   
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The present study aims to determine whether the α5β1 integrin mediates the 
synergistic effects of surface roughness and 1α,25(OH)2D3 on osteoblast proliferation 
and differentiation.  To determine the role of the α5β1 integrin, osteoblast-like MG63 cells 
were transduced with lentiviral particles containing a plasmid with shRNA targeting the 
α5 integrin subunit.  Control and α5-silenced MG63 cells were plated on titanium 
substrates with different surface chemistries and microtopographies to determine 
whether loss of the α5β1 integrin altered osteoblast proliferation or differentiation. 
 
4.2. Materials and Methods 
Titanium Surfaces 
Institut Straumann AG (Basel, Switzerland) supplied the PT, SLA, and modSLA 
titanium disks used in this study.  Surfaces were manufactured and characterized as 
described in chapter 2.  TCPS surfaces were also used as controls. 
 
Lentiviral-based Transfection of MG63 Cells with α5-shRNA 
MG63 cells were used as a model in this study and are described in chapter 2. 
Sigma MISSION® shRNA Lentiviral Transduction Particles targeting the alpha 5 integrin 
gene (ITGA5, NM_002205) were purchased from Sigma-Aldrich (St. Louis, MO).  Five 
different clones were purchased in order to maximize the chance for knockdown.  The 



















 In addition to these lentiviral vectors (clones 49, 50, 51, 52, 53), control vectors 
were also used including MISSION® pLKO.1-puro Control Transduction Particles.  
Control MG63 cells with and without selection media were also used as transduction 
controls. Transduction of MG63 cells was performed under biosafety level 2 safety 
precautions.  Briefly, MG63 cells were plated in 24-well plates at a seeding density of 
10,000 cells/cm2 in DMEM + 10% FBS + 1% Penicillin/Streptomycin.  Cells were 
transduced after reaching 60-70% confluence.  On the day of transduction, media was 
changed to DMEM + 10% FBS and cells were transduced with lentiviral particles at a 
multiplicity of infection (MOI) of 30.  Each vector was transduced into two wells of the 24-
well plate.  After 18 hours, media was discarded into bleach solution and was replaced 
by DMEM + 10% FBS + 1% Penicillin/Streptomycin.  On the following day, 0.5 ug/mL of 
puromycin was added to every well except the control MG63 cells.  Control cells and 
vectors not expressing puromycin resistance genes were killed.  Clone 50 did not 
survive transduction.  Transduced cells (pLKO.1-puro “vector” control; α5-shRNA clones 
49, 51, 52, and 53) containing the puromycin resistance gene survived and were passed 
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to T-25s at confluence.  Puromycin selection was continued throughout passaging.  
Cells were then passed to T-75s for expansion. 
 
Testing Silencing Efficiency:  qRT-PCR and Western Blots 
The effectiveness of the α5-shRNA silencing was determined first by quantitative 
reverse transcription polymerase chain reaction (qRT-PCR). All five clones were 
screened using qRT-PCR to determine relative α5 mRNA expression.  Total RNA was 
isolated using the TRIZOL reagent (Invitrogen) from wild-type MG63 cells as well as 
from cells treated α5-shRNA clones.  Following RNA isolation, RNA was quantified using 
a NanodropTM spectrophotometer (Thermo Scientific, Wilmington, DE).  All samples were 
normalized to 1ug RNA/uL with diethylpyrocarbonate (DEPC)-treated water.  Reverse 
transcription was performed using OmniscriptTM reverse transcriptase (Invitrogen) and 
random primers.  qRT-PCR was performed was carried out in a total volume of 25 µl in 
PCR master mix containing 12.5 µl SYBR® green, 200 ng each of sense and antisense 
primer, 1uL 25mM MgCl2, and RNAase free water.  All reactions were carried out for 40 
cycles on an i-cyclerTM (Bio-Rad Laboratories, Hercules, CA) using software i-cycler 
iQTM, version 3.0a.  The following primers and conditions were used for each gene: 
 ITGA5     R 57ºC 5‟-AAGTTCCCTGGGTGTCTG-3‟ 
 ITGA5     F 57ºC  5‟-ATCTGTGTGCCTGACCTG-3‟ 
 GapDH   R 54ºC  5‟-GCTCTCCAGAACATCATCC-3‟ 
 GapDH   F 54ºC  5‟-TGCTTCACCACCTTCTTG-3‟ 
 
To normalize the content of cDNA samples, we used the comparative threshold 
(Ct) cycle method, which consists of the normalization of ITGA5 versus the endogenous 
reference gene GAPDH.  Expression of the α5 integrin gene (ITGA5) normalized to 
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GapDH was measured in Control MG63, vector control, and α5-shRNA clones.  Clone 50 
did not survive puromycin selection.  Clone 49/51 is transfected with both the clone 49 
and 51 lentiviral particles.  Expression of ITGA5 (Figure 4-1) demonstrates that clone 52 
exhibits the highest level of suppression. 
 
Figure 4-1:  qRT-PCR of ITGA5/GapDH expression levels in Control MG63, vector 
control, and α5-shRNA clones. 
 
 Knockdown efficiency was also measured using western blot analysis.  Control 
cells and α5-shRNA clones were grown in T-75 tissue culture flasks until confluence.  
Cells were harvested using RIPA lysis buffer and were scraped to collect protein.  
Westerns were run on 10% SDS-polyacrylamide gels and were stained with antibodies 
for integrin α5 (H-104, Santa Cruz Biotechnology, Santa Cruz, CA) and GapDH (MAB374 
Chemicon, Billerica, MA).  Protein expression of integrin α5 by western blot analysis 





Figure 4-2:  Two representative western blots for integrin α5 and GapDH in Control 
MG63, vector control, and α5-shRNA clones.  Clone 52 was selected for silencing. 
 
Functional Response of Osteoblast-like MG63 Cells 
 The functional ability of α5β1 to mediate cell attachment was also measured in 
order to determine if α5-silencing was effective.  To measure attachment, 96-well plates 
were coated for one hour with 1% BSA solution, 10 µg/mL collagen I, or 10 µg/mL 
fibronectin.  Following coating, plates were then blocked for an hour with 1% BSA 
solution.  Wild type MG63 cells and two α5-silenced clones (52 and 53) were incubated 
with a calcein solution for 30 minutes at 37ºC prior to plating.  Each group of cells was 
then plated at 10,000 cells / cm2 on the coated 96-well plates (N=7) and the bottom row 
was left blank.  Cells were allowed to attach for 45 minutes at room temperature (21ºC).  
The plate was then centrifuged upside-down at 350g to detach weakly attached cells.  
Preliminary studies had identified 45 minutes and 350g as the time point and speed as 
optimal for the cell type and conditions described here.  Cells were observed under a 
light microscope and calcein levels were measured using a microplate reader.  Figure 4-
3 on the following page shows that calcein intensity is reduced on fibronectin coated 
surfaces in both clones 52 and 53 compared to wild-type MG63 cells, thus indicating that 
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silencing of the α5 integrin subunit impaired cell ability to attach to fibronectin.  Clone 53 
also demonstrated reduction in calcein intensity.  Attachment to collagen I surfaces was 
also low in all cell types due to the relatively short attachment time.   
 
Figure 4-3:  Attachment of control MG63 and α5-shRNA clones 52 and 53 determined 
by measure of calcein intensity following centrifugation at 350g.  The α5β1 integrin binds 
primarily to fibronectin.  Attachment was reduced in both α5-shRNA clones on 
fibronectin.  * α5-shRNA clone vs. control. 
 
Calcein readings were corroborated by images taken under light microscopy.  
Two representative images each for control cells and α5-shRNA clones 52 and 53 are 
shown in Figure 4-4 on the following page.  The α5-shRNA clone 52 showed more 
reduction in attachment than clone 53 based on qualitative visual observation, but 
calcein intensity measurements were similar.  Based on the combined results from qRT-
PCR, western blots, and functional testing, α5-shRNA clone 52 was chosen for use in 




Figure 4-4:  Visual images of control MG63 and α5-shRNA clones 52 and 53 cells on 
fibronectin-coated surfaces following centrifugation at 350g.  The α5-shRNA clones 52 
and 53 showed reduction in attachment based on visual observation, which was 
confirmed by calcein intensity readings in the previous figure. 
 
Surface Protein Expression:  Flow Cytometry 
 Surface protein expression of integrin α5 in control MG63 and α5-silenced cells 
(clone 52) was analyzed using flow cytometry.  In addition, expression levels of other 
integrins were measured to determine if integrin α5 silencing leads to increases in 
expression of other alpha subunits to compensate for loss of integrin α5.  Briefly, we 
purchased an alpha integrin blocking and IHC kit (Millipore, Temecula, CA) containing 
integrins α1 (MAB1973Z-20), α2 (MAB1950Z-20), α3 (MAB1952Z-20), α4 (MAB1698Z-20), 
α6 (MAB-1378-20), and αV (MAB1953Z-20).  Secondary antibodies were FITC tagged 
and selected to bind to the respective IgG isotypes (anti-mouse IgG1-FITC, anti-rat IgG-
FITC, Santa Cruz Biotechnology) of the primary antibodies.  IgG-FITC antibodies were 
used in the absence of primary antibodies as controls.  The integrin α5 antibody (NKI-
SAM1-FITC, Santa Cruz Biotechnology) did not require a secondary antibody.  Mouse 
IgG2b-FITC (Santa Cruz Biotechnology) was used as a control for integrin α5.  Flow 
cytometry was performed on a Becton Dickinson LSR II flow cytometer.  Histograms 
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were compiled from 5,000 counts within threshold side- and forward-scatter values.  
Positive expression is considered to be FITC values above the top 1% of FITC values in 
the control cell population.  Histograms for the integrin α5 expression are shown below in 
Figure 4-5. Integrin α5 expression is low in both control and α5-silenced cells.  Silencing 
of α5 only led to only a very small reduction in surface levels of the α5 integrin. 
Figure 4-5:  Flow cytometry of the α5 integrin in MG63 and α5-shRNA clones.  Lines 
represent “percent positive” cells based on the top 1% of wild type IgG labeled cells.   
 
Histograms of the expression of the α1, α2, α3, α4, α6, and αV integrins in MG63 
and α5-silenced cells are shown in Figure 4-6 on the next page.  Slight increases in 
expression of integrins α3 and α4 were observed in α5-silenced cells versus control cells.  
Integrin α1 was not detected in either cell type.  Integrin α3 was the most strongly 
detected integrin in both cell types. Integrin α2 and α6 levels were not affected by α5 




Figure 4-6:  Alpha integrin expression in control MG63 and α5-silenced MG63 cells.  
Lines represent “percent positive” cells based on the top 1% of wild type IgG labeled 
cells.  Lines and unsmoothed histograms are displayed for α3, α4, and α5 cells where 




Physiological Responses of Osteoblasts MG63 Cells 
Wild type MG63 and α5-silenced MG63 cells (clone 52) were grown to confluence 
in T-75 tissue culture flasks and then subcultured into 24-well plates on six discs each of 
TCPS, PT, SLA, or TPS surfaces.  When the cells reached confluence on tissue culture 
plastic, media in all wells were replaced with experimental media containing ethanol 
vehicle or 10-8 M 1α,25(OH)2D3.  Cells were cultured an additional 24 h. At that time, 
cells were harvested and conditioned media were collected.  Osteoblast phenotype was 
assessed by measuring cell number, alkaline phosphatase activity, and levels of 
osteocalcin, TGF-β1, and OPG according to protocols discussed in chapter 2.  
 
Statistical Analysis 
The data presented are from one of two separate sets of experiments, both of 
which yielded comparable results for surface roughness effects.  The effects of 
1α,25(OH)2D3 were only tested in one experiment.  Each data point represents the mean 
± standard error of the mean (SEM) of six independent cultures. Data were analyzed by 
analysis of variance and statistical significance between groups was determined using 
Bonferroni‟s modification of Student‟s t-test. p<0.05 was considered to be significant. 
 
4.3. Results 
 Assessment of α5 silencing effectiveness presented in the previous section 
demonstrated that mRNA levels of α5 were reduced by nearly 94% (Figure 4-1), protein 
levels of α5 were reduced between 60-83% (Figure 4-2), and the functional ability of α5 to 
mediate adhesion to fibronectin was reduced by roughly 60% (Figures 4-3 and 4-4) in 
α5-silenced cells compared to control MG63 cells.  Surface expression levels of integrin 
α5 were only slightly reduced (49.9% positive vs. 33.6% positive) in α5-silenced cells 
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(Figure 4-5).  Expression of other alpha integrin subunits was altered (Figure 4-6), 
possibly to compensate for lower levels of α5.  Slight increase in expression of integrins 
α3 and α4 was observed in α5-silenced cells versus control cells; however, expression of 
no other integrins appeared to be affected.  The lack of silencing observed using flow 
cytometry raises significant concerns in comparing control to α5-silenced cells. 
 The physiological response of α5-silenced cells and control MG63 cells to surface 
roughness and surface chemistry was similar in both cell types.  Treatment with 10-8 M 
1α,25(OH)2D3 did not affect either control MG63 or α5-silenced cells.  These data are 
similar to untreated cells and so the 1α,25(OH)2D3 treated groups are not shown.  Cell 
number decreased in both control MG63 and α5-silenced cells as surface roughness was 
increased (Figure 4-7).  Rough and high surface energy surfaces (modSLA) caused the 
most reduction in cell number.  No differences were observed between control MG63 
and α5-silenced cells. 
 
 
Figure 4-7:  Effect of surface roughness on cell number in control MG63 and α5-silenced 
cells.  * Ti surface vs. Plastic (TCPS); • α5 shRNA vs. control. 
 
Markers for osteoblast differentiation were not affected by silencing of the α5 
integrin.  Alkaline phosphatase activity was slightly increased in control cells on modSLA 
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surfaces compared to PT and TCPS (Figure 4-8).  There was no surface effect in α5-
silenced cells, but alkaline phosphatase activity in α5-silenced cells was not statistically 
different from control cells on any surfaces.  Osteocalcin levels were also very similar in 
control MG63 and α5-silenced cells.  Increasing surface roughness and high surface 
energy increased osteocalcin levels in both control and α5-silenced cells (Figure 4-9).   
 
 
Figure 4-8:  Effect of surface roughness on alkaline phosphatase activity in control 
MG63 and α5-silenced cells.  * Ti surface vs. Plastic (TCPS); • α5 shRNA vs. control. 
 
 
Figure 4-9:  Effect of surface roughness and on osteocalcin levels in control MG63 and 
α5-silenced cells.  * Ti surface vs. Plastic (TCPS); • α5 shRNA vs. control. 
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Local factor production was also examined.  Active and total TGF-β1 were similar 
in α5-silenced versus control MG63 cells.  Both active and total TGF-β1 levels increased 
with increasing surface roughness in control MG63 and α5-silenced cells (Figure 4-10).   
 
 
Figure 4-10:  Effect of surface roughness on active and total TGF-β1 in control MG63 
and α5-silenced cells.  * Ti surface vs. Plastic (TCPS); • α5 shRNA vs. control. 
 
 
 Osteoprotegerin levels were also not affected by α5-silencing.  Increasing surface 
roughness and high surface energy increased osteoprotegerin levels in both control and 
α5-silenced cells (Figure 4-11). 
 
 
Figure 4-11:  Effect of surface roughness on osteoprotegerin levels in control MG63 and 





 The results herein demonstrate that α5-silencing did not lead to large changes in 
osteoblast response to surface chemistry or topography in MG63 cells; however, the 
lack of α5-silencing at the cell surface level (flow cytometry) raises significant concerns 
regarding the validity of any conclusions made from this data.  The α5-silenced cells had 
altered TGF-β1 production in response to 1α,25(OH)2D3, but no other measures for 
osteoblast proliferation, differentiation, or local factor production were altered 
consistently in α5-silenced cells.  If the α5 integrin was truly „knocked down‟ in this study, 
then the results suggest that the α5 integrin is not required in the response of MG63 cells 
to respond to changes in surface chemistry and surface topography.  This result is 
somewhat surprising since various other studies have suggested that the α5 integrin is 
important in promoting proliferation and early differentiation in osteoblasts [162, 163], 
and that the α5 integrin is involved in initial attachment of osteoblasts and 
osteoprogenitor cells to titanium surfaces [37, 146].  Because of the limited silencing 
achieved at the cell surface level, future α5-silencing studies will be necessary to confirm 
these findings. 
Previous studies using blocking antibodies against α5β1 showed that cells 
exhibited decreased proliferation ([3H]-thymidine incorporation), that cell number was 
slightly decreased on TCPS and PT  (but not SLA or TPS) surfaces seven days post-
seeding, and that alkaline phosphatase activity was slightly decreased at 7 days post-
seeding [178].  The results from the present study did not show differences in cell 
number, nor did the results show changes in alkaline phosphatase activity due to surface 
roughness or chemistry.  Clear differences exist between the previous study and the 
current study.  Although both studies used MG63 cells, the previous used blocking 
antibodies, which may be bind and affect integrins not on the surface side of the cell 
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[167, 168].  Cells also likely differed in the level of confluence since the previous 
experiment tested cells at particular day post-seeding while the present study used cells 
harvested at visual confluence of TCPS surfaces. 
 Since the observed effects of α5-silencing were minimal in terms of altering 
osteoblast response to surface roughness and topography, it obviously raises concerns 
over silencing efficiency.  Results showed that transduction of α5-shRNA led to 
significantly decreases in α5 mRNA levels and α5 protein levels.  Surface receptor 
expression measured by flow cytometry was only slightly reduced.  The flow cytometry 
results are certainly concerning given that integrins function at the cell surface; however, 
the ability of α5 to mediate attachment to fibronectin coated surfaces was demonstrated 
to be reduced in α5-silenced cells.  It is possible that α5-silencing affects initial 
attachment in a more pronounced manner because high levels of α5β1 would presumably 
be required to bind fibronectin coating surfaces.  However, low levels of α5 expression 
may be sufficient for later α5β1 functions that affect osteoblast phenotype.  Insufficient 
knockdown is often a limitation of shRNA-based studies, although the results here do 
suggest that α5 mRNA and protein expression and α5β1-mediated attachment were 
impaired. 
 Surface expression levels of integrin subunits α3 and α4 were slightly upregulated 
in α5-silenced cells.  The α3 integrin subunit was highly expressed on surfaces of control 
MG63 and α5-silenced cells.  The α3β1 integrin can bind to collagen, fibronectin, and 
laminin and has been shown to be highly expressed in osteoblasts synthesizing bone 
[38].  The α4β1 integrin can bind an alternative splice variant of fibronectin.  Studies have 
reported that α4β1 is not found in osteoblasts in vivo [38], but that it is expressed on 
osteoblasts grown on titanium surfaces [37].  It is possible that MG63 cells may 
compensate for loss of α5β1 integrins by upregulating expression of α3β1 or α4β1, but 
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relatively little is known if these integrins play a role in osteoblast function in vivo or 
osteoblast response to surface properties in vitro. 
 Overall, the results suggest that the α5β1 does not regulate the response of 
MG63 cells to surface roughness and topography, although limited silencing of α5 as 
measured by flow cytometry raises doubts onto the validity of this conclusion.  Even if 
α5-silencing was effective, there are also concerns regarding the use of a single cell line 
for this study.  MG63 cells are an osteosarcoma cell that has characteristics of an 
immature osteoblast.  It is possible that normal human osteoblasts might respond 
differently since MG63 cells are cancerous and have multiple mutations that affect cell 
cycle regulation and other functions likely targeted by α5β1 signaling.  In addition, other 
reports have suggested that the α5β1 integrin is important in the differentiation of 
osteoprogenitor cells to osteoblasts [146, 162, 163].  Silencing of the α5β1 integrin in 
osteoprogenitor models might alter cell response to surfaces, although that possibility 
was not tested here.  In contrast, studies silencing the α2β1 integrin have shown that it is 
critical in MG63 cell response to surfaces [102].  Perhaps the α5β1 integrin regulates the 
attachment and proliferation of osteoprogenitors, but the α2β1 integrin is critical in 
differentiation of osteoblasts.  This possibility will have to be explored in future tests.   
 
4.5. Conclusion 
 This study suggests that the α5β1 integrin is not required for the response of 
osteoblast-like MG63 cells to changing surface topography and surface energy; 
however, limited α5-silencing at the cell surface level (flow cytometry) makes it 
impossible to definitively make these conclusions.  Markers for osteoblast proliferation, 
differentiation, and local factor production were similar in control and α5-silenced MG63 
cells on TCPS, PT, SLA, and modSLA surfaces.  TGF-β1 levels were slightly increased 
in α5-silenced cells treated with 1α,25(OH)2D3 versus control cells treated similarly, but 
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no other markers showed a consistent effect of α5-silencing on osteoblast response to 
1α,25(OH)2D3.  Overall, these results and the results of β1-silencing in previous chapter 
suggest that osteoblast response to surface roughness is not mediated by α5β1, but by 
other αβ pairs including α2β1.  Because of low cell surface level silencing, future tests 
using α5-silenced cells are necessary to confirm these results and make definitive 
conclusion regarding the role of α5β1.  In addition, silencing of other osteoblast cell lines 
is necessary to determine if α5β1 affects differentiation at other stages of osteoblast 
maturation.  Integrin expression certainly changes as osteoblasts mature, although the 










Recent efforts by bioengineers have focused on the development of 
biocompatible surfaces engineered to elicit specific biological responses and even mimic 
native tissue.  Methods for controlling the surface chemistry and energy can affect 
protein adsorption on the surface of an implant; however, the surface in such cases does 
not interact directly with attached cells, nor is there controllability over the types of cells 
that attach or the types of signaling cues that are presented to attached cells. Because 
of these limitations, researchers have turned to the use of biologically modified surfaces 
using specific proteins, peptides, and attachment chemistries. 
Many researchers believe that surfaces functionalized with specific proteins or 
peptides can aid in the osteointegration of implants by favoring attachment of 
osteoprogenitor cells and by promoting osteoblastic differentiation and the formation of 
mineralized bone matrix [5, 42, 179].  Moreover, functionalized surfaces could 
discourage early attachment of macrophages and fibroblasts that may be associated 
with chronic inflammation, fibrosis, and eventual implant failure.  Peptide 
functionalization methods can be used in conjunction with rough implant surface 
topographies already known to enhance osteoblast differentiation in vitro and increase 
implant pull-out strength in vivo [5, 31, 69].  The combination of osteoblast-specific 
ligands with rough surface microtopographies would provide initial cues to enhance early 
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osteoblast attachment and differentiation, and would also provide a rough surface 
topography known to sustain long-term osteointegration and implant fixation. 
Integrins are cell receptors involved with recognition and cell attachment to the 
extracellular matrix, and are often the target of bioengineered surfaces [32, 180].  The 
most common design approach is to attach short oligopeptides, which contain specific 
amino acid sequences that bind specific cell surface receptors. Oligopeptides are more 
cost-effective and less susceptible to degradation than full-length proteins [93].  In 
addition, oligopeptide conformation and presentation of binding domains are easier to 
control than for full-length proteins. One of the most commonly used oligopeptides is 
RGD, which is found in various extracellular matrix proteins, including fibronectin, 
vitronectin, and bone sialoprotein [181-183].  Depending on how it is presented in its 
native protein, it is recognized by multiple integrins including αVβ3.  RGD is also 
recognized by the α5β1 integrin, an integrin that is highly expressed in osteoblasts, 
although high affinity binding of α5β1 to RGD requires the PHSRN synergy site to 
maximize activation of osteoblastic signaling pathways [184]. 
RGD has been extensively shown to enhance osteoblast attachment and 
proliferation [88, 181, 182] and several studies examining cell behavior on TCPS have 
shown that RGD enhances differentiation and bone matrix mineralization [42, 185].  
However, when osteoblasts were grown on sand-blasted/acid etched titanium substrates 
(SLA) that were coated with RGD-functionalized PLL-g-PEG, osteoblast differentiation 
was reduced compared to PLL-g-PEG coated surfaces [95].  The effect of RGD was to 
block the stimulatory effect of the PLL-g-PEG coating on osteoblast differentiation.  
These studies suggest that osteoblast differentiation may be promoted by substrates 
fostering reduced spreading like microtextured titanium and PLL-g-PEG [69, 95].   
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In vivo, RGD has been shown reported to increase osteointegration in some 
studies [86-88], but not others [89, 90].  The biological activity of RGD is less potent than 
that of native fibronectin or the fibronectin fragment FNIII7-10 [42, 91].  This suggests 
that the linear RGD peptide alone may be insufficient for optimal interaction of the cell 
with its substrate or extracellular matrix.  In addition, it is unlikely that any one mimetic is 
responsible for all responses of osteoblasts on a functionalized surface.  It is likely that 
proliferation and differentiation are regulated through separate pathways, which would 
necessitate the use of multiple ligands providing different signaling cues.  Other peptides 
have been found to affect osteoblast attachment and phenotype including KRSR 
(heparan sulfate-binding), GFOGER (α2β1-binding), PHSRN (α5β1-binding), and 
FHRRIKA (heparan sulfate-binding) [42, 186].  Several recent studies suggest that 
increased biological activity can be achieved through the combination of binding 
domains like RGD and GFOGER, RGD and FHRRIKA, or RGD and PHSRN [42, 186-
188].  Taken together, these studies suggest that a combination of binding domains 
presented in the proper spatial configuration is necessary to maximize biological activity 
[42, 188-190].  These studies also suggest that surfaces can be functionalized with 
peptides from two or more proteins, thereby driving optimal attachment, proliferation, 
and differentiation through a combination of signaling cues.   
The present study was based on the hypothesis that osteoblast attachment, 
proliferation and differentiation on a microstructured Ti surface could be enhanced by a 
biomimetic peptide coating that presented a combination of amino acid motifs that 
targeted two different signaling pathways: RGD to target integrin signaling and KRSR to 
target transmembrane proteoglycans.  KRSR was designed based on its basic-basic-
nonbasic-basic (BBXB) amino acid charge structure that was proposed by Cardin et al. 
to bind heparan sulfate, a component of transmembrane proteoglycans expressed by 
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osteoblasts [191].  BBXB patterns are also found in various bone adhesive proteins 
including fibronectin, vitronectin, bone sialoprotein, thrombospondin, and osteopontin 
[151, 192].  KRSR was shown to selectively increase osteoblast adhesion to TCPS 
relative to uncoated controls [192].  In contrast, KSSR, which has a basic-nonbasic-
nonbasic-basic (BXXB) amino acid charge structure, did not support attachment.  These 
two peptides differ in only one amino acid residue, demonstrating the specificity of the 
KRSR effect on attachment.  Whether one or both peptides modulate osteoblast 
differentiation is not known, nor is it known if they have the potential to modify cell 
response to RGD.  
Material surface chemistry affects how cells respond to surfaces via the 
differential adsorption of proteins and other serum components almost immediately 
following implantation [31, 193].  Surface chemistry also greatly affects the conformation 
and presentation of ligands at the surface, making it critical for scientists to consider not 
just the ligands chosen, but also the underlying surface chemistry and the desired 
peptide conformation [42].  Many studies have examined the effects of various ligands 
on polymer surfaces or thin metallic films [179], but these studies may not be relevant to 
rough titanium surfaces given differences in surface energy, surface charge, and 
effective surface area.  Various methods exist for adsorbing or chemically attaching 
proteins or peptides directly to titanium surfaces, including direct adsorption or 
attachment of proteins to adlayers [42, 179].  While methods such as dip-coating 
peptides directly from solution are simple, peptides can assume denatured 
conformations on the surface or other adsorbed proteins may act to shield or displace 
engineered peptides [93, 95, 194].  The use of self-assembled monolayers, which 
include assembling chemistries based on alkanethiols, silanes, alkanephosphonates, 
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interpenetrating polymer networks, or PLL-g-PEG, can overcome many of these 
aforementioned limitations [93].   
PLL-g-PEG was chosen in this study because of its advantages in terms of its 
ease of functionalization, ease of synthesis, stability on titanium surfaces, and ability to 
resist protein adsorption [93, 94].  PLL-g-PEG is a copolymer that forms a comb-like 
monolayer on titanium surfaces and acts to limit non-specific protein adsorption.  PLL-g-
PEG self-assembles on titanium as the positively charged PLL backbone adsorbs to the 
negatively charged titanium oxide surface layer, while the more hydrophilic PEG chains 
are presented at the surface.  PEG has been shown to reduce protein adsorption to less 
than 5 ng/cm2 as well as to greatly reduce cell adhesion [94].  The PEG chains can be 
functionalized at the terminal end, resulting in presentation of the biologically active 
ligand with minimal interference from adsorbed proteins or other sources [95].  Previous 
experiments showed that osteoblast attachment and proliferation are markedly reduced 
on PLL-g-PEG coated titanium surfaces compared to control titanium surfaces, although 
markers for differentiation are significantly increased [95].  PLL-g-PEG functionalized 
with RGD greatly increased osteoblast proliferation, but decreased differentiation 
compared to PLL-g-PEG controls.  These results illustrate the need for attaching ligands 
that not only increase osteoblast attachment and proliferation, but also drive osteoblastic 
differentiation following the initial stages of implantation.   
In the present study, rough titanium surfaces were coated with PLL-g-PEG with 
varying combinations of the peptides RGD and KRSR.  It was hypothesized that RGD 
would support early attachment and proliferation via integrin signaling, and that KRSR 
would drive osteoblastic differentiation via interaction with transmembrane 
proteoglycans.  These combinations of ligands were intended not just to balance cues 
for proliferation and differentiation, but also to potentially lead to synergistic effects on 
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osteoblastic phenotype. Finally, it was hypothesized that the combination of these 
ligands with rough titanium surfaces would provide a mixture of topographic and biologic 




SLA surfaces were manufactured as described extensively in chapter 2. Although 
SLA is normally hydrophobic with an advancing contact angle of 139.88° [74], the SLA 
substrates used in the present study were plasma cleaned prior to use and therefore, 
were hydrophilic.   
 
Synthesis of PLL-g-PEG/PEG-peptide 
Unfunctionalized PLL-g-PEG was synthesized according to protocols by Huang 
et al. and Pasche et al. [195, 196].  Briefly, poly(L-lysine) hydrobromide (PLL-HBr; 
Sigma-Aldrich, Buchs, CH) was dissolved in sodium borate buffer and sterilized with a 
0.22 μm filter.  Succinimide propionate methoxy-PEG (mPEG-SPA; Nektar Therapeutics, 
Bradford, UK) at a molecular ratio corresponding to a grafting ratio g=3.5 was added and 
the reaction was allowed to proceed for 6 hours at room temperature.  Dialysis was done 
first against phosphate buffered saline (PBS, pH 7.4) and then deionized water each for 
24 hours before the product was freeze-dried and stored at -20 ◦C.  
PLL-g-PEG/PEG-peptide polymers were synthesized by Martin Schuler 
according to techniques developed in the Laboratory for Surface Science and 
Technology at ETH Zurich [151]. Briefly, peptides and N-hydroxysuccinimide 
polyethylene glycol vinylsulfone (NHS-PEG-VS, Nektar Therapeutics, Bradford, UK) 
90 
 
were reacted for 5 minutes in a salt buffer solution containing 10 mM N-(2-hydroxyethyl)-
piperazine-N‟-2-ethanesulfonic acid (HEPES; Sigma-Aldrich, Buchs, CH) at pH 8.4.  PLL 
hydrobromide was dissolved in HEPES and added to the reaction.  After one hour 
mPEG-SPA was dissolved in HEPES and added to the final mixture that was stirred for 
24 hours at room temperature.  50 μl of β-mercaptoethanol (Fluka, Buchs, CH) was used 
for quenching.  Prior to freeze-drying, the mixture was dialyzed against deionized water 
for 48 hours.  Deionized water was changed twice a day.  Polymers resulted in a white 
powder and were kept frozen at -20 ◦C before use.  The peptide sequences used were 
N-acetyl-GCRGYGRGDSPG-NH2, N-acetyl-GCRGYGKRSRG-NH2, and N-acetyl-
GCRGYGKSSRG-NH2 (all purchased from JPT Peptide Technologies, GmbH, Berlin, 
Germany).  The Gly-Cys-Arg (GCR) sequence of the linker is critical because reaction 
occurs between the vinylsulfone group of PEG-VS and the thiol group of the cysteine.  
The Gly-Tyr-Gly (GYG) sequence is primarily used as a spacer, but is also used to 
measure grafting efficiency based on the specific hydrogen nuclear magnetic resonance 
(H-NMR) signal of the tyrosine.  Neither peptide alone or in sequence has been reported 
to have biological activity in osteoblasts.   
Several quality control steps were taken to ensure appropriate synthesis and 
functionalization of each batch of polymer [93, 94].  The grafting ratio g and degree of 
peptide functionalization were measured using H-NMR and polymer adsorption was 
measured using optical waveguide lightmode spectroscopy (OWLS) [196].  The surface 
peptide densities were calculated by Dr. Martin Schuler as published elsewhere and are 
shown in Table 5-1 on the following page [88, 94].  Competitive binding was examined in 
earlier studies and showed no preferential binding between different PLL-g-PEG/PEG-
peptide combinations [95].  OWLS was also used to confirm resistance to protein 
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adsorption of all PLL-g-PEG polymer surfaces in full serum, which was estimated at less 
than 5 ng/cm2 [94]. 
Table 5-1:  Molecular weight, grafting ratio, peptide functionalization, polymer/protein 
adsorption and peptide surface density for all polymers and peptides used in creating 





Prior to coating SLA discs, frozen batches of PLL-g-PEG and peptide-
functionalized PLL-g-PEG were warmed to room temperature, dissolved in a salt buffer 
solution (HEPES 2) containing 10 mM HEPES (MicroSelect, Fluka Chemie GmbH, 
Buchs, Switzerland) and 150 mM NaCl at pH 7.4 (to reach a final concentration of 
0.5 mg/ml), filter sterilized using a 0.22 µm filter (Milian, Basel, CH) and used to prepare 
the designated peptide surface densities.  Solutions containing PLL-g-PEG/PEG-peptide 
were mixed with unfunctionalized PLL-g-PEG in order to yield desired surface peptide 
densities.  Multi-peptide PLL-g-PEG surfaces were created by mixing solutions 
containing PLL-g-PEG/PEG-RGD and PLL-g-PEG/PEG-KRSR in varying peptide 
concentrations.  All SLA discs used in this study were sterilized using an oxygen plasma 
cleaner (PDC-32G, Harrick Plasma, Ithaca, NY) for 5 minutes under low vacuum and 
then placed in 24-well plates.  Solutions containing the desired polymer-peptide 
combinations were pipetted immediately onto the appropriate surfaces for 30 minutes 
followed by two washings in sterile HEPES 2 buffer solution. 
 
Experimental Design 
Control groups included (1) tissue culture polystyrene (TCPS), (2) plasma-
cleaned titanium SLA, and (3) titanium SLA coated with unfunctionalized PLL-g-PEG.  
These groups are similar to the controls used in a previous study by Tosatti et al. [95], 
which examined the dose-dependent effects of RGD functionalized to PLL-g-PEG.  
Experimental groups were formed by coating disks with PLL-g-PEG solutions containing 
varying concentrations of RGD, KRSR, and KSSR.  Figure 5-1 on the following page 
shows a schematic of the PLL-g-PEG surface and a chart of the RGD/KRSR 




Figure 5-1:  A) Schematic of peptide-functionalized poly-L-lysine grafted polyethylene 
glycol (PLL-g-PEG) following self-assembly on the titanium SLA surface.  B) Array 
showing the experimental groups used in this study to evaluate the interaction of RGD 
and KRSR.  The large gray dots represent the previous study by Tosatti et al [95].  
Values are measured in pmol/cm2.   
 
KRSR surface peptide density was varied from 0, 5, 10, 15, to 20 pmol/cm2, and 
RGD surface peptide density was varied from 0, 0.05, to 1.26 pmol/cm2.  KSSR surface 
peptide density was 10 pmol/cm2 in combination with RGD varied at surface peptide 
densities of 0, 0.05, and 1.26 pmol/cm2.  The dose-dependent response to RGD was 
measured with the following experimental groups coated on titanium SLA: (4) PLL-g-
PEG/PEG-RGD(0.05) and (5) PLL-g-PEG/PEG-RGD(1.26).  The dose-dependent 
response to KSSR was measured with the following experimental groups coated on 
titanium SLA: (6) PLL-g-PEG/PEG-KSSR(10), (7) PLL-g-PEG/PEG-RGD(0.05)/PEG-
KSSR(10), and (8) PLL-g-PEG/PEG-RGD(1.26)/PEG-KSSR(10).  The dose-dependent 
response to KRSR was measured with the following experimental groups coated on 
titanium SLA: (9) PLL-g-PEG/PEG-KRSR(5), (10) PLL-g-PEG/PEG-KRSR(10), (11) 
PLL-g-PEG/PEG-KRSR(15), and (12) PLL-g-PEG/PEG-KRSR(20).  Multifunctional 
peptide experimental groups included:  (13) PLL-g-PEG/PEG-RGD(0.05)/PEG-KRSR(5), 
(14) PLL-g-PEG/PEG-RGD(0.05)/PEG-KRSR(10), (15) PLL-g-PEG/PEG-
RGD(0.05)/PEG-KRSR(15), (16) PLL-g-PEG/PEG-RGD(1.26)/PEG-KRSR(5), (17) PLL-
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g-PEG/PEG-RGD(1.26)/PEG-KRSR(10), and (18) PLL-g-PEG/PEG-RGD(1.26)/PEG-
KRSR(15).  KRSR at a surface peptide density of 20 pmol/cm2 was near the saturating 
surface peptide density and therefore could not be combined with RGD.   
 
Cell Culture and Biological Assays 
Osteoblast-like MG63 cells were used in this study and are described extensively 
in chapter 2 and in the literature [69].  Following the coating and washing steps, MG63 
cells were plated in 24-well plates at an initial density of 10,000 cells/cm2.  Cells were 
cultured in 500 µL Dulbecco‟s modified Eagle medium (DMEM) containing 10% fetal 
bovine serum (FBS) and 1% penicillin/streptomycin at 37˚C in an atmosphere of 5% CO2 
and 100% humidity.  Media were changed at 24 hours and then every 48 hours.  All 
groups were harvested 24 hours after confluence was reached for the cells on TCPS.  
Media were collected and the cell layers were washed twice with DMEM.  Cells were 
released from the surfaces by two sequential 10 min incubations in 0.25% trypsin at 
37˚C to ensure that all cells were removed from the SLA surfaces.  The cells were 
collected to measure cell number, total protein, and alkaline phosphatase specific 
activity while the media were used to measure osteocalcin, TGF-β1, PGE2 levels.  
Methods for these assays are described in chapter 2.  
 
Statistical Analysis 
 Each data point was calculated from six independent cultures (n=6) and is 
presented as the mean ± SEM.  The data were analyzed using ANOVA and significant 
differences between groups were determined using Bonferroni‟s modification of 
Student‟s t-test. P<0.05.  All experiments were repeated to ensure validity of the results.  
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The data presented are from a representative experiment for each parameter.  
Observations were consistent among experiments unless otherwise stated, although the 
absolute baselines value differed between experiments.  
 
5.3 Results 
Cell number was regulated by both surface roughness and surface chemistry.  
Cell number was lower on SLA surfaces compared to TCPS, and was lower on PLL-g-
PEG surfaces than both SLA and TCPS (Figure 5-2A).  Functionalizing PLL-g-PEG with 
1.26 pmol/cm2 of RGD increased cell number, restoring it to near-SLA levels (Figure 5-
2B).  These results were expected and confirm earlier results by Tosatti et al. [95].  
KSSR caused a further decrease in cell number compared to SLA and PEGylated 
surfaces.  Cell number was partially restored on KSSR surfaces by the addition of RGD.  
The effects of KRSR were very weak.  KRSR alone had no effect on cell number and 
only increased cell number at a relatively high peptide surface density of 15 pmol/cm2 in 
combination with 1.26 pmol/cm2 of RGD.   
 
Figure 5-2:  A) Comparison of cell number on TCPS, SLA, PLL-g-PEG controls, and 
KSSR surfaces.  B) Comparison of cell number on KRSR and RGD surfaces at varying 
peptide densities. A: *p<0.05, Ti surfaces v. plastic; **p<0.05, PEG surfaces v. SLA • 
p<0.05, KSSR v. PEG.  B: +p<0.05, RGD v. KRSR alone (0 RGD); ‡<0.05, KRSR v. 




Alkaline phosphatase activity was also regulated by surface roughness and 
surface chemistry.  Alkaline phosphatase activity was increased on SLA surfaces coated 
with PLL-g-PEG (Figure 5-3A).  KSSR did not affect alkaline phosphatase specific 
activity.  The addition of 0.05 pmol/cm2 or 1.26 pmol/cm2 of RGD peptide decreased 
alkaline phosphatase activity (Figure 5-3B).  Addition of KRSR also caused a decrease 
in alkaline phosphatase activity, though not as strongly as the decrease caused by RGD.  
The effect of combining RGD and KRSR seemed to be dominated by RGD, since there 
was weak supplemental inhibition by KRSR even at high peptide densities. 
 
Figure 5-3:  A) Comparison of alkaline phosphatase activity on TCPS, SLA, PLL-g-PEG 
controls, and KSSR surfaces.  B) Comparison of alkaline phosphatase activity on KRSR 
and RGD surfaces at varying peptide densities. A: *p<0.05, Ti surfaces v. plastic; 
**p<0.05, PEG surfaces v. SLA; B: +p<0.05, RGD v. KRSR alone (0 RGD); ‡<0.05, 
KRSR v. RGD alone (0 KRSR). 
 
Surface roughness and surface energy affected osteoblast differentiation as 
determined by osteocalcin levels.  Osteocalcin levels increased on SLA surfaces and 
further increased on SLA surfaces coated with PLL-g-PEG (Figure 5-4A).  The addition 
of RGD at a concentration of 1.26 pmol/cm2 significantly decreased levels of osteocalcin.  
KSSR further increased osteocalcin levels, but this effect was masked with the addition 
of RGD.  KRSR alone did not affect osteocalcin levels (Figure 5-4B).  There was a slight 
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decrease in osteocalcin levels on PLL-g-PEG/PEG-RGD(1.26)/PEG-KRSR(15) surfaces, 
although no other peptide combinations showed any effect of KRSR. 
 
Figure 5-4:  A) Comparison of osteocalcin levels on TCPS, SLA, PLL-g-PEG controls, 
and KSSR surfaces.  B) Comparison of osteocalcin levels on KRSR and RGD surfaces 
at varying peptide densities. A: *p<0.05, Ti surfaces v. plastic; **p<0.05, PEG surfaces v. 
SLA • p<0.05, KSSR v. PEG.  B: +p<0.05, RGD v. KRSR alone (0 RGD); ‡<0.05, KRSR 
v. RGD alone (0 KRSR). 
 
Levels of autocrine and paracrine factors were also affected by changes in 
surface roughness and surface energy, and by the addition of bioactive peptides.  Levels 
of latent and active TGF-β1 (Figures 5-5A and 5-5C) and PGE2 (Figure 5-6A) were 
increased on SLA versus TCPS, and were further increased on PLL-g-PEG coated SLA 
surfaces.  Addition of 1.26 pmol/cm2 RGD to the PLL-g-PEG surfaces caused a 
significant decrease in levels of latent and total TGF-β1 (Figures 5-5A and 5-5C) and 
PGE2 (Figure 5-6A), confirming earlier results [95].  Levels of latent and active TGF-β1 
on KSSR coated surfaces were not statistically different from PEGylated controls; 





Figure 5-5:  Comparison of latent (A) and active (B) TGF-β1 levels on TCPS, SLA, PLL-
g-PEG controls, and KSSR surfaces.  Comparison of latent (C) and active (D) TGF-β1 
levels on KRSR and RGD surfaces at varying peptide densities. A: *p<0.05, Ti surfaces 
v. plastic; **p<0.05, PEG surfaces v. SLA • p<0.05, KSSR v. PEG.  B: +p<0.05, RGD v. 
KRSR alone (0 RGD); ‡<0.05, KRSR v. RGD alone (0 KRSR). 
 
Addition of 15 pmol/cm2 of KRSR reduced levels of active and latent TGF-β1 
(Figures 5-5Band 5-5D) and the addition of 10, 15, or 20 pmol/cm2 of KRSR reduced 
levels of PGE2 (Figure 5-6B).  Interaction effects between RGD and KRSR were not 
observed.  RGD appeared to be the dominant cause of reduction in TGF-β1 levels.  
Combining RGD and KRSR caused further inhibition of PGE2 levels than using either 
ligand alone, but this combination did not lead to synergistic responses.  Altogether, 
KRSR was observed to affect osteoblastic phenotype only at high surface peptide 
densities, and did not affect cell phenotype as strongly as RGD.  Surprisingly, KSSR did 
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promote an osteoblastic phenotype, shown by decreased cell number and increased 
levels of osteocalcin and PGE2. 
 
Figure 5-6: A) Comparison of PGE2 levels on TCPS, SLA, PLL-g-PEG controls, and 
KSSR surfaces.  B) Comparison of PGE2 levels on KRSR and RGD surfaces at varying 
peptide densities. A: *p<0.05, Ti surfaces v. plastic; **p<0.05, PEG surfaces v. SLA • 
p<0.05, KSSR v. PEG.  B: +p<0.05, RGD v. KRSR alone (0 RGD); ‡<0.05, KRSR v. 




The results of this study support previous observations [95] showing that addition 
of attachment factors like RGD or KRSR to PEGylated surfaces promotes cell 
attachment and growth, but inhibits osteoblast differentiation.  Addition of RGD to the 
PLL-g-PEG surface increased cell number, but reduced markers for differentiation and 
local factor production.  The effects of KRSR on cell number were weak compared to 
RGD; the peptide had no effect on cell number or osteocalcin levels, but it did cause a 
decrease in TGF-β1 and PGE2 levels at high surface peptide densities.  In combination, 
KRSR and RGD at high surface peptide densities caused a decrease in alkaline 
phosphatase activity, and levels of osteocalcin, TGF-β1, and PGE2.  Surprisingly, KSSR, 
which does not promote osteoblast attachment to TCPS [192], caused an increase in 
osteoblastic differentiation.  These results support the hypothesis that attachment and 
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proliferation are differentially regulated and further support the hypothesis that osteoblast 
differentiation is favored by reduced cell spreading. 
The results from this study regarding the bioactivity of KRSR differ from other 
reports in the literature.  Previous studies had suggested that KRSR increased both 
attachment and migration of rat calvarial osteoblasts [197].  Although KRSR increased 
outgrowth of osteoblasts from newborn rat calvarial bone chips after 8 days of incubation 
time, outgrowth on RGD-coated surfaces was much greater.  Others have shown that 
human bone marrow stromal cells (hBMSCs) are sensitive to KRSR as well [198].  In the 
present study we did not examine cell attachment per se but the number of cells 
remaining on the surface at time of harvest.  We found that KRSR did not increase cell 
number by itself, but did increase cell number in combination with RGD.  This result 
confirms earlier observations that RGD supports greater proliferation than KRSR in 
newborn rat calvarial osteoblasts [197].  However, the previous report did indicate that 
KRSR increased cell number, while the current study does not.  This difference may be 
due to the cell source or to differences in the state of maturation in the osteoblast 
lineage.  The MG63 cell model we used is a relatively immature osteoblast cell line 
whereas the Schuler group used primary newborn rat calvarial osteoblasts obtained as 
outgrowths from bone chips. 
The functional role of KRSR may depend in part on its presentation to 
responding cells, which can depend upon flanking amino acids, ligand presentation, and 
spatial patterning.  RGD and KRSR were presented randomly at the surface and not at 
defined distances/positions of cell-binding and heparin-binding sites as found in native 
tissues.  Previous studies suggest that proper spatial arrangement of heparin- and 
integrin-binding domains may enhance cell attachment and response, although these 
studies did not specifically consider KRSR [199, 200].  Flanking residues may also affect 
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the biological activity of KRSR.  Both attachment and differentiation were increased 
when hBMSCs were cultured on surfaces functionalized with one of the binding domains 
in fibroblast growth factor-2 (FGF-2), residues 105-111, which has the sequence 
YKRSRYT [198].  This sequence matches the XBBXBX pattern proposed by Cardin et 
al. to be a cell attachment peptide [191], but differs from the ligand used in the present 
study (GCRGYGKRSRG), which supported attachment but not differentiation of MG63 
cells.  The differences in the two outcomes could arise from using hBMSCs, which are a 
mixed population that includes osteoprogenitor cells, rather than osteoblast-like MG63 
cells.  This difference could also be due to using hydrophobic tyrosines to flank the 
KRSR binding region, compared to the hydrophilic glycines chosen in the present study.   
In contrast to KRSR, the KSSR peptide used in the present study did increase 
osteoblast differentiation.  This result could arise from specific biological activity of the 
KSSR, although no previous studies have suggested that KSSR has such activity.  
Alternatively, KSSR could promote differentiation by inhibiting cell attachment and 
spreading.  PLL-g-PEG surfaces also limit cell attachment and spreading, which could 
explain why osteoblasts are more differentiated on PLL-g-PEG surfaces compared to 
SLA surfaces. Our results indicate that KRSR plays a weak inhibitory role on the 
differentiation of osteoblasts on PLL-g-PEG surfaces, though the KSSR results do 
support the possibility of strong biological activity for other ligands based on the 
XBBXBX design. 
Osteoblast attachment is often one of the first properties of a peptide that 
researchers evaluate; however, this measure may not be a good indicator of whether a 
peptide will affect differentiation.  As observed previously [192], KRSR increased 
attachment whereas KSSR did not.  In contrast, KRSR did not increase osteoblast 
differentiation.  As noted previously by Dee et al., KSSR was not shown to affect 
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osteoblast attachment, but our results indicate a potent effect on osteoblast 
differentiation.  The additional information provided in the present study demonstrates 
that attachment and proliferation assessments alone are insufficient for characterizing 
the response of cells to peptides.  Assays for differentiation should be a primary tool for 
characterizing the biological activity of peptides.  Even still, studies examining 
attachment, proliferation, and differentiation in vitro cannot replace the full insight gained 
from in vivo studies since bone formation requires each of these actions at different 
timepoints.  Future work will be needed to evaluate the osteointegrative potential of 
multifunctional PLL-g-PEG systems both in vitro and in vivo. 
Successful multifunctional peptide surfaces should increase the osteoblast 
population at the implant surface, increase osteoblastic differentiation of attached cells, 
and discourage the development of inflammation and fibrosis; although the combinations 
of peptides we used did not achieve this goal with respect to in vitro demonstration of 
enhanced proliferation and osteogenic differentiation of attached cells.  RGD has been 
used effectively to increase bone formation in some in vivo studies [5, 42, 179], but our 
results indicate its primary effect is on osteoblast proliferation, not differentiation. This 
role of RGD may certainly be important in vivo though, since increased attachment and 
proliferation of osteoprogenitors enhances bone formation.  In fact, attachment of ligands 
promoting differentiation might actually be counterproductive to bone formation if they 
greatly mask the effects of attachment ligands such as RGD.  Ligands promoting 
differentiation may be important at later stages of bone formation after a sufficient 
osteoblast population has arrived.  While the present study suggests that KSSR does 
stimulate expression of an osteogenic phenotype, this effect was not increased when 
used in combination with RGD, nor did the combination of RGD and KSSR lead to a 
state of high proliferation and high differentiation.  RGD and KSSR appeared to act in 
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opposite directions on osteoblast phenotype, although it is difficult to reach a definitive 
conclusion since high RGD levels masked the effect of KSSR.  Moreover, the effects of 
KSSR may be non-specific by preventing cell attachment.  Thus, the present study 
cannot definitively state whether the combination of attachment and differentiation 




The present study examined the effects of PLL-g-PEG-based multifunctional 
RGD and KRSR peptide surfaces on the enhancement of markers for both osteoblast 
proliferation and differentiation.  RGD was effective in increasing cell proliferation on the 
PLL-g-PEG surface, but RGD inhibited differentiation present on the PLL-g-PEG 
surface.  KSSR promoted an osteogenic phenotype, shown by decreased cell number 
and increased levels of osteocalcin and PGE2.  Overall, KRSR had a very weak effect on 
osteoblast phenotype either alone or in combination with RGD.  The combination of 
RGD and KSSR did not lead to a state of high osteoblast proliferation and high 
differentiation, although the non-specific nature of KSSR activity makes it difficult to 
reach broader conclusions regarding the efficacy of combining RGD with osteogenic 
peptides in multifunctional surfaces to promote initial osteoblast attachment and 
subsequent osteoblastic differentiation. Multifunctional peptide surfaces offer the ability 
to gain better control over the biological cues provided to cells at the surface; however, 
choosing which combinations of biological cues to provide is a daunting task, but one 




CHAPTER 6:  
VDR Mediates the Osteogenic Effects of 1α,25(OH)2D3 
 
6.1. Introduction 
The vitamin D metabolite 1α,25(OH)2D3 is essential for mineral ion homeostasis 
and the normal development and structure of bone.  1α,25(OH)2D3 regulates bone 
turnover directly through its effects on osteoblasts, and indirectly through its regulation of 
blood calcium and phosphorus levels [101].  The biological actions of the 1α,25(OH)2D3 
are mediated by VDR and by a membrane associated mechanism involving Pdia3, also 
known as ERp60, ERp57, and 1,25D3-MARRS [51, 114].  The classical effects of 
1α,25(OH)2D3 on osteoblasts are to promote an osteogenic phenotype, as evidenced by 
a decrease in proliferation and an increase in differentiation [100, 103]; however, the 
relative roles of the VDR and Pdia3 in 1α,25(OH)2D3 signaling in osteoblasts are only 
recently being defined.  Moreover, increasing evidence suggests that integrin and 
membrane 1α,25(OH)2D3 signaling may act to modulate activity of VDR or other nuclear 
receptors in ways that could promote or inhibit differentiation depending on extracellular 
cues and the state of differentiation of the cell [108, 114, 201]. 
Understanding the differential contributions of the VDR and Pdia3 in 
1α,25(OH)2D3 signaling could aid in the creation of pharmacological analogs of vitamin D 
for treatment of osteoporosis or for promoting improved osteointegration of orthopaedic 
implants [111].  Studies examining the response of osteoblasts to surfaces used on 
titanium dental implants show that when cells are grown on microstructured substrates, 
they exhibit increased levels of osteocalcin, PGE2, TGF-β1, and OPG, as well as 
enhanced responsiveness to 1α,25(OH)2D3 in comparison to cells grown on smooth Ti or 
TCPS surfaces [69, 202].  This increase in expression of a differentiated phenotype due 
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to the surface microstructure appears to precede the enhanced response to 
1α,25(OH)2D3, suggesting that activity of one or both receptors may be sensitive to 
integrin signaling, which could give rise to synergy between the effects of surface 
roughness and 1α,25(OH)2D3 on osteoblast differentiation. 
It is currently unclear whether VDR and Pdia3 target transcription of different 
genes, or whether membrane 1α,25(OH)2D3 signaling modulates gene transcription via 
downstream phosphorylation of VDR.  Studies have shown that Pdia3 is required for the 
1α,25(OH)2D3-dependent increase in PKC activity and rapid release of intracellular Ca
++ 
[113, 115].  Studies using osteoblasts and chondrocytes from VDR deficient mice show 
that these cells still exhibit 1α,25(OH)2D3-dependent rapid activation of PKC and release 
of intracellular Ca++ despite the lack a functional VDR [112].  Moreover, 1α,25(OH)2D3 
treatment has been shown in chondrocytes to increase ERK1/2 and other MAP kinases 
known to broadly affect gene transcription [120].  While osteocalcin and osteopontin 
expression are known to be regulated by 1α,25(OH)2D3 via VDR binding to specific 
VDREs [101, 203], other genes upregulated by 1α,25(OH)2D3  lack such sites.  For 
example, PGE2 production is increased by 1α,25(OH)2D3-induced rapid production of 
diacylglycerol and arachidonic acid (AA) and the cyclooxygenase-mediated conversion 
of AA to PGE2  [204].  These results demonstrate that the rapid, non-genomic events of 
1α,25(OH)2D3 could occur independently of the VDR; however, there are still questions 
regarding how VDR and Pdia3 dependent 1α,25(OH)2D3 signaling pathways differentially 
affect osteoblast phenotype.  Furthermore, the enhanced response of osteoblasts to 
1α,25(OH)2D3 on roughened Ti surfaces may involve crosstalk between integrins and 
1α,25(OH)2D3 signaling pathways, although it is not clear whether this response 
depends on VDR or Pdia3.   
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To address these questions, we took advantage of VDR(-/-) mice developed by Li 
et al [121]. These mice develop hypocalcemia, hypophosphatemia, hyperparathyroidism, 
rickets, osteomalacia, and alopecia.  When VDR(-/-) mice are placed on a rescue diet 
containing high calcium, phosphate, and lactose, they exhibit normal mineral ion 
homeostasis and do not exhibit signs of rickets, thus demonstrating the critical systemic 
role of VDR in calcium and phosphate regulation [205, 206].  Still, studies using VDR 
deficient mice have supported the importance of the direct actions of 1α,25(OH)2D3 on 
osteoblast phenotype and bone morphology.  Overexpression of VDR in mature 
osteoblasts leads to increases in bone formation, mineralization rate, and overall bone 
strength [207].  VDR(-/-) mice on a “rescue diet” have decreased trabecular bone 
volume, mineral apposition rate, alkaline phosphatase staining, and cbfaI/Runx2 
expression compared to wild-type mice, indicating a role of 1α,25(OH)2D3 and VDR in 
promoting osteogenesis [206].  However, Sooy et al. suggest that VDR deficient 
osteoblasts have enhanced osteoblast activity in vitro due to a role of 1α,25(OH)2D3 in 
inhibiting osteogenesis [208].  Taken together, studies using VDR(-/-) mice suggest that 
while the most critical and best understood role of 1α,25(OH)2D3 is on mineral ion 
homeostasis, 1α,25(OH)2D3 also plays a complex role in controlling bone turnover via its 
direct effects on osteoblasts through VDR and Pdia3. 
The present study uses VDR(+/+) and VDR(-/-) calvarial osteoblasts to examine 
whether VDR is required to mediate the osteogenic effects of 1α,25(OH)2D3, or whether 
VDR independent signaling, presumably through Pdia3, can lead to changes in 
osteoblastic phenotype.  In addition, this study examines whether VDR is essential for 
synergistic signaling of 1α,25(OH)2D3 and integrins, or whether 1α,25(OH)2D3 can modify 




6.2. Materials and Methods 
Vitamin D Receptor Deficient Osteoblasts  
The study used cavarial osteoblasts from knockout VDR(-/-) mice and “wild-type” 
VDR(+/+) littermates.  Complete methods are described in Chapter 2. 
 
Titanium Surfaces 
Institut Straumann AG (Basel, Switzerland) supplied the PT, SLA, and TPS 
titanium disks used in this study.  Surfaces were manufactured and characterized as 
described in chapter 2. 
 
Cell Culture 
Cells were cultured in DMEM plus 10% FBS and 1% penicillin/streptomycin.  The 
culture media used in these studies contains 10% FBS.  Because the FBS was not 
charcoal stirred it contained low levels of 1α,25(OH)2D3; thus, the culture media had 10
-
12 to 10-13 M 1α,25(OH)2D3.  Initial experiments compared baseline production of 
osteocalcin in VDR(+/+) cells and VDR(-/-) osteoblasts.  For these experiments second 
passage cells were grown to confluence on TCPS and osteocalcin in the media was 
assayed.  To assess the effects of growth on microstructured titanium, VDR(+/+) or 
VDR(-/-) osteoblasts were plated at a density of 10,000 cells/cm2 into 24-well plates 
containing 6 wells each of TCPS, PT, SLA, and TPS surfaces.   
 
Physiological Responses of VDR(-/-) and VDR(+/+) Osteoblasts 
At confluence, which was determined from cells on TCPS surfaces, each group 
was treated with 10-8 M 1α,25(OH)2D3 (Biomol, Plymouth Meeting, PA) or vehicle control 
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(ethanol) for 24 hours. At harvest, experimental media were collected and the cell layers 
were washed twice with DMEM.  Osteoblasts were removed using two subsequent 
treatments for 10 minutes with 0.25% trypsin.  Osteoblast phenotype was assessed by 
measuring cell number, total protein, alkaline phosphatase activity, and media levels of 
osteocalcin, TGF-β1, OPG, and PEG2 according to protocols discussed in chapter 2.  
 
Expression of VDR and Pdia3 in MG63 Cells 
Expression of Pdia and VDR was measured in MG63 cells plated on TCPS, PT, 
SLA, and TPS surfaces.  The purpose of this experiment was to determine if surface 
roughness directly affected expression of either Pdia3 or VDR.  Cells were grown on four 
discs each of TCPS, PT, and SLA.  At confluence, cells were treated with 1α,25(OH)2D3 
for 24 hours and then harvested for mRNA using an RNeasyTM kit (Qiagen, 
Germantown, MD) according to the manufacturer‟s protocols. Quantitative RT-PCR was 
performed on an i-cyclerTM (Bio-Rad Laboratories, Hercules, CA) using software i-cycler 
iQTM, version 3.0a.  PCRs were carried out in a total volume of 25 µl in PCR master mix 
containing 12.5 µl SYBR® green, 200 ng each of sense and antisense primer, 25mM 
MgCl2, and 3 µl of the reverse transcription product.  The volume was adjusted with 
DEPC-treated water.  The primers used were: 
 
VDR   F  CAT CAG AAG GAG AAG GAA GG  
  R  TGA GGC AAC AGC ATT ATC C  
 
GapDH  F  GCT CTC CAG AAC ATC ATC C  
  R  TGC TTC ACC ACC TTC TTG 
 
PDIA3   F  GCC TAC CCT GGT GAT TAG AAC 
  R  GAG CAG AGA ACA GTC CTT GG  
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The results from this preliminary study shown in the appendix in Figure A-3 
demonstrate that surface roughness does not alter expression of VDR.  Expression of 
Pdia3 was slightly decreased on SLA and TPS surfaces.  Addition of 1α,25(OH)2D3 had 
no effect on expression of either VDR or Pdia3. 
 
Gene Expression Changes in VDR(-/-) and VDR(+/+) Osteoblasts 
 Expression of the genes for GapDH (Control), Pdia3, integrin beta 1, integrin 
alpha 2, integrin alpha 5, caveolin-1, Runx2, and integrin beta 3 were measured in 
VDR(+/+) and VDR(-/-) osteoblasts.  Cells were grown on six discs each of TCPS, PT, 
and SLA surfaces in a similar manner as described above.  In addition, a separate set of 
experiments was grown on TCPS surfaces of 6-well plates and was treated at 
confluence for 24 hours with 1α,25(OH)2D3.  Cells were harvested for mRNA using an 
RNeasyTM kit (Qiagen, Germantown, MD) according to the manufacturer‟s protocols.  
Following RNA isolation, RNA was quantified using a NanodropTM spectrophotometer 
(Thermo Scientific, Wilmington, DE).  All samples were normalized to 1ug RNA/uL with 
diethylpyrocarbonate (DEPC)-treated water.  Gene expression was assessed by qRT-
PCR using a QuantiFastTM SYBR Green RT-PCR Kit (Qiagen) according to 
manufacturer‟s protocols.  Briefly, 12.5 µL SYBR green master mix, 1 µL (1 µmol) of 
each primer, 0.25 µL RT mix, 1 µg mRNA, and DEPC-treated water were combined for a 
total volume of 25 µL.  All reactions were carried out for 40 cycles on an i-cyclerTM (Bio-
Rad Laboratories, Hercules, CA) using software i-cycler iQTM, version 3.0a.  The primers 
and annealing temperatures used in the experiments were: 
 
 CAV-1  R  ACA GTG AAG GTG GTG AAG C   54.2 




ITGA2   R  GGT CAA AGG CTT GTT TAG G   57.1 
F  ACT GTT CAA GGA GGA GAC 
 
ITGA5   R  AAG TTC CCT GGG TGT CTG   57.1 
F  ATC TGT GTG CCT GAC CTG 
 
ITGB1   R  TCC TCC TCA TTT CAT TCA TC   57.1 
F  ATT ACT CAG ATC CAA CCA C 
 
 PDIA3   R     TTC ATA CTC AGG GGC AAG C  57.9 
  F  CGA TGT GTT GGA ACT GAC G 
 
RUNX2  R  GAT AGG ATG CTG ACG AAG TAC C  56.0 
F  CCG CCA CCA CTC ACT ACC 
 
 GAPDH  R  TCT CGC TCC TGG AAG ATG G  55.0  
  F  TTC AAC GGC ACA GTC AAG G 
 
ITGB3   R  GCT CAC CGT GTC TCC AAT C   57.1 
  F AAT GCC ACC TGC CTC AAC 
 
 Unfortunately, the data from qRT-PCR for VDR(+/+) and VDR(-/-) osteoblasts 
was not consistent between experiments for many of the genes tested.  In addition, the 
yield of RNA harvested on SLA surfaces was low in all groups.  Levels of GapDH 
(control) were also lower on SLA surfaces despite adjustment based on RNA 
measurements.  Because of the low levels of RNA and inconsistency between 
experiments, it is difficult to draw definitive conclusion from the data.  The data is shown 
in the appendix in Figures A-1, A-2, A-3, and A-4.  The pooled data from all of the 





Data for each experiment were calculated from six independent cultures (n=6) per 
group and presented as the mean ± standard error of the mean (SEM). Data were 
analyzed via analysis of variance (AVONA) and statistical difference between groups 
determined using Bonferroni‟s modification of the Student‟s t-test.  Values with p<0.05 
were considered significant.  Each experiment was performed twice to ensure the 
consistency of the results.  The data presented are from one of two representative 
experiments for each end point assay. 
 
6.3. Results 
 The levels of mRNA expression for the genes Pdia3 and VDR were measured in 
MG63 cells using quantitative PCR.  The results show no statistical difference in either 
Pdia3 or VDR expression in response to changing surface roughness or treatment with 
1α25(OH)2D3.  There was a reduction in Pdia3 expression on some of the titanium 
surfaces versus TCPS (Figure 6-1).  These results indicate that surface roughness and 
1α25(OH)2D3 do not directly affect mRNA levels of either 1α25(OH)2D3 receptor in 




Figure 6-1:  Pdia3 and VDR mRNA expression in osteoblast-like MG63 cells.  * Titanium 
Surface vs. TCPS.  Significant if p < 0.05. 
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At confluence on TCPS, VDR(-/-) osteoblasts produced 10-fold higher levels of 
osteocalcin than VDR(+/+) osteoblasts (Figure 6-4).  Repeats of the experiment did not 
show significant differences in baseline levels osteocalcin or other factors (Figure 6-2), 
although alkaline phosphatase activity was significantly reduced in VDR(-/-) osteoblasts 
compared to VDR(+/+) osteoblasts.  These differences may be due to experimental 
variance because of the nature of harvesting osteoblasts from separate batches of mice.  
VDR (-/-) osteoblasts did not respond to 1α25(OH)2D3, but neither did VDR(+/+) 
osteoblasts in this particular repeat.  All other experiments showed a strong effect of 
1α25(OH)2D3 on osteoblast phenotype. 
 
Figure 6-2:  Baseline comparison of VDR (+/+) and „Rescued‟ VDR (-/-) osteoblasts on 
TCPS, PT, SLA, and TPS surfaces.  Statistics:  * Surface vs. TCPS; • SLA/TPS vs. PT; # 




When the cells were grown on titanium substrates, VDR(-/-) and VDR(+/+) cells 
behaved in a similar manner.  There was a decrease in cell number on all titanium 
substrates compared to TCPS with the greatest reduction in cultures grown on SLA and 
TPS (Figure 6-1).  Both VDR(+/+) and VDR(-/-) osteoblasts displayed a similar reduction 
in cell number due to surface roughness, although cell number in VDR(-/-) osteoblasts 
was lower on all surfaces compared to VDR(+/+) osteoblasts. 
 
Figure 6-3:  Comparison of cell number in VDR(+/+) and VDR(-/-) osteoblasts. 
 
Measures for osteoblast differentiation show a loss in VDR(-/-) osteoblasts of 
responses typically observed following treatment with 1α,25(OH)2D3.  VDR(+/+) and 
VDR(-/-) cells both exhibited increases in alkaline phosphatase specific activity on SLA 
and TPS substrates (Figure 6-2); however, VDR(+/+) osteoblasts treated with 
1α,25(OH)2D3 exhibited an increase in alkaline phosphatase specific activity whereas no 




Figure 6-4:  Comparison of alkaline phosphatase specific activity in VDR(+/+) and 
VDR(-/-) osteoblasts. 
 
Osteocalcin levels were also increased in the media from VDR(+/+) and VDR(-/-) 
osteoblasts grown on SLA and TPS surfaces (Figure 6-3).  Interestingly, osteocalcin 
levels were much higher on all surfaces in VDR(-/-) osteoblasts. 1α,25(OH)2D3 caused 
an increase in osteocalcin levels in VDR(+/+) osteoblasts that was synergistic with the 
effect of the microstructured surface on SLA and TPS.  However, 1α,25(OH)2D3 did not 
cause any increase in osteocalcin levels in VDR(-/-) osteoblasts on any surfaces. 
 
Figure 6-5:  Comparison of osteocalcin levels in VDR(+/+) and VDR(-/-) osteoblasts. 
Local factor production was also increased by surface roughness and 
1α,25(OH)2D3 treatment in VDR(+/+) osteoblasts.  Levels of PGE2 increased in response 
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to increasing surface roughness in both VDR(+/+) and VDR(-/-) osteoblasts (Figure 6-4).  
Addition of 1α,25(OH)2D3 caused an increase in levels of PGE2 in VDR(+/+) osteoblasts, 
but 1α,25(OH)2D3 did not affect PGE2 levels in VDR(-/-) regardless of the surface. 
 
Figure 6-6:  Comparison of PGE2 levels in VDR(+/+) and VDR(-/-) osteoblasts. 
 
Production of latent and active TGF-β1 was modulated in a similar manner as 
PGE2.  Both VDR(+/+) and VDR(-/-) osteoblasts had greater amounts of latent and 
active growth factor in their conditioned media when grown on titanium substrates 
compared to TCPS (Figure 6-5) with the greatest levels on TPS.  Interestingly, TGF-β1 
levels were higher on all surfaces in VDR(-/-) osteoblasts compared to VDR(+/+) 
osteoblasts.  In VDR(+/+) osteoblasts 1α,25(OH)2D3 increased levels of active and latent 
TGF-β1 on nearly all substrates.  In contrast, in VDR(-/-) osteoblasts 1α,25(OH)2D3 did 




Figure 6-7:  Comparison of active (Top) and latent (bottom) TGF-β1 levels in VDR(+/+) 
and VDR(-/-) osteoblasts. 
 
6.4. Discussion 
These results clearly demonstrate that VDR is required for the effects of 
1α,25(OH)2D3 on osteoblast phenotype.  In osteoblasts lacking a functional VDR, 
1α,25(OH)2D3 did not alter cell proliferation, osteogenic differentiation, or levels of 
osteogenic paracrine factors.  Previous studies have shown that VDR does not mediate 
the rapid effects of 1α,25(OH)2D3 on PKC activity and intracellular calcium release [177].  
Despite the fact that these membrane pathways remain intact, 1α,25(OH)2D3 is not able 
to alter osteoblast phenotype in the absence of VDR.  This result corroborates in vivo 
results from other groups that have suggested a similar role for VDR in promoting an 
osteogenic phenotype.  Gardiner et al. showed that overexpression of VDR leads to 
increases in bone formation and mineralization rate [207], while Panda et al. showed 
that VDR(-/-) mice on a “rescue diet” have impaired bone formation and mineralization 
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[206].  These results support the conclusion that the directs effects of 1α,25(OH)2D3 on 
osteoblast phenotype are mediated by VDR and lead to increased osteogenic phenotype 
both in vitro and in vivo. 
While this study shows that 1α,25(OH)2D3 does not directly alter osteoblast 
phenotype via VDR independent pathways, it does not rule out a role for Pdia3 in 
1α,25(OH)2D3 signaling in osteoblasts.  Pdia3 is highly expressed in osteoblasts and is 
found in the cell membrane, caveolae, and matrix vesicles [113, 117].  It is still 
hypothesized that Pdia3-mediated 1α,25(OH)2D3 signaling could modulate VDR 
transcriptional activity through action of PKC, MAPK, casein kinase II, or 
Ca2++/calmodulin-dependent kinase IV (CaMKIV)kinases [105, 123, 124], although direct 
evidence of such action has not been established.  Such a role for rapid 1α,25(OH)2D3 
signaling would require an intact VDR and so was not observed in the present study. 
Rapid 1α,25(OH)2D3 signaling may also be important in the matrix mineralization, 
but these actions were not tested in the present study.  Previous studies by Boyan et al 
using chondrocytes showed that 1α,25(OH)2D3 acts through Pdia3 to release 
lysophospholipids that destabilize matrix vesicles [122].  It is theorized that these 
vesicles could then release stored calcium, phosphate, matrix metalloproteinases, and a 
myriad of proteins that may be involved in matrix mineralization.  This theory is 
supported by evidence that caveolin-1 and Pdia3 are present both in caveolae and 
matrix vesicles in chondrocytes and osteoblasts [122].  A recent study by Sawada et al. 
demonstrated that overexpression of caveolin-1 leads to a large increase in osteoblast 
matrix mineralization [134].  This possibility would mean that both VDR and Pdia3 are 
important in the formation and turnover of bone in response to 1α,25(OH)2D3.   
The results in this study demonstrate that absence of VDR does not alter the 
effects of increasing surface roughness on osteoblast phenotype, although VDR is 
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required for any enhanced osteoblastic differentiation due to the combination of 
1α,25(OH)2D3 and increasing surface roughness.  Differences in the response to 
surfaces alone in VDR(+/+) and VDR(-/-) osteoblasts might have been expected since 
basal levels (10-13 M) of 1α,25(OH)2D3 exist in non-treated media and since previous 
work by Sooy et al. that showed VDR(-/-) osteoblasts had enhanced osteoblastic activity 
versus VDR(+/+) osteoblasts [208].  1α,25(OH)2D3 is also known to act through VDR to 
repress Runx2 expression, although it promotes other osteoblast genes including 
osteocalcin and osteopontin [107, 123]. Still, the results herein demonstrate that the 
effects of surface roughness alone are consistent in VDR(+/+) and VDR(-/-) osteoblasts, 
which means that baseline levels of signaling in the VDR-1α,25(OH)2D3 system do not 
alter osteoblast phenotype. 
The results suggest that the synergistic response of osteoblasts to surface 
roughness and 1α,25(OH)2D3 is controlled by genomic VDR signaling, rather than 
through events downstream of rapid Pdia3-mediated signaling.  Synergy between 
integrin and 1α,25(OH)2D3 signaling may occur via upregulation of integrin pathways by 
traditional VDR-mediated 1α,25(OH)2D3 signaling.  This theory is supported by earlier 
work by Raz et al showing that 1α,25(OH)2D3 increased expression of the β1 integrin 
[40], an integrin subunit shown to be critical in osteoblast differentiation on surfaces [32, 
188].  Although it was hypothesized that increasing surface roughness would increase 
expression of VDR, qRT-PCR data showed that mRNA levels of VDR were not affected 
by surface roughness (Appendix, Figure A-3).  Pdia3 was decreased on SLA and TPS 
surfaces, perhaps suggesting an inhibitory role of Pdia3 on osteoblastic differentiation.  
However, whatever 1α,25(OH)2D3-mediated effect Pdia3 has on osteoblastic 
differentiation appears to require an intact VDR.  The findings in this study suggest that 
synergy between surface roughness and 1α,25(OH)2D3 requires VDR for crosstalk 
between integrins and 1α,25(OH)2D3 signaling pathways, although there could still be a 
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role of membrane 1α,25(OH)2D3 signaling in modulating VDR signaling.  Further work 
will be necessary to determine exactly which genes and signaling pathways are involved 
in these interactions. 
 
6.5. Conclusions 
 This study demonstrates that VDR is essential to the inhibitory effects of 
1α,25(OH)2D3 on osteoblast proliferation, and to the stimulatory effects of 1α,25(OH)2D3 
on osteoblast differentiation and production of osteogenic paracrine factors.  
Furthermore, this study demonstrates that VDR is required for the effects of 
1α,25(OH)2D3 in modulating the response of osteoblasts to substrate microtopography, 
possibly via upregulation of osteoblast-specific proteins and integrin expression.  These 
results do not rule out a role for Pdia3 in modulating VDR activity, nor do they rule out a 
role of Pdia3 in bone matrix deposition and mineralization.  Studies using Pdia3 
knockdown or knockout models may be necessary to fully elucidate the role of 
membrane 1α,25(OH)2D3 signaling in bone.  The effects of 1α,25(OH)2D3 on bone are 
complex and intertwined with other signaling pathways; however, fully understanding the 
relative roles of membrane and nuclear 1α,25(OH)2D3 signaling in osteoblasts could 
yield new insights for the treatment of bone diseases such as osteoporosis.  
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CHAPTER 7:  
Altered Response of Caveolin-1 Deficient Osteoblasts to 
1α,25(OH)2D3 and Surface Microtopography 
 
7.1. Introduction 
 Caveolae are a specialized form of cholesterol-enriched lipid rafts that are 
involved in endocytosis, lipid and cholesterol regulation, and a wide variety of cellular 
signaling pathways.  As discussed extensively in chapter 1, caveolae are 60-80 nm 
„cave-like‟ organelles in the cell membrane that are stabilized by caveolin-1 [129, 130].  
In bone cells, caveolae are involved in the modulation of extracellular matrix and integrin 
interactions, mechanical stress transduction, bone morphogenic protein (BMP) signaling, 
and 1α,25(OH)2D3 signaling [129, 131-133].  Moreover, caveolae may also serve as a 
nexus for crosstalk between many of these signaling pathways, giving rise to potential 
synergies between ECM and growth factor signaling. 
Despite the presence of so many different signaling molecules located in 
caveolae, Cav-1(-/-) mice exhibit a mild phenotype without any gross abnormalities, 
suggesting other lipid rafts or endosomes compensate for the lack of caveolae and the 
loss of caveolae-dependent signaling pathways [135].  Surprisingly, loss of caveolin-1 in 
Cav-1(-/-) mice actually causes an increase in bone mass.  The growth plates of Cav-1(-
/-) mice are widened and have abnormally high numbers of hypertrophic cells [117].  The 
femurs of Cav-1(-/-) mice show a significant increase in bone mass, cortical bone 
thickness, elastic modulus, stiffness, and overall yield strength compared to wild-type 
bones [137].  Osteoblasts in Cav-1(-/-) mice also display increased mineral apposition 
rate and bone formation rate compared to osteoblasts in Cav-1(+/+) mice.   
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The molecular mechanism by which loss of caveolae increases the rate of bone 
formation is unclear; however, studies suggest that caveolae might function to suppress 
signals for osteoblastic differentiation, thus slowing the rate of bone formation.  
Knockdown of cav-1 has been shown to lead to enhanced MAP kinase activity in NIH 
3T3 cells [209], and has been shown to lead to increased levels of runx2 and osterix 
bone marrow stromal cells [137].  In addition, caveolae have been shown sequester β-
catenin, which suppresses canonical Wnt/β-catenin signaling important in the 
osteoblastic differentiation of osteoprogenitors cells [139].  However, the role of caveolin-
1 in osteoblast function may not be as simple as just repressing differentiation.  Because 
of the involvement of caveolae such a wide variety of signaling pathways, it is likely that 
caveolae act to enhance, suppress, or modulate different osteogenic signals depending 
on extracellular cues or the state of differentiation of the cell.  For instance, caveolin-1 
has been shown to either enhance or inhibit BMP receptor function depending on which 
isoform of cav-1 binds to BMP receptors I or II.  Cav-1β appears to inhibit BMP signaling, 
whereas Cav-1α appears to promote it [133].  Caveolae may also act in concert with 
Pdia3-mediated membrane 1α,25(OH)2D3 pathways to modulate VDR activity through 
phosphorylation by PKC or other kinases [105, 124], although this possibility has not 
been directly proven.  While it appears that caveolin-1 delays early differentiation, it 
appears that it might actually promote mineralization [136] by mediating matrix vesicle 
biogenesis.  This theory is supported by evidence that caveolin-1 is present both in 
caveolae and matrix vesicles in chondrocytes and osteoblasts [134].  Furthermore, 
overexpression of caveolin-1 leads to a large increase in osteoblast matrix 
mineralization.  Overall, these findings point to a complex and dynamic role of caveolae 
in osteoblast function depending on the state of differentiation of the cell. 
 Rough surface microtopography and 1α,25(OH)2D3 treatment cause a synergistic 
increase in markers for osteoblastic differentiation, including alkaline phosphatase 
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activity, and levels of osteocalcin, OPG, and PGE2 [69].  Caveolae may be involved in 
cell response to each of these stimuli individually, and may also be responsible for 
crosstalk that leads to synergistic effects on osteoblast differentiation.  Osteoblast 
response to surfaces is mediated by integrin binding to adsorbed proteins.  Separate 
studies have shown that integrins α2β1 and α5β1 can traffic through caveolae.  Loss of 
cav-1 decreases the stability and number of focal adhesions [144], alters Ras/Erk, 
PI3K/Akt and Rac/Pak signaling downstream of integrins [138], and disrupts cell 
polarization and migration [143].  Moreover, integrin binding has been shown to regulate 
caveolae internalization, which may enhance spatial and temporal control of signaling by 
quickly up- or downregulating caveolae-dependent signaling pathways [138, 145].  
However, it is not clear if loss of these functions of caveolae actually would alter how 
cells response to changes in surface topography and chemistry.   
 Caveolae also play a critical role in membrane 1α,25(OH)2D3 signaling.  Recent 
studies have shown that both VDR and Pdia3 are present in caveolae [117, 141].  More 
importantly, chondrocytes deficient in caveolin-1 and caveolae lack a rapid increase in 
PKC activity and intracellular calcium concentration normally associated with treatment 
of 1α,25(OH)2D3 [117].  Rapid membrane 1α,25(OH)2D3 signaling leads to activation of 
MAP kinases such as ERK 1/2 [120], although the exact effects on gene transcription 
remain to be elucidated.  Interaction between integrin and 1α,25(OH)2D3 signaling 
pathways may occur at multiple points in the signaling cascade.  [136, 142].  Signaling of 
1α,25(OH)2D3 could be affected through attachment mediated control over caveolae 
internalization or through crosstalk between secondary signaling molecules.  
Alternatively, 1α,25(OH)2D3 signaling could alter integrin signaling directly, through 
downstream crosstalk, or through changes in integrin or ECM component gene 
expression.   The purpose of the present study is not to determine the exact nature of 
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such crosstalk between integrin and 1α,25(OH)2D3 signaling, rather, the purpose is to 
determine whether caveolae are necessary for such crosstalk to occur. 
The present study uses Cav-1(+/+) and Cav-1(-/-) calvarial osteoblasts to 
examine whether caveolae are required to mediate the osteogenic effects of 
1α,25(OH)2D3 via rapid response mechanisms involving Pdia3 and/or VDR.  The present 
study also examines whether loss of caveolae alters osteoblast response to surface 
energy and topography, and whether loss of caveolae disrupts synergistic signaling 
between 1α,25(OH)2D3 and integrin signaling pathways. 
 
7.2. Materials and Methods 
Caveolin-1 Deficient Osteoblasts  
Cavarial osteoblasts from knockout Cav-1(-/-) mice and “wild-type” Cav-1(+/+) 
littermates.  Complete methods are described in Chapter 2. 
 
Titanium Surfaces 
Institut Straumann AG (Basel, Switzerland) supplied the PT, SLA, and TPS 
titanium disks used in this study.  Surfaces were manufactured and characterized as 
described in chapter 2. 
 
Cell Culture 
Cells were cultured in DMEM plus 10% FBS and 1% penicillin/streptomycin.  The 
culture media used in these studies contains 10% FBS.  Because the FBS was not 




12 to 10-13 M 1α,25(OH)2D3.  Initial experiments compared baseline production of 
osteocalcin in Cav-1(+/+) cells and Cav-1(-/-) osteoblasts.  For these experiments 
second passage cells were grown to confluence on TCPS and osteocalcin in the media 
was assayed.  To assess the effects of growth on microstructured titanium, Cav-1(+/+) 
or Cav-1(-/-) osteoblasts were plated at a density of 10,000 cells/cm2 into 24-well plates 
containing 6 wells each of TCPS, PT, SLA, and TPS surfaces.   
 
Physiological Responses of Cav-1(+/+) and Cav-1(-/-) Osteoblasts 
At confluence, which was determined from cells on TCPS surfaces, each group 




 (Biomol, Plymouth Meeting, PA) or vehicle control 
(ethanol) for 24 hours. At harvest, experimental media were collected and the cell layers 
were washed twice with DMEM.  Osteoblasts were removed using two subsequent 
treatments for 10 minutes with 0.25% trypsin.  Osteoblast phenotype was assessed by 
measuring cell number, total protein, alkaline phosphatase activity, and media levels of 
osteocalcin, TGF-β1, OPG, and PEG2 according to protocols discussed in chapter 2.  
 
Gene Expression Changes in Cav-1(+/+) and Cav-1(-/-) Osteoblasts 
 Expression of the genes for GapDH (Control), VDR, integrin beta 1, integrin 
alpha 2, integrin alpha 5, caveolin-1, Runx2, and integrin beta 3 were measured in Cav-
1(+/+) and Cav-1(-/-) osteoblasts.  Cells were grown on six discs each of TCPS, PT, and 
SLA surfaces in a similar manner as described above.  In addition, a separate set of 
experiments was grown on TCPS surfaces of 6-well plates and was treated at 
confluence for 24 hours with 1α,25(OH)2D3.  Cells were harvested for mRNA using an 
RNeasyTM kit (Qiagen, Germantown, MD) according to the manufacturer‟s protocols.  
Following RNA isolation, RNA was quantified using a NanodropTM spectrophotometer 
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(Thermo Scientific, Wilmington, DE).  All samples were normalized to 1ug RNA/uL with 
diethylpyrocarbonate (DEPC)-treated water.  Gene expression was assessed by qRT-
PCR using a QuantiFastTM SYBR Green RT-PCR Kit (Qiagen) according to 
manufacturer‟s protocols.  Briefly, 12.5 µL SYBR green master mix, 1 µL (1 µmol) of 
each primer, 0.25 µL RT mix, 1 µg mRNA, and DEPC-treated water were combined for a 
total volume of 25 µL.  All reactions were carried out for 40 cycles on an i-cyclerTM (Bio-
Rad Laboratories, Hercules, CA) using software i-cycler iQTM, version 3.0a.  The primers 
and annealing temperatures used in the experiments were the same as described on 
page 110, although VDR primers were used instead of cav-1 primers.  The VDR primers 
are: 
VDR   R  AGG GAT GAT GGG TAG GTT GTG  59.4 
  F  AGG CAG GCA GAA GAG ATG AG  
 
Unfortunately, the data from qRT-PCR for Cav-1(+/+) and Cav-1(-/-) osteoblasts 
exhibited similar problems as the qRT-PCR study using VDR(+/+) and VDR(-/-) 
osteoblasts from the previous chapter.  Results were not consistent between 
experiments and RNA yields were low on SLA surfaces.  Levels of GapDH (control) 
were also lower on SLA surfaces despite adjustment based on RNA measurements.  
Because of the low levels of RNA and inconsistency between experiments, it is difficult 
to draw definitive conclusion from the data.  The data is shown in the appendix in 
Figures A-5, A-6, A-7, and A-8.  The pooled data from all of the Cav-1(+/+) and Cav-1(-/-
) experiments are shown in Tables A-3 and A-4. 
 
Statistical Analysis 
Data for each experiment were calculated from six independent cultures (n=6) per 
group and presented as the mean ± standard error of the mean (SEM). Data were 
126 
 
analyzed via analysis of variance (AVONA) and statistical difference between groups 
determined using Bonferroni‟s modification of the Student‟s t-test.  Values with p<0.05 
were considered significant.  Each experiment was performed twice to ensure the 
consistency of the results.  The data presented are from one of two representative 
experiments for each end point assay. 
 
7.3. Results 
The results indicate that caveolae have a role in proliferation, differentiation, and 
local factor production of osteoblasts, although the results are somewhat perplexing 
since not all markers for osteoblast phenotype were affected.  The osteogenic effects of 
surface roughness do not appear to require functional caveolae, as decreases in 
proliferation and increases in osteogenic differentiation and local factor production are 
present on SLA and TPS surfaces in both Cav-1(+/+) and Cav-1(-/-) osteoblasts. 
However, 1α,25(OH)2D3 does appear to require caveolae for some of its effects. 
Cell number in Cav-1(-/-) osteoblasts was lower on all surfaces compared to 
Cav-1(+/+) osteoblasts (Figure 7-2); however repeats varied in baseline cell number 
values depending on the harvest batch (Figure 7-1).  A repeat on TCPS, PT, and SLA 
surfaces using Cav-1(+/+) and Cav-1(-/-) osteoblasts was performed using batches of 
cells grown in parallel and harvested at the same time.  No differences in cell number, 
alkaline phosphatase activity, or osteocalcin levels were observed between Cav-1(+/+) 
and Cav-1(-/-) osteoblasts.  This result suggests that differences in baseline levels of 
osteocalcin or other factors measured are due to experimental variance inherent with 




Figure 7-1:  Baseline comparison of Cav-1 (+/+) and Cav-1 (-/-) osteoblasts on TCPS, 




In the full experiment using TCPS, PT, SLA, and TPS surfaces, loss of caveolin-1 
appeared to affect proliferation of osteoblasts.  Increasing surface roughness caused a 
decrease in cell number in both Cav-1(+/+) and Cav-1(-/-) osteoblasts (Figure 7-2).  
1α,25(OH)2D3 caused a further decrease in cell number in Cav-1(+/+) osteoblasts.  The 
1α,25(OH)2D3-dependent decrease was minimal in Cav-1(-/-) osteoblasts, suggesting 




Figure 7-2:  Comparison of cell number in Cav-1(+/+) and Cav-1(-/-) osteoblasts.  * Ti 
surface vs. Plastic (TCPS); # 1,25 treatment vs. vehicle control. 
 
Alkaline phosphatase specific activity was also altered by the absence of 
caveolae.  Increasing surface roughness caused an increase in alkaline phosphatase 
specific activity in both Cav-1(+/+) and Cav-1(-/-) osteoblasts (Figure 7-2).  
1α,25(OH)2D3 caused a further increase in alkaline phosphatase activity in Cav-1(+/+) 
osteoblasts; however, treatment with 1α,25(OH)2D3 on Cav-1(-/-) osteoblasts caused a 
decrease in alkaline phosphatase activity on all surfaces.  Cav-1(-/-) osteoblasts treated 
with 1α,25(OH)2D3 also did not display an effect of surface roughness.  These results 
suggest a role for caveolae in 1α,25(OH)2D3 signaling, although it is unclear why alkaline 
phosphatase activity was reduced below control levels after 1α,25(OH)2D3 treatment. 
 
Figure 7-3:  Comparison of alkaline phosphatase specific activity in Cav-1(+/+) and Cav-




One obvious observation in Cav-1(-/-) osteoblasts is the nearly 100-fold increase 
in levels of osteocalcin in all groups compared to Cav-1(+/+) controls (Figure 7-3).  
These baseline differences were not observed in Cav-1(+/+) and Cav-1(-/-) osteoblasts 
grown, harvested, and tested at the same time (Appendix, A-2).  Previous studies have 
indicated increases in differentiation in Cav-1(-/-) osteoblast compared to Cav-1(+/+) 
controls [137], although it is not clear if that is the case in this study.  Osteocalcin levels 
increased in both Cav-1(+/+) and Cav-1(-/-) osteoblasts due to increasing surface 
roughness.  1α,25(OH)2D3 caused an increase in osteocalcin levels on all surfaces in 
Cav-1(+/+) and Cav-1(-/-) osteoblasts. 
Figure 7-4:  Comparison of osteocalcin levels in Cav-1(+/+) and Cav-1(-/-) osteoblasts.  
* Ti surface vs. Plastic (TCPS); # 1,25 treatment vs. vehicle control. 
 
 
Local factor production was also affected in osteoblasts lacking caveolin-1.  
PGE2 levels were nearly 100-fold higher in Cav-1(-/-) osteoblasts than Cav-1(+/+) 
osteoblasts (Figure 7-4).  PGE2 levels increased in both Cav-1(+/+) and Cav-1(-/-) 
osteoblasts due to increasing surface roughness.  1α,25(OH)2D3 caused an increase in 




Figure 7-5:  Comparison of PGE2 levels in Cav-1(+/+) and Cav-1(-/-) osteoblasts.  * Ti 
surface vs. Plastic (TCPS); # 1,25 treatment vs. vehicle control. 
 
TGF-β1 levels were also nearly 100-fold higher in Cav-1(-/-) osteoblasts than 
Cav-1(+/+) osteoblasts.  TGF-β1 levels increased in both Cav-1(+/+) and Cav-1(-/-) 
osteoblasts due to increasing surface roughness (Figure 7-5).  1α,25(OH)2D3 caused a 
further increase in latent TGF-β1 levels on all surfaces and active TGF-β1 levels on SLA 
and TPS surfaces.  1α,25(OH)2D3 did not have in effect on active or latent TGF-β1 levels 




Figure 7-6:  Comparison of active (top) and latent (bottom) TGF-β1 levels in Cav-1(+/+) 
and Cav-1(-/-) osteoblasts. 
 
7.4. Discussion 
 The results demonstrate that loss of caveolae do affect osteoblast phenotype 
and responsiveness to 1α,25(OH)2D3; however, osteoblast response to surface 
roughness did not appear to be impaired.  Interestingly, levels of osteocalcin, active and 
latent TGF-β1, and PGE2 were nearly 100-fold higher in the absence of caveolae.  Part 
of this effect may be due to lower cell number observed in Cav-1(-/-), although even non-
normalized levels of these factors were still 30-fold higher in caveolae deficient cells.  
Part of this effect may also be due to experimental variance.  All cells is the experiment 
were primary osteoblasts harvested from separate batches of Cav-1(+/+) and Cav-1(-/-) 
mice.  Repeats did not show differences in levels of osteocalcin (Appendix, Figure A-2).  
TGF-β1, and PGE2 levels were not measured again.  Still, the fact that levels of 
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osteocalcin, active and latent TGF-β1, and PGE2 were so highly expressed in Cav-1(-/-) 
osteoblasts from both primary experiments suggests that this result cannot be ignored.  
Previous studies suggest that one of the main roles of caveolae in osteoblasts is to 
repress signals for differentiation [136, 137].  These findings include higher levels in 
Cav-1(-/-) osteoblasts of runx2 and osterix, both of which are potent osteoblast 
transcription factors.  Previous work has also shown that MAP kinase activity appears to 
be hyperactive in cav-1 deficient cells [209].  MAP kinase activity is known upregulate 
runx2 and other transcription factors to promote osteoblast differentiation.  Alternatively, 
canonical Wnt/β-catenin signaling or BMP-signaling could also be increased in Cav-1(-/-) 
osteoblasts due to the inability of caveolin-1 to sequester β-catenin or BMP receptors, 
respectively.  Finally, TGF-β1 levels could be increased given reports that caveolae are 
involved in internalization and degradation of TGF-β receptors [210].  Each of these 
possible scenarios could partially explain why Cav-1(-/-) osteoblasts undergo more rapid 
differentiation than their wild-type counterparts. 
 Despite multiple reports that caveolae are involved in cell polarity, migration, 
integrin signaling, and the assembly of focal adhesions [138, 143, 144], this study did not 
demonstrate any alteration in the response of Cav-1(-/-) osteoblasts to increasing 
surface roughness.  Previous studies have investigated the role of caveolae under more 
dynamic conditions, whereas the present study measured markers for osteoblast 
proliferation and differentiation at a set time point 24 hours post-confluence.  Although It 
is still possible that cav-1(-/-) osteoblasts might have impaired or delayed response to 
surface roughness at short time points, the present results clearly show that loss of 




 Osteoblast response to 1α,25(OH)2D3 appears to be partially under the control of 
caveolae.  The results show that without caveolae, 1α,25(OH)2D3 was not able to 
decrease cell number.  In addition, lack of caveolae disrupted 1α,25(OH)2D3-mediated 
increases in alkaline phosphatase activity and levels of active and latent TGF-β1.  
However, 1α,25(OH)2D3-dependent increases in osteocalcin and PGE2 levels were not 
affected by the lack of caveolae.  These findings suggest the possibility that these 
phenotypic responses are regulated by caveolae-dependent and independent 
mechanisms.  For instance, it is well known that traditional 1α,25(OH)2D3 binding to VDR 
is able to upregulate osteocalcin transcription through VDR-RXR binding to VDREs in 
the promoter region of the osteocalcin gene [107].  Loss of a 1α,25(OH)2D3-mediated 
decrease in cell number in Cav-1(-/-) osteoblasts is also not surprising given reports that 
cav-1(-/-) cells shown changes in proliferation [136, 138].  It has been suggested that 
rapid membrane signaling can activate multiple kinases that either directly affect G1-S 
transition or act through crosstalk with the VDR to upregulate VDR target genes [51]. 
The finding that 1α,25(OH)2D3-mediated upregulation of PGE2 is not regulated 
via caveolae is surprising given that previous reports showed that rapid membrane 
1α,25(OH)2D3 signaling can increase PGE2 production via increases in arachidonic acid 
[204].  The finding that 1α,25(OH)2D3-mediated increases in active TGF-β1 require 
caveolae supports earlier work that shows that rapid 1α,25(OH)2D3 produces 
stromelysin-1 (MMP-3), which releases and activates latent TGF-β1 in the ECM [211].  
However, the 1α,25(OH)2D3 signaling mechanisms regulating latent TGF-β1 levels via 
caveolae are unclear.  In addition, effects of 1α,25(OH)2D3 on reducing alkaline 
phosphatase activity in Cav-1(-/-) osteoblasts are difficult to explain given the fact that 
1α,25(OH)2D3 treatment appeared to inhibit any surface effects.  Overall, the findings 
that caveolae regulate, some, but not all of the effects of 1α,25(OH)2D3 points to 
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increased complexity in 1α,25(OH)2D3 signaling, perhaps due to extensive crosstalk 
between membrane and nuclear 1α,25(OH)2D3 signaling pathways. 
 
7.5. Conclusion 
 The data suggest that caveolin-1 deficient osteoblasts exhibited differences in 
state of differentiation and responsiveness to 1α,25(OH)2D3 compared to littermate 
controls.  Levels of osteocalcin, active and latent TGF-β1, and PGE2 were nearly 100-
fold higher in the absence of caveolae, although it is not clear whether this is due to 
enhanced differentiation or is an artifact of the experiment.  When osteoblasts lacking 
caveolae were treated with 1α,25(OH)2D3, they did not exhibit decreases in cell number 
and increases in alkaline phosphatase activity and active and latent TGF-β1 
characteristic of „wild-type‟ osteoblasts treated similarly.  Lack of caveolae did not affect 
osteoblast response to surface energy or roughness, nor did lack of caveolae affect 
1α,25(OH)2D3-induced increases in osteocalcin or PGE2 levels.  Overall, the results 
support other reports that suggest that lack of caveolae enhances osteoblastic 
differentiation.  Moreover, the results suggest that 1α,25(OH)2D3 signaling relies on both 




CHAPTER 8:  Discussion 
 
The results highlighted in the previous chapters of this thesis demonstrate that 
integrins, VDR, and caveolae play important roles in mediating osteoblast response to 
implant surface properties and 1α,25(OH)2D3.  While these studies have answered 
questions regarding the roles of the β1 integrin or VDR in mediating these responses, the 
studies have also opened up many more questions regarding the complexity of the 
mechanisms regulating interaction between integrins, caveolae, and vitamin D mediated 
signaling. The following sections will discuss the findings with regard to cell-surface 
interactions, the design of multifunctional peptide-based surfaces, and vitamin D 
signaling.  The thesis will conclude with a discussion of potential future directions in light 
of these findings and other reports in the scientific literature. 
 
8.1. Cell Response to Surfaces 
 Osteoblast response to increasing surface roughness was shown in Chapter 3 to 
be regulated by the β1 integrin subunit.  While much of the research in the literature has 
focused on the roles of the α2β1 and α5β1 integrins in osteoblast biology, many other 
integrins likely play supportive roles in differentiation.  Osteoblasts express multiple 
integrin pairs that vary at different times as osteoblasts mature from osteoprogenitor 
cells to mature, mineralizing osteoblasts.  These osteoblasts include integrins α1β1, α2β1 
α3β1, α4β1, α5β1, α6β1, α8β1, αVβ3, αVβ5, [34], and possibly others that have not been 
measured.  It has been shown that surface roughness and time in culture increases β1 
and α2 expression and decreases α5 expression, which demonstrates that integrin 
expression varies not only by surface properties, but also by the state of differentiation of 
the cells.  Such differences in integrin expression, particularly α2β1 and α5β1, along with 
changes in osteocalcin and other markers for differentiation, suggest that changes in 
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integrin expression could associated with increased osteoblast differentiation [40].  
However, for many integrins it is not known whether increased expression is the cause 
of or the result of increased osteoblastic differentiation. 
Variance in integrin expression and the existence of disparate integrin functions 
is expected given the requirements of osteoblasts in producing bone.  Early 
osteoprogenitor cells must reach the implant surface where they attach to a provisional 
matrix containing both fibronectin and collagen I.  Reports in the literature suggest that 
the α5β1 integrin is important in the early attachment, proliferation, and differentiation of 
osteoprogenitor cells [146, 162, 163].  Silencing of the α5-integrin did not have any effect 
on the response of immature osteoblast-like MG63 cells to surface roughness; however, 
confirmation of these results is necessary given the possibly of insufficient silencing of 
the α5-integrin at the cell surface.  While studies suggest that the α5β1 integrin is critical 
to osteoprogenitor cell differentiation [146, 162, 163], its role may change as these cells 
mature into osteoblasts.  The α5β1 integrin likely plays a central role in providing cell 
survival and proliferative cues necessary to generate sufficient osteoblast population 
from osteoprogenitor cells.  However, as osteoblasts begin to mature, they tend to 
produce less fibronectin and more collagen I and bone-specific proteins like osteocalcin.  
Thus, a switch from α5β1 to α2β1 signaling might be important in switching from signals 
promoting proliferation/survival to those promoting osteoblastic differentiation and 
mineralization.  The α5-silencing study presented in this thesis only investigated the role 
of the α5β1 integrin in immature osteoblasts.  Even if issues with α5 silencing efficiency 
are ignored and we conclude that α5β1 does not mediate the effects of surface 
roughness in MG63 cells, it is not clear whether this finding would hold true in normal 
human osteoblasts or other osteoblast cell models. 
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 In an effort to limit variables, experimenters must often look at the role of single 
integrins or peptides.  This simplification is necessary, but ignores the complexity of 
biological systems.  Multiple integrins other than α2β1 and α5β1 are involved in osteoblast 
interaction with the ECM including α1β1, α3β1, αVβ3, and others.  It is well known that the 
binding of multiple different ligands to different components of the ECM can lead to 
synergies in signals for proliferation or differentiation.  Thus, while α2β1 has been shown 
to be critical to differentiation in mature osteoblasts, other integrins could also play 
important supporting roles.  This possibility suggests that knockdown of some of these 
others integrins might also impair osteoblast response to surface microtopography.  
Integrin binding has been shown to affect growth factor signaling through 
caveolae or other mechanisms.  In this manner, the osteogenic functions of some 
integrin signaling pathways can be amplified in a way by enhancing the actions of 
various growth factors or steroid hormones.  It is likely that integrin expression and 
binding affects growth factor signaling, and vice versa, growth factors can alter integrin 
expression or activity.  For example, treatment with 1α,25(OH)2D3 leads to increased 
expression of the β1 integrin [40].  In addition, cells often require both the proper 
attachment signals and growth factor signals to maximize signaling.  For instance, 
internalization of caveolae, and thus caveolae based signaling, can be mediated by 
association of pY14Cav-1 with the β1 integrin [138].  Thus, better understanding of cell-
surface interactions requires indentifying not only the integrins involved in osteoblastic 
differentiation, but also other associated signaling molecules that interact with integrins 






8.2. Multifunctional Peptide Coated Implant Surfaces 
 The use of proteins, peptides, or other molecules to modify surfaces to elicit 
specific biological responses is a rapidly developing field of research.  One of the keys to 
designing successful peptide-based surfaces is being able to understand the biology 
well enough to design ligands that can enhance osteoblast differentiation.  The results 
using RGD and KRSR surfaces were disappointing in this regard because of lack of 
biological activity of KRSR.  RGD on the other hand had biological activity, but promoted 
osteoblast proliferation, not differentiation.  Unfortunately, it is difficult to predict whether 
a ligand will promote differentiation, especially since many ligands are selected based on 
initial attachment studies rather than actual measures for differentiation.  Selection of 
ligands for even initial tests can be difficult.  While the RGD sequence is found in many 
different proteins, KRSR is based off a BBXB design where the amino acid sequence 
varies by protein, making biologically active BBXB groups difficult to identify without 
resorting to complex screening assays. 
 Interestingly, KSSR was able to promote an osteoblastic phenotype, although the 
exact mechanism for this effect is unknown.  Earlier reports show that KSSR was not 
able to increase cell attachment [192], which creates doubt regarding any biological 
specificity of the sequence.  An alternative hypothesis is that the KSSR ligand inhibits 
cell attachment and reduces cell spreading.  The PLL-g-PEG coating has a similar effect 
on cells although it is even more pronounced by addition of KSSR.  The mechanisms 
behind how these surfaces act to enhance osteoblast differentiation are largely 
unknown.  Much of the discussion of osteoblast differentiation in this thesis has focused 
on the role of integrin binding and attachment, so it seems almost counterintuitive that 
surfaces limiting attachment would enhance differentiation.  One possible theory is that 
the types of integrins binding adsorbed proteins on such surfaces strongly promote 
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osteoblast differentiation, but not proliferation.  This point reiterates earlier suggestions 
that signals for proliferation and differentiation may compete against one another.  Still, 
very little is known regarding which integrins are expressed differentially on PLL-g-PEG 
or modSLA surfaces, or how a reduction in cell spreading leads to increased 
differentiation.   
 KSSR was effective in promoting osteoblast differentiation, but the combination 
of RGD and KSSR did not lead to a state of enhanced osteoblast proliferation and 
differentiation.  Instead, RGD at high peptide densities appeared to mask the effects of 
KSSR.  Clearly, ligands used in multifunctional peptide surfaces should work 
synergistically, not antagonistically.  Other multifunctional peptide surfaces, such as 
those composed of RGD/GFOGER, RGD/FHRRIKA, or RGD/PHSRN have 
demonstrated enhanced binding [42, 186-188], which suggests that selectivity of ligands 
is critical to achieving enhanced cell attachment, proliferation, or differentiation.  Thus, 
the development of truly advanced multifunctional peptide surfaces requires better 
understanding of ligand bioactivity, ligand combinations, spacing, and surface 
attachment chemistries in order to eliminate much of trial and error that is currently the 
basis for ligand design and evaluation.   
 
8.3. Vitamin D and Caveolae 
 The combination of surface microtopography and 1α,25(OH)2D3 treatment leads 
to synergistic effects on osteoblast differentiation, although it is still unclear how 
1α,25(OH)2D3 and integrin signaling pathways interact to give rise to this synergy.  The 
results in Chapter 6 suggest that VDR is required for the effects of 1α,25(OH)2D3 on all 
measured markers for osteoblastic differentiation; however, this finding is somewhat 
surprising given the role of VDR-independent pathways in increasing Ca++ and PKC 
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[212].  The very fact that these responses exist suggests that some downstream effects 
of rapid 1α,25(OH)2D3 signaling exist and are yet to be identified.  One of the most 
plausible explanations for this finding is that both Pdia3 and VDR are required for the 
rapid responses to 1α,25(OH)2D3.  Both VDR and Pdia3 have been found in the 
caveolae [117], although no evidence has yet shown that these proteins interact.  
Interestingly, VDR transcriptional activity can be mediated by multiple phosphorylation 
sites that can be targeted by PKC-β, CaMKIV, casein kinase II, MAPK, and PKA [105], 
although it is not clear which, if any of these signaling molecules might be affected by 
rapid 1α,25(OH)2D3 signaling.  The existence of such modulation of nuclear receptor 
activity by rapid membrane pathways is not uncommon in either growth factor or steroid 
hormone signaling [213], so it would not be surprising if membrane signaling did in fact 
modulate VDR transcriptional activity and activation of target genes.  This possibility will 
have to be explored in future studies. 
 Surprisingly, lack of caveolae did not affect cell response to the surface 
properties tested in this study despite reports that lack of caveolae affects focal adhesion 
assembly, cell polarity, migration, proliferation, and differentiation [136].  None of these 
functions were totally inhibited by lack of caveolae in these referenced studies, but the 
spatial and temporal control over these events was impaired.  Previous tests in the 
literature examined short time points, whereas the experiments in this thesis measured 
cell response at confluence, possibly making these differences in dynamics irrelevant.  
Still, given previous reports of increased differentiation in cav-1(-/-) osteoblasts and the 
increased levels of osteocalcin, TGFβ1, and PGE2 observed in this study, it is surprising 
that no differences were seen in the relative responses of cav-1(-/-) and cav-1(+/+) 
osteoblasts to changing surface roughness.   
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It is well known that lipid rafts or other mechanisms can compensate for the 
critical roles of caveolae, therefore making it difficult to determine exactly what functions 
are mediated by caveolae and what functions are mediated by signaling molecules or 
lipid rafts that are simply associated with caveolae.  Still, the interplay between caveolae 
and integrins is certainly an area of intense interest.  The fact that integrin binding can 
directly affect caveolae internalization and signaling suggests the possibility that there is 
anchorage dependent modulation of many growth factor signaling pathways [136, 145].  
Moreover, growth factor signaling can in turn affect integrin binding and focal adhesion 
stability through the interactions with phosphorylated caveolin-1.  Further work will be 
needed to explore whether these actions of caveolae have direct roles in crosstalk 
between integrin and 1α,25(OH)2D3 signaling pathways. 
 
8.4. Future Studies 
 Although rough implant topographies have been used in orthopaedic and dental 
implants for several decades now, there is still a tremendous amount of work that needs 
to be performed to understand how these surface features actually affect integrin 
signaling and osteoblast phenotype.  The design of advanced implant surfaces or 
combination therapies based on such increased understanding of osteoblast biology will 
also require advances in surface engineering and improvements our ability to select 
appropriate signaling motifs.  Understanding how osteoblasts interact with implant 
surfaces requires a deeper understanding of cell-surface interactions and a deeper 
understanding of the mechanisms promoting osteointegration.   Integrins certainly play a 
significant role in the ability of osteoblasts to respond to surface roughness; however, 
studies investigating the roles of integrins in bone turnover and peri-implant healing in 
vivo are still lacking in large numbers.  Some studies have focused on the α2β1 and α5β1 
integrins in osteoblast interactions with surfaces, but few studies have deeply 
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investigated the role of the integrins in affecting in vivo bone formation.  Moreover, there 
is a need for more comprehensive studies examining temporal expression of multiple 
integrins throughout both bone turnover in vivo and osteoblast response to titanium 
surface properties in vitro.  Such studies would provide better information about when 
different integrins are expressed, thus providing insight on how integrin expression 
progresses as osteoblasts differentiate.  This information would be useful to 
bioengineers in terms of indentifying targets for the design of peptide coated surfaces. 
 Experiments on protein or peptide based surfaces appear to be limited by the 
biological activity of the ligands attached to the surfaces.  As demonstrated with the 
KRSR peptide, even ligands proven to increase osteoblast-specific adhesion do not 
necessarily lead to promotion of an osteoblastic phenotype.  In theory, a ligand like 
KRSR that increases osteoblast-specific adhesion but actually promotes osteoblastic 
differentiation would be an important discovery.  While it is very difficult to identify and 
prove the osteogenic capability of new ligands, such discoveries could lead to novel 
surfaces that promote osteointegration in vivo.  Furthermore, studies exploring the 
combination of ligands on titanium implant surfaces may show increased osteogenic 
potential than single ligands. 
 Better understanding of the relative roles of the membrane and nuclear 
1α,25(OH)2D3 pathways could lead to novel targets for drug design.  While the results 
herein this thesis demonstrate that VDR is required for the effects of 1α,25(OH)2D3 on all 
measured markers for osteoblast proliferation and differentiation, the results do not rule 
out a role for membrane 1α,25(OH)2D3 signaling in modulating VDR transcriptional 
activity and affecting VDR target gene transcription.  Future studies should specifically 
investigate the role of rapid 1α,25(OH)2D3 signaling in activating PKC-β, PKA, casein 
kinase II, MAPK, or Ca2++/calmodulin-dependent kinase IV (CaMKIV) dependent 
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signaling mechanisms that have been previously shown to phosphorylate the VDR [105, 
124].  These studies should further attempt to establish a direct link between rapid 
1α,25(OH)2D3 signaling, phosphorylation of the VDR, and altered transcriptional activity 
of target genes.  Furthermore, the role of caveolae should be explored to determine if 
and how these signaling pathways are modulating by integrin signaling. Such a 
discovery regarding interactions between membrane 1α,25(OH)2D3  and traditional VDR 
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Selected Gene Expression in VDR (+/+) and VDR(-/-) Osteoblasts on Surfaces 
 
Figure A-1:  Effect of changing surface roughness on expression of GapDH (Control), 
Pdia3, integrin beta 1, integrin alpha 2, integrin alpha 5, caveolin-1, Runx2, and integrin 
beta 3 in osteoblasts harvested from VDR(+/+) and VDR(-/-) mice.  Statistics:  * Surface 




Figure A-2:  Effect of changing surface roughness on expression of GapDH (Control), 
Pdia3, integrin beta 1, integrin alpha 2, integrin alpha 5, caveolin-1, Runx2, and integrin 
beta 3 in osteoblasts harvested from VDR(+/+) and VDR(-/-) mice.  Statistics:  * Surface 




Selected Gene Expression in VDR (+/+) and VDR(-/-) Osteoblasts ± 1α25(OH)2D3 
 
Figure A-3:  Effect of 1α25(OH)2D3 on expression of GapDH (Control), Pdia3, integrin 
beta 1, integrin alpha 2, integrin alpha 5, caveolin-1, Runx2, and integrin beta 3 in 
osteoblasts harvested from VDR(+/+) and VDR(-/-) mice.  Statistics:  * Control vs. 




Figure A-4:  Effect of 1α25(OH)2D3 on expression of GapDH (Control), Pdia3, integrin 
beta 1, integrin alpha 2, integrin alpha 5, caveolin-1, Runx2, and integrin beta 3 in 
osteoblasts harvested from VDR(+/+) and VDR(-/-) mice.  Statistics:  * Control vs. 




Selected Gene Expression in Cav-1 (+/+) and Cav-1(-/-) Osteoblasts on Surfaces 
 
Figure A-5:  Effect of changing surface roughness on expression of GapDH (Control), 
Pdia3, integrin beta 1, integrin alpha 2, integrin alpha 5, VDR, and Runx2 in osteoblasts 
harvested from Cav-1(+/+) and Cav-1(-/-) mice.  Statistics:  * Surface vs. TCPS; • SLA 




Figure A-6:  Effect of changing surface roughness on expression of GapDH (Control), 
Pdia3, integrin beta 1, integrin alpha 2, integrin alpha 5, VDR, Runx2, and integrin beta 3 
in osteoblasts harvested from Cav-1(+/+) and Cav-1(-/-) mice.  Statistics:  * Surface vs. 
TCPS; • SLA vs. PT; # WT vs. KO.  Significant if p < 0.05.  Experiment #2. 
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Selected Gene Expression in Cav-1 (+/+) and Cav-1(-/-) Osteoblasts ± 1α25(OH)2D3 
 
Figure A-7:  Effect of 1α25(OH)2D3 on expression of GapDH (Control), Pdia3, integrin 
beta 1, integrin alpha 2, integrin alpha 5, VDR, and Runx2 in osteoblasts harvested from 
Cav-1(+/+) and Cav-1(-/-) mice.  Statistics: * Control vs. 1α25(OH)2D3; # WT vs. KO.  





Figure A-8:  Effect of 1α25(OH)2D3 on expression of GapDH (Control), integrin beta 1, 
and integrin alpha 5 in osteoblasts from Cav-1(+/+) and Cav-1(-/-) mice.  Statistics:  




Pooled Gene Expression in VDR (+/+) and VDR (-/-) Osteoblasts 
 
Table A-1:  Pooled VDR(+/+) and VDR(-/-) data investigating the effect of surface 
roughness on expression of GapDH (Control), Pdia3, integrin beta 1, integrin alpha 2, 
integrin alpha 5, caveolin-1, Runx2, and integrin beta 3.  Data is shown as mean ± 95% 
confidence interval.  The bottom table displays ratios of gene expression on SLA versus 
PT surfaces in VDR(+/+) and VDR(-/-) osteoblasts.  All data is pooled from two different 





Table A-2:  Pooled VDR(+/+) and VDR(-/-) data only on TCPS surfaces to establish 
differences in baseline expression of the genes listed below.  Data is shown as mean ± 
95% confidence interval.  Statistically significant values are shown in bold.  Significance 
has been verified using ANOVAs blocked for the experimental batch. All data is pooled 





Pooled Gene Expression in Cav-1 (+/+) and Cav-1 (-/-) Osteoblasts 
 
Table A-3:  Pooled Cav-1(+/+) and Cav-1(-/-) data only on TCPS surfaces to establish 
differences in baseline expression of the genes listed below.  Data is shown as mean ± 
95% confidence interval.  Statistically significant values are shown in bold.  Significance 
has been verified using ANOVAs blocked for the experimental batch. All data is pooled 





Table A-4:  Pooled Cav-1(+/+) and Cav-1(-/-) data only on TCPS surfaces to establish 
differences in baseline expression of the genes listed below.  Data is shown as mean ± 
95% confidence interval.  Statistically significant values are shown in bold.  Significance 
has been verified using ANOVAs blocked for the experimental batch. All data is pooled 
from the TCPS controls from four different experiments each with an n=6 per group. 
 
 
 
